

# 2020

## Version 2018.02

PROTOCOL FOR AUDITORY BRAINSTEM RESPONSE – BASED AUDIOLOGICAL ASSESSMENT (ABRA)



Ministry of Children, Community and Social  
Services

Ontario Infant Hearing Program  
October 6, 2020

## CONTRIBUTORS

Marlene Bagatto  
Viji Easwar  
Rana El-Naji  
Martyn Hyde  
April Malandrino  
Vanessa Martin  
Marie Pigeon  
David Purcell  
Susan Scollie  
Jill Witte

## CORRESPONDENCE

Vanessa Martin  
Children with Special Needs Division  
Ministry of Children, Community and Social Services  
101 Bloor Street West, 3rd Floor,  
Toronto, ON M5S 2Z7  
Tel: (416) 327-4872  
E-mail: [vanessa.martin@ontario.ca](mailto:vanessa.martin@ontario.ca)

## TABLE OF CONTENTS

TABLE OF CONTENTS .....	3
VERSION HISTORY AND REVISION SUMMARY .....	5
PROTOCOL EXECUTIVE SUMMARY .....	8
Section 1: The Infant Hearing Program (IHP) Service Context .....	8
Section 2: ABRA Preliminaries.....	11
Section 3: High-Efficiency ABR Threshold Measurement .....	13
Section 4: Auditory Neuropathy Spectrum Disorder (ANSD) Sub-Protocol .....	18
Section 5: Ancillary Procedures .....	20
PROTOCOL TOPIC DETAILS & RATIONALE.....	21
Section 1: The Ontario Infant Hearing Program (IHP) Service Context.....	21
1.01 WHAT IS IHP ABRA? .....	21
1.02 WHO CAN CONDUCT ABRA? .....	21
1.03 PROTOCOL ADHERENCE IS A REQUIREMENT.....	21
1.04 LEGITIMATE DEPARTURE FROM PROTOCOL.....	22
1.05 CHANGES TO THE ABRA PROTOCOL .....	22
1.06 TARGET POPULATION .....	22
1.07 TARGET DISORDERS .....	23
1.08 CONDUCTIVE HEARING LOSS (CHL).....	23
1.09 ABRA OBJECTIVES.....	24
1.10 AGE AT START OF INITIAL ABRA.....	24
1.11 AGE AT COMPLETE INITIAL ABRA.....	25
1.12 SCREENING BYPASS IN VERY HIGH RISK BABIES.....	25
1.13 IHP DESIGNATED TRAINING CENTRES (DTC) .....	27
1.14 ABRA PROTOCOL SUPPORT BY DTCS .....	27
1.15 DTC CONSULTATION OR REFERRAL.....	27
1.16 TIMELINESS OF ABRA COMPLETION .....	28
1.17 PARENT/GAURDIAN-DRIVEN SECOND OPINION.....	29
1.18 ABR TESTING OUTSIDE THE IHP .....	29
1.19 ABRA THAT IS OUT-OF-PROTOCOL.....	29
1.20 CONTINUOUS QUALITY IMPROVEMENT (CQI).....	29
1.21 IHP STANDARD PRACTICE REVIEWS.....	30
1.22 ADVERSE EVENT REVIEWS & AUDITS & REVIEW FOR AUDIOLOGIST COMPETENCY .....	30
1.23 INFECTION CONTROL (IC) STANDARDS .....	30
1.24 APPROVED TEST ENVIRONMENTS .....	30
1.25 APPROVED TEST INSTRUMENTATION & SUPPLIES .....	30
1.26 APPROVED DEVICE PROTOCOLS & PARAMETERS .....	30
1.27 CLINICAL RECORDS & DATABASE REPORTING .....	31
1.28 PERSONAL HEALTH INFORMATION.....	31
Section 2: ABRA Preliminaries.....	31
2.01 URGENCY OF ABRA APPOINTMENTS .....	31
2.02 REQUIRED STATE FOR SUCCESSFUL ABRA .....	32
2.03 PRE-TEST BABY STATE .....	33
2.04 TEST ENVIRONMENT & PARTICIPANTS .....	33
2.05 TONEPIP STIMULUS PARAMETERS.....	34
2.06 STIMULUS CALIBRATION & CHECKING.....	35
2.07 STIMULUS TRANSDUCERS.....	35
2.08 ELECTRODE POSITION .....	35
2.09 ELECTRODE IMPEDANCES .....	36
2.10 RECORDING CHANNELS.....	36
2.11 SORTING AND DISPLAYING TRACINGS FOR PRINTOUT.....	38
Section 3: High-Efficiency ABR Threshold Measurement .....	38
3.01 TEST EFFICIENCY IS CRUCIAL & FEASIBLE .....	38
3.02 OPTIMIZING CLINICAL INFORMATION GAIN.....	39

3.03 MANDATORY & DISCRETIONAL PROCEDURES .....	40
3.04 AC & BC TEST FREQUENCIES .....	41
3.05 MINIMUM (SMIN) & MAXIMUM (SMAX) TONEPIP LEVELS .....	41
3.06 AMPLIFIER GAIN & KALMAN WEIGHTED AVERAGING .....	42
3.07 DIMINISHING RETURNS IN AVERAGING.....	42
3.08 SUITE OF TRACINGS .....	44
3.09 RESPONSE JUDGEMENT CATEGORIES & CRITERIA.....	44
3.10 RESIDUAL NOISE (RN) LEVELS & 'NO RESPONSE' (NR) JUDGEMENTS.....	46
3.11 ACTUAL VS ADJUSTED NUMBERS OF SWEEPS .....	47
3.12 TONEPIP ABR THRESHOLD DEFINITION .....	47
3.13 ESTIMATED HEARING LEVELS.....	48
3.14 THRESHOLD SEARCH & BRACKET PHASES.....	49
3.15 NUMBER OF SWEEPS & TRACINGS .....	49
3.16 SUMMING COMPOUND TRACINGS.....	50
3.17 THRESHOLD BRACKET STEP SIZE .....	51
3.18 CONFIRMATION OF UPPER BRACKET RESPONSE.....	51
3.19 STRATEGY OF STIMULUS FREQUENCY & ROUTE.....	51
3.20 BC STIMULUS ARTIFACT .....	52
3.21 BC RESPONDING COCHLEA INFERENCE .....	52
3.22 BC CONTRALATERAL MASKING .....	53
3.23 ELECTROMAGNETIC 60 HZ ARTIFACT & NOTCH FILTERING.....	53
3.24 ABRA UNDER GENERAL ANAESTHESIA.....	54
Section 4: Auditory Neuropathy Spectrum Disorder (ANSD) Sub-Protocol.....	55
4.01 OVERVIEW.....	55
4.02 ANSD SUB-PROTOCOL ENTRY CRITERION .....	56
4.03 ANSD SUB-PROTOCOL TIMING.....	56
4.04 ANSD TEST PROCEDURES .....	57
4.05 INTERPRETATION OF CM/ABR TRACINGS .....	57
4.06 CLICK ABR WAVEFORM & THRESHOLDS .....	58
4.07 DPOAE ROLE.....	58
4.08 ACOUSTIC REFLEX (AR) ROLE .....	59
4.09 ANSD OUTCOME CATEGORIES.....	59
4.10 CONDUCTIVE COMPONENTS IN ANSD.....	59
4.11 DTC CONSULTS & ADDITIONAL TESTS.....	60
4.12 EARLY MANAGEMENT.....	60
4.13 ANSD FIELD ENTRY IN THE IHP DATABASE.....	61
4.14 POST-ABRA REFERRALS.....	61
Section 5: Ancillary Procedures .....	61
5.01 DISTORTION PRODUCT OTOACOUSTIC EMISSION (DPOAE) TESTING.....	61
5.02 MIDDLE EAR ANALYSIS: TYMPANOMETRY.....	62
5.03 MIDDLE EAR ANALYSIS: ACOUSTIC REFLEXES .....	63
APPENDICES.....	64
Appendix A: References.....	64
Appendix B: Accessing a Designated Training Centre (DTC) for Consultation or Referral.....	66
Appendix C: Summary of Key Integrity Stimulation and Recording Parameters .....	67
Appendix D: IHP Vivosonic Integrity Stimulus Transducer Calibration .....	68
Appendix E: IHP Vivosonic Integrity Protocols.....	69
Appendix F: Clinical Tips for a Hand-Held or Tensor Bandage Bone Oscillator .....	71
Appendix G: IHP Minimum Stimulus Levels & ABRA Threshold Corrections for dB eHL .....	72
Appendix H: DPOAE Parameters.....	73
Appendix I: Middle-Ear Analysis Technical Summary .....	74
Appendix J: ANSD Plotting Examples .....	75

## VERSION HISTORY AND REVISION SUMMARY

This version of the Protocol for Auditory Brainstem Response-Based Audiological Assessment (2018.02) supersedes all previous versions of this document. Notable revisions/additional protocol elements and dates are listed below.

VERSION DATE	DOCUMENT TITLE	PREVIOUS VERSION
APRIL 2016	Protocol for ABRA 2016.01	IHP Audiological Assessment Protocol 2008
JUNE 2016	Protocol for ABRA 2016.02	Protocol for ABRA 2016.01
OCTOBER 2018	Protocol for ABRA 2018.01	Protocol for ABRA 2016.02
OCTOBER 2020	Protocol for ABRA 2018.02	Protocol for ABRA 2018.01

Revisions within this version are largely due to a change in the equipment being used to conduct ABRA within the IHP from the Biologic NavPro to the Vivosonic Integrity. Most reflect technological differences with the current equipment that require a modification in strategies used to determine thresholds. Others are changes due to updated evidence and/or experience with the previous protocol. Minor revisions related to the implementation of the hearing loss risk factor screen on the dried blood spot have been included.

TOPIC	DESCRIPTION	SECTION
Sorting tracings	The Clinical Sort feature should be used to display the suite of tracings. The compound tracing, its primary waveforms A and B, and A-B (A minus B) make up the suite of tracings. The clinical sort feature groups tracings by descending level with the compound tracing above the A and B primaries, which are separated to improve the ability to follow individual waveforms. A-B (A minus B) should also be displayed for all tracings below the A and B primaries. <b>For every BC ipsi suite of tracings, the contra suite must also be displayed.</b>	2.11
Mandatory & Discretionary Procedures	BC ABR threshold at 4 kHz is conditionally mandatory when 4 kHz is the only AC threshold abnormality. DPOAEs are mandatory for suspected or confirmed sensorineural hearing loss. They remain mandatory for the ANSD sub-protocol and discretionary for infants with ABR consistent with normal hearing or conductive hearing loss.	3.03 4.07 5.01
Minimum levels for 500 Hz Air Conduction	Mandatory minimum for 500 Hz AC is 40 dB nHL. AC Smin for 1, 2 and 4 kHz are 35, 30 and 25 dB nHL, respectively.	3.05
Amplifier Gain & Kalman-weighted Averaging	Using Kalman-weighted averaging, artifact rejection is not necessary. Due to the nature of Kalman-weighted averaging, there is no need for an artifact rejection criterion. Amplifier gain is fixed at 150,000.	3.06
Tracings and the use of A and B primaries, and the A-B feature	In addition to the compound tracing there are two primaries, each with half the sweeps of the compound tracing; these are referred to as the A and B primary tracings. The A and B primaries have the same statistical independence as if they were obtained sequentially. Comparison of A and B is used to verify RP or NR. Only when A and B do not replicate should an additional tracing at that particular frequency/intensity be collected. A-B must be displayed as part of the suite of tracings. By subtracting B from A, it provides a visual representation of the noise and helps to verify NR or RP.	3.08

Response judgement categories & criteria	The software provides labels for 'RP' (Response Positive), 'NR' (No Response), 'TH' (Threshold), or 'INC' (Inconclusive). For any frequency with hearing loss for which bracketing is complete, TH should be used to label the intensity (dB level) one step above NR. This applies to AC and BC where bracketing is completed. It is acceptable on occasion to have one level of INC in between TH and NR. However, once all mandatory and conditionally mandatory elements have been completed an attempt should be made to resolve any INC with an additional tracing. If INC occurs regularly, consultation with a DTC is required	3.09
Residual noise and No Response judgements	Identifying a small ABR near threshold requires an RN of no more than about 20 nanovolts (nV) or 0.020 $\mu$ V.	3.10
Adjusted vs Actual number of sweeps	If a group of sweeps in a particular tracing is very noisy (high noise, low SNR) they are weighted less. Gathering more sweeps will be necessary to achieve the necessary amount of adjusted (quiet) sweeps. This results in a discrepancy between the actual number of sweeps and the number of adjusted sweeps.	3.11
Estimated hearing levels	The ABR threshold estimate in dB nHL at 500 Hz will be corrected by 15 to derive perceptual threshold in eHL at this frequency. This is due to the change in Smin at 500 Hz (See 3.05).	3.13 and Appendix G
Number of sweeps & tracings	For compound tracings, the recommended adjusted sweep count is between ~2000-4000 sweeps. This will result in the A and B primaries having between ~1000 to 2000 sweeps each. Generally, compound tracings in the search phase will have ~2000 sweeps, and those in the bracketing phase or for MRL will have ~4000.	3.15
Summing compound tracings	Two compound tracings that are collected for a given frequency/intensity may be summed together to create one tracing, the 'SUM'. This tool is useful for resolving INC tracings and for converting a tracing from the search phase into one that meets the criteria for bracketing.	3.16
ABRA under anaesthesia	For an ABR assessment collected under general anaesthesia to be accepted for IHP purposes it must meet protocol requirements with the exception of test environment (1.24). Other deviations might be necessary but these must be documented. Additionally, specifically for ABR under general anesthetic (GA) the following is required: <ul style="list-style-type: none"> <li>• Documentation that reasonable effort was made to reduce noise</li> <li>• Indication of whether the ABR was done in combination with other medical/surgical procedures. If yes, documentation of what those procedures were, when the ABR was performed in relation to them, and any limitations they may have posed for the interpretation of the ABR.</li> <li>• Documentation of physician's report of middle ear status if immittance is not performed by the audiologist.</li> <li>• Otoscopy must be performed preferably by the audiologist, immediately before the ABR with documentation of results.</li> </ul>	3.24
DPOAE Test Frequencies	The DPOAE test frequencies have been modified to align with the protocol for Audiometric Assessment for Children aged 6 to 60	5.01

	Months: 1.5, 2, 3, and 4 kHz. The frequency 1 kHz is no longer required (Hunter et al, 2018).	
Summary of key Integrity stimulation and recording parameters	Added appendix for quick reference	Appendix C
Integrity Protocol	Added appendix for quick reference	Appendix E

## PROTOCOL EXECUTIVE SUMMARY

This protocol document includes a tabular synopsis of all key protocol elements, followed by expanded sections that may include additional details, rationale, challenges, and solutions for each topic area, plus appendices with selected references and further technical or procedural specifications. There are numerous changes from the 2016 Infant Hearing Program Audiologic Assessment document; the most important areas of change or emphasis are indicated by shading of the topic section number.

The following synopsis can stand alone as a summary of the current ABRA protocol including all changes from previous versions. Areas within the 2008 IHP Assessment Protocol that relate to the protocol for Visual Reinforcement Audiometry (VRA) and Conditioned Play Audiometry (CPA) are included in the Protocol for Audiometric Assessment for Children Aged 6 to 60 months.

### SECTION 1: THE INFANT HEARING PROGRAM (IHP) SERVICE CONTEXT

TOPIC	DESCRIPTION
1.01 WHAT IS IHP ABRA?	Auditory brainstem response-based audiological assessment (ABRA) is an audiological assessment that is authorized & funded by the IHP. Its core components include puretone air and bone conduction threshold estimation & site-of-lesion inference using ear-specific, frequency-specific ABRA, and tympanometry. Additional techniques may include click-evoked cochlear and neural potentials, distortion product otoacoustic emissions (DPOAE), and acoustic reflexes.
1.02 WHO CAN CONDUCT ABRA?	Only Audiologists registered and in good standing with the College of Audiologists and Speech Language Pathologists of Ontario (CASLPO), who are in good standing with the College and who are trained and authorized by the IHP to conduct this protocol may provide ABRA services with IHP funding. The IHP audiologist must personally conduct the testing and interpret the results. A trained assistant such as a communication disorder assistant (CDA) may prepare the baby for the ABRA. Students and trainees may also participate with full supervision from the IHP audiologist.
1.03 PROTOCOL ADHERENCE IS A REQUIREMENT	All IHP ABRA must be conducted in adherence to this protocol; such adherence is an expectation for continued authorization to provide IHP ABRA services. Continued failure to adhere to the protocol may result in a competency review  The protocol includes three classes of procedure: <i>mandatory</i> , <i>conditionally mandatory</i> in specific circumstances, and <i>discretionary</i> . Discretionary procedures can be carried out provided they do not compromise accuracy or timeliness of the mandatory components. See section 3.03 for details.
1.04 LEGITIMATE DEPARTURE FROM PROTOCOL	It is acknowledged that case-specific situations that justify departure from mandatory protocol elements can arise. Such departures must be noted in the ABR records with a brief explanation. All such notes must be accessible to IHP standard practice review or case audits (see later) as well as to other IHP audiologists sharing the care of the child.
1.05 CHANGES TO THE ABRA PROTOCOL	Prior approval by MCCSS is required in order to change substantively any element of this protocol. Program-wide changes can occur only through MCCSS directive or by a systematic process that may include survey of Audiologists' experiences or concerns, evidence review, and recommendation by a Designated Training Centre (DTC).
1.06 TARGET POPULATION	Candidates for ABRA include all Ontario-resident babies who bypass or do not pass newborn hearing screening, or who test positive on hearing loss risk factor screening on the dried blood spot, and any other child under 6 years authorized for testing by an IHP Coordinator, a DTC or the MCCSS.



1.07	TARGET DISORDERS	The IHP target disorder set includes permanent hearing loss (PHL) of 30 dB HL or more at 0.5, 1, 2, or 4 kHz in any ear, ANSD, and auditory brainstem pathway disorders that may be detectable using ABR techniques.
1.08	CONDUCTIVE HEARING LOSS (CHL)	The IHP is complementary to OHIP-based, physician-driven audiology services and does not replace them routinely. Purely conductive hearing loss identified by ABRA is not an IHP target unless obviously or presumptively structural, such as in congenital atresia or if a syndrome associated with structural, conductive anomalies is identified or suspected. For minor conductive losses, discharge from the IHP with caregiver counseling and discretionary referral to a physician is the norm.
1.09	ABRA OBJECTIVES	The objectives of ABRA are to detect and quantify hearing loss and, wherever feasible, to infer the site(s) of lesion(s) in each ear. The overall assessment goes beyond audiometry itself and includes informational and counselling components that help families to become informed, engaged, and empowered.
1.10	AGE AT START OF INITIAL ABRA	'Initial ABRA' is the first audiologic assessment in a young infant, typically following either referral from hearing screening (i.e., refer result on AABR or screening bypass) or a positive result on the hearing loss risk factor screening on the dried blood spot. Initial ABRA may involve more than one test session. With the exception of cCMV and confirmed meningitis, the first ABRA session is targeted to occur by six weeks and no later than eight weeks corrected age, wherever medically feasible. Widespread achievement of this target is a high priority. See 1.12 regarding exceptions to this.
1.11	AGE AT COMPLETE INITIAL ABRA	A widely-accepted international performance benchmark is completion of ABRA by three months corrected age at the latest, wherever medically feasible. To improve the provincial level of achievement of this objective is a high priority for IHP Continuous Quality Improvement (CQI).
1.12	SCREENING BYPASS IN VERY HIGH RISK BABIES	Babies with congenital aural atresia, proven meningitis, proven congenital cytomegalovirus (cCMV) infection, or CHARGE syndrome should bypass IHP hearing screening. For babies with confirmed meningitis or cCMV, ABRA is targeted to occur as soon as possible after acute recovery which may be as early as 2-4 weeks corrected age. The others listed here should be routed directly to ABRA by six weeks and no later than eight weeks corrected age, as a high priority.
1.13	IHP DESIGNATED TRAINING CENTRES (DTC)	DTCs are authorized by the MCCSS to provide IHP support, including advanced training, consultative and ABRA referral services, protocol support, and clinical decision support to IHP Audiologists. DTCs also conduct standard IHP practice reviews, provide second opinions on IHP funded assessments and interventions, provide continuous quality improvement review for competency of IHP trained audiologists, and implement audits of services as directed by MCCSS.  The DTCs for ABRA and conditioned behavioural audiometry (CBA) are CHEO, (Ottawa) and Humber River Hospital (HRH, Toronto). The National Centre for Audiology (NCA; Western University, London) is the DTC for Amplification and Screening.
1.14	ABRA PROTOCOL SUPPORT BY DTCS	Audiologists who have questions or concerns about any aspect of the ABRA protocol are encouraged to contact the CHEO or HRH DTC. This is also a mechanism for protocol clarification and improvement.

1.15	DTC CONSULTATION OR REFERRAL	IHP Audiologists are encouraged to consult a DTC if they wish to discuss ABRA procedure, interpretation, or next steps for any specific child. Real-time support during testing is not feasible. Email contact is preferred. Records sent by email for review must be anonymized, with a unique numeric or alphanumeric identifier. Audiologists may also elect to refer a baby to a DTC for ABRA. Such referral may be in response to case complexity, or difficulty obtaining a satisfactory test. See Appendix B for the referral procedure.
1.16	TIMELINESS OF ABRA COMPLETION	Incomplete ABRA after two appointments attended compromises the IHP's primary objective; it is a quality-of-care challenge and a CQI priority. DTC consultation must be considered in a timely manner, then testing under general anaesthesia/sedation or referral to the DTC may be the next step. Prolonged deferral of assessment, such as to VRA several months later, must be avoided wherever possible and rationale for deferral must be clearly documented.
1.17	CAREGIVER-DRIVEN SECOND OPINION	<p>The IHP does not support repetition of initial complete ABRA unless it is elected by the primary IHP Audiologist or is determined to be appropriate by a DTC, in which cases the process is considered as consultative referral.</p> <p>Where a second opinion request is driven by a caregiver, the Audiologist can offer the option of a DTC review as the IHP's standard procedure. In consultation with the Audiologist, the DTC will examine results and issue a written report on diagnostic inferences and recommendations. The recommendations may include retesting locally or at a DTC.</p> <p>The Audiologist must ensure that the caregiver is aware of the right to seek audiology services outside the IHP, but must be informed that the results of any such testing may have no impact on any future IHP services. See IHP Guidance Document for second opinion procedure details.</p>
1.18	ABR TESTING OUTSIDE THE IHP	Results of ABR testing done outside of the IHP must be reviewed by a DTC for validity, accuracy, and relevance, prior to provision of subsequent services funded by the IHP.
1.19	ABRA THAT IS OUT-OF-PROTOCOL	ABRA results that are suspected by any IHP Audiologist to be substantively non-adherent to the relevant IHP protocol at the time the results were obtained must be reviewed by a DTC prior to being considered in relation to further audiologic services from the IHP.
1.20	CONTINUOUS QUALITY IMPROVEMENT (CQI)	The IHP is required to implement quality assurance and quality management on an ongoing basis, for funding accountability. This is being done through a CQI program that targets all major service components, including ABRA. The CQI includes enhanced training and clinical decision support, as well as performance monitoring. Test timeliness, accuracy, efficiency, protocol adherence, and use of supports and referrals are areas of focus for improvements.
1.21	IHP STANDARD PRACTICE REVIEWS	ABRA providers must participate in document-based practice review. A streamlined process specified by the MCCSS will be implemented through DTCs. Practice review is a routine, support-oriented procedure aimed at quality of care verification and improvement. See IHP Guidance Document for process specifics.
1.22	ADVERSE EVENT REVIEWS & AUDITS & REVIEW FOR AUDIOLOGIST COMPETENCY	The IHP is obligated to review instances of possible shortfalls in quality of care for individual children and families, irrespective of how such events come to light. If an adverse event is verified, a case-specific clinical remedy will be sought. Depending on the nature of the event, the service involved may be

		subject to a detailed audit by a DTC, where directed by MCCSS. This may in turn lead to a Continuous Quality Improvement Review for Audiologist competency (Feb 23, 2018 v1)
1.23	INFECTION CONTROL (IC) STANDARDS	Infection control practices are typically governed by site-specific, institutional, or agency protocols and are outside the purview of this document. If local protocols are not available, generally accepted standards must be applied. The guidelines issued by Speech-Language and Audiology Canada (SAC-OAC) in 2010 are a possible source of further information.
1.24	APPROVED TEST ENVIRONMENTS	With the exception of medical/surgical facilities used for ABRA under sedation or general anaesthesia (see 3.24), ABRA test areas must satisfy current ANSI standards for manual puretone audiometry. If deviations from this cannot be avoided, they must be clearly documented. If PHL is suspected in a test area other than a surgical suite that does not satisfy ANSI standards, it must be confirmed at a later date in a test area that meets the standards.
1.25	APPROVED TEST INSTRUMENTATION & SUPPLIES	All instrumentation and supplies used for ABRA must be approved by the MCCSS. ABRA testing must be done using the Vivosonic Integrity with its appropriate corresponding software and hardware. Ancillary equipment for DPOAEs, tympanometry, and acoustic reflex testing must satisfy the functional specifications detailed in the relevant Appendices and must be approved by MCCSS.
1.26	APPROVED DEVICE PROTOCOLS & PARAMETERS	All device protocols and parameters <b>must</b> be configured <b>exactly</b> as specified in relevant Appendices. Departure from specified parameters may compromise ABRA validity or efficiency and will be considered to be out-of-protocol. Setup is recommended to be done by the IHP Audiologist who will conduct the ABRA, with support from a DTC if required. Vivosonic Integrity software and hardware setup may be arranged with the local device supplier (Vivosonic), for new devices.
1.27	CLINICAL RECORDS & DATABASE REPORTING	Clinical records must include the test session listing of records that details the exact order of acquisition of tracings. This information is available in both the Abbreviated and Comprehensive Report printouts within the Integrity software.
1.28	PERSONAL HEALTH INFORMATION	Requirements of the Personal Health Information Protection Act, 2004, S.O. 2004, c. 3, Sched. A must be met. ABRA data files stored on laptops and removable media must not be identifiable. Data communicated for approved monitoring and review procedures must be de-identified and code-referenced.

## SECTION 2: ABRA PRELIMINARIES

	TOPIC	DESCRIPTION
2.01	URGENCY OF ABRA APPOINTMENTS	Timely attendance for ABRA is critical for achievement of international benchmarks for ABRA completion. It is affected by timeliness of screening, appropriateness of messaging to caregivers at screening referral, and the effectiveness of ABRA appointment scheduling, all of which are IHP CQI priorities.
2.02	REQUIRED STATE FOR SUCCESSFUL ABRA	Accurate ABRA threshold measurement is possible only in natural sleep or under general anaesthesia/sedation. Natural sleep is the first choice, except given long-distance travel or prior failure to sleep, when GA/sedation may be indicated. Success at sleep induction and maintenance depends on the child's age, pre-test instruction adherence, test environment, and tester skills. Natural

		sleep is readily achieved in most infants under 3 months corrected age, but becomes increasingly challenging thereafter.
2.03	PRE-TEST BABY STATE	The baby should arrive for ABRA hungry and tired but not asleep. Variable adherence to pre-test instructions was identified by IHP Audiologists as a barrier to timely ABRA completion. More effective processes and stronger messaging about pre-test sleep and testing failure are both essential and feasible.
2.04	TEST ENVIRONMENT & PARTICIPANTS	Test areas should be as conducive as possible to baby sleep and caregiver comfort. Important factors are low sound levels, adequate heating, ventilation, and air conditioning (HVAC), low lighting, good electrical shielding, negligible in-room 60 Hz electrical interference, and effective positioning of the equipment and all persons present. Caregiver presence is preferred and their assistance is often effective, given appropriate instruction.
2.05	TONEPIP STIMULUS PARAMETERS	IHP tonepip parameters of 2-1-2 cycle linear rise/plateau/fall modulation <b>must</b> be used. The accuracy of ABRA thresholds and derived behavioural threshold estimates are specific to these parameters and to all the other parameters and procedures specified in this ABRA protocol (see Appendices E and G).
2.06	STIMULUS CALIBRATION & CHECKING	IHP stimulus transducer calibration settings must be used (Appendix D), with annual electroacoustic checks, daily listening checks, and stimulus verification if non-response occurs at high levels. Poor plug contact or defective leads are common causes of stimulus failure or intermittency. Backup transducers and leads are an obvious precaution.
2.07	STIMULUS TRANSDUCERS	IHP-approved insert and bone conduction transducers are required. Inserts must be used for AC testing. Supra-aural headphones are not supplied as they are not part of the routine protocol. Individual clinics can purchase headphones through Vivosonic at their own discretion. BC transducers may be discretionally hand-held by the audiologist or secured by a tensor band, with appropriate technique and/or instruction (see Appendix F).
2.08	ELECTRODE POSITION	The non-inverting electrode must be on the forehead midline, as high and as close as possible to the hairline. The inverting electrodes must be on each mastoid and the common must be on the forehead, with at least 3 cm between the proximal electrode margins.
2.09	ELECTRODE IMPEDANCES	The target electrode impedances are less than 5 k $\Omega$ . High impedances increase pickup of electromagnetic and movement artifacts. Furthermore, the target electrode impedance differences are less than 1 k $\Omega$ . Different impedances at non-inverting and inverting electrodes degrade the differential amplifier's ability to decrease noise present at both electrode sites, which is the case for many types of large noise. These effects will reduce ABRA accuracy and increase testing time.
2.10	RECORDING CHANNELS	For both AC and BC tonepip ABRA thresholds, two differential recording channels are required. For AC ABR measurements, ensure that only the ipsilateral channel is displayed <b>unless</b> there is a unilateral sensorineural loss, severe or greater, with either normal hearing or a conductive loss in the other ear. This is necessary to ensure that in the case of unilateral SN loss, the responses in the test ear are not due to crossover from the non-test ear. (see example on page 35). For BC ABRA measurements, two channels must be used, with the high-forehead (non-inverting) electrode referenced to each mastoid (inverting) electrode, displaying both ipsilateral and contralateral channels.

2.11	SORTING AND DISPLAYING TRACING FOR PRINTOUT	The clinical sort feature should be used to display the suite of tracings. The compound tracing, its primary waveforms A and B, and A-B (A minus B) make up the suite of tracings. The clinical sort feature groups tracings by descending level with the compound tracing above the A and B primaries, which are separated to improve the ability to follow individual waveforms. A-B (A minus B) should also be displayed for all tracings below the A and B primaries. <b>For every BC ipsi suite of tracings, the contra suite must also be displayed.</b>
------	---	--

### SECTION 3: HIGH-EFFICIENCY ABR THRESHOLD MEASUREMENT

TOPIC	DESCRIPTION	
3.01	TEST EFFICIENCY IS CRUCIAL & FEASIBLE	<b>Efficient IHP ABRA is necessary and achievable.</b> There are techniques which are scientifically valid and proven by experience in other EHDI programs which help. Examples include stronger control of EEG noise and stimulus strategies that improve the speed with which crucial clinical information is acquired.
3.02	OPTIMIZING CLINICAL INFORMATION GAIN	ABRA is a decision art quite unlike routine audiometry in a cooperative adult. <b>In high-quality ABRA, every choice made for the next stimulus condition must be the one that would yield the greatest net clinical impact if the test were to be terminated immediately thereafter.</b> The shift from standardized, rote procedures to adaptively optimizing the rate of information gain under time constraints is challenging, but is a defining feature of true ABR expertise. The following sections address key aspects of test efficiency optimization.
3.03	MANDATORY & DISCRETIONAL PROCEDURES	There are three categories of procedure: mandatory, conditionally mandatory ('conditional') and discretionary. AC ABR thresholds are mandatory at 0.5, 2 and 4 kHz, with 1 kHz conditional. BC ABR is conditional and may be done at 2 kHz and/or 0.5 and 4 kHz, where clinically indicated. DPOAEs are mandatory if part of a conditional sub-protocol for ANSD/retrocochlear lesions and for suspected or confirmed sensorineural HL. They are discretionary for infants whose ABRs show conductive hearing loss or normal hearing. Tympanometry is always mandatory. Acoustic reflexes are discretionary and should be done using either 1 kHz or broad-band noise (BBN) stimuli, the latter being preferable.
3.04	AC & BC TEST FREQUENCIES	The only stimulus conditions for which ABR normative data and clinical experience are available and therefore acceptable for use in the IHP are: Air Conduction: 0.5, 1, 2 and 4 kHz      Bone Conduction: 0.5, 2 and 4 kHz
3.05	MINIMUM ( $S_{MIN}$ ) & MAXIMUM ( $S_{MAX}$ ) TONEPIP LEVELS	Mandatory minima for stimulus levels are: AC $S_{min}$ : 40, 35, 30 and 25 dB nHL at 0.5, 1, 2 and 4 kHz, respectively BC $S_{min}$ : 30 dB nHL at 2 kHz (any age), 25 dB nHL at 4 kHz (any age), 25 dB at 0.5 kHz (under 1 year of age) or 30 dB nHL (over 1 year of age)  These equate to perceptual thresholds of approximately 25 dB HL, reflecting IHP targeted hearing loss of 30 dB HL or more. Current normative data to estimate hearing levels below 30 dB HL with ABR is lacking.  Maximum AC levels ( $S_{max}$ ) are 105, 105, 100 and 95 dB nHL at 0.5, 1, 2 and 4 kHz, respectively; these correspond to about 95 dB HL, for which detailed calculations indicate no known hearing damage risk from tonepip ABRA.

3.06	AMPLIFIER GAIN & KALMAN WEIGHTED AVERAGING	Gain is set to 150,000. Due to the nature of Kalman-weighted averaging, there is no need for an artifact rejection criterion. Large discrepancies between number of stim and noise adjusted sweeps (Neq) means either that there is too much noise and intervention is required, or that the stimulus was paused for part of the collection.
3.07	DIMINISHING RETURNS IN AVERAGING	The efficiency of averaging in terms of signal-to-noise ratio improvement per unit test time decreases rapidly as the number of sweeps increases (see Table in Details and Rationale Section).
3.08	TRACINGS AND THE USE OF A AND B PRIMARIES	<p>In addition to the main waveform ('the compound tracing'), the software also concurrently generates two primary tracings, referred to as "A" and "B", each with half the sweeps of the compound tracing. These two waveforms have the same statistical independence as if they were obtained sequentially and allow the clinician to compare the A and B waveforms without having to replicate the test. The A and B buffering is based on a statistical distribution of the estimated noise between the two concurrently generated waveforms.</p> <p>The compound tracing gives the best overall waveform estimate, whereas the A and B waveforms allow you to assess reproducibility. Do not be misled by inevitable similarity between the tracing and its component waveforms (A and B primaries).</p> <p>An "A-B" (A minus B) tracing is the difference between the two independent waveforms and serves as a Residual Noise estimate. This waveform gives the clinician a visual estimate of the noise in the tracing which can help in determining response absence or presence.</p> <p>If response presence or absence is still not clear, repeating the tracing at that same intensity level is an option. The two tracings can then be added together, and a judgement made on the summated tracing and its primaries. If it is still not clear, consider marking the intensity/frequency INC, and testing at a higher intensity. If the level in question is the upper or lower bracket, obtain a third tracing and compare. The need to collect three tracings at any frequency/intensity should occur only very occasionally. If this occurs regularly, consultation with a DTC is recommended.</p>
3.09	RESPONSE JUDGEMENT CATEGORIES & CRITERIA	<p>In each ear, for any single stimulus route-frequency-level (such as AC 2kHz 60, for example), there will be one or more tracings but <b>only one</b> overall judgement of ABR presence or absence, aided by defined criteria (see the Details and Rationale Section, Topic 3.09). Each stimulus level, not each individual tracing, must have one overall judgement and be annotated with a single label as either 'RP' (Response Positive), 'NR' (No Response), 'TH' (Threshold), or 'INC' (Inconclusive). At each stimulus route-frequency (such as AC 2kHz), TH need only be marked for babies who have elevated thresholds to distinguish between RP during the Search phase and TH for confirmation of threshold estimation. See 3.13 for conversion of ABR thresholds to estimates of perceptual thresholds.</p> <p>When determining TH, only one intensity can be labelled INC between RP and NR. If sequential intensities are judged INC, one must be resolved as either RP or NR with further testing before bracketing can be deemed completed and TH designated. In grossly abnormal ABR, multiple sequential intensities may be designated INC, but it is understood that consequently, thresholds not determined, and TH cannot be used.</p>
3.10	RESIDUAL NOISE (RN) LEVELS & 'NO	The RN is the standard deviation of EEG noise in the accumulating tracing so far. It generally decreases as the sweep count increases - doubling the number

	RESPONSE' (NR) JUDGEMENTS	of quiet sweeps reduces RN by about 30%. Identifying a small ABR near threshold requires an RN of no more than about 20 nanovolts (nV) or 0.020 $\mu$ V. Low RN is an indicator of acceptable averaged noise but <b>subjective flatness of the tracing is essential for any NR decision.</b>
3.11	ACTUAL VS ADJUSTED NUMBER OF SWEEPS	All sweeps are generally included in the compound tracing. If a group of sweeps is very noisy (high noise, low SNR) then it is weighted less and more sweeps are required for these to have as much weight as a quiet group of sweeps in the waveform. This creates a discrepancy between the actual number of sweeps and the number of noise adjusted sweeps.
3.12	TONEPIP ABR THRESHOLD DEFINITION	Threshold is defined by upper (TH) and lower (NR) bracket stimulus levels separated by 10 dB or less; the upper bracket is the threshold in dB nHL. In cases of an INC response, the upper and lower brackets may be separated by as much as 20 dB HL. This large step size is why the use of INC between RP and NR should be relatively rare. An RP at an Smin or an NR at an Smax levels yield threshold ranges of $\leq$ Smin or $>$ Smax, respectively, not unique threshold values.
3.13	ESTIMATED HEARING LEVELS	Tonepip ABR threshold estimates in dB nHL must be adjusted by the correction factors listed in Appendix G, in order to derive threshold estimates in dB eHL. The core of ABRA is the estimation of key puretone hearing thresholds in dB HL. This is based on determination of tonepip ABR threshold estimates in dB nHL, followed by adjustments that are based on known, normative statistical relationships between tonepip ABR and VRA-based behavioural thresholds.
3.14	THRESHOLD SEARCH & BRACKET PHASES	For each air conduction tonepip threshold frequency, there is a Search phase that gets to the threshold region as quickly as possible and a Bracket phase that focusses on accuracy of response decisions. The 2 kHz Search starts at the Smin value and ascends <b>in large steps</b> (30 dB) to find an RP quickly and use its morphology and latency as a detection guide for any lower levels. Descent step size after a 30 dB ascent depends on the RP clarity and speed of emergence. The 4kHz Search starts at 10 dB above 2kHz TH. The 0.5 kHz search starts discretionally at 50 dB nHL or at the Smin. <b>Multiple, inconclusive tracings at the starting level should always be avoided in the Search phase. Go up in intensity instead.</b>
3.15	NUMBER OF SWEEPS & TRACINGS	Each compound tracing should contain between ~2000 to~4000 adjusted sweeps (i.e. A, and B primaries with ~1000 to~2000 adjusted sweeps). ABRA is a balance between accuracy and efficiency. Where accuracy is paramount (e.g. upper and lower brackets, and minimum levels (Smin)), the sweep count should be at the higher end (i.e. ~4000). In the Search phase efficiency is paramount and so the sweep count is often in the lower range (~2000). Tracings with as few as 1000 adjusted sweeps (~500 in primaries A and B) showing a clear RP may be used in the Search phase.  A tracing with an RN under 0.020 $\mu$ V that is subjectively flat provides the lower bracket for an NR conclusion. If the candidate upper bracket is inconclusive, increasing the intensity is recommended (see section 3.17).
3.16	SUMMING COMPOUND TRACINGS	Two compound tracings at the same frequency intensity may be added together to make one tracing (SUM tracing). The handle will indicate which two tracings have been added to make the SUM tracing. This tool is useful for resolving INC tracings, and for converting a search-phase tracing into a lower or upper bracket tracing.
3.17	THRESHOLD BRACKET STEP SIZE	The threshold bracket size is 10 dB until all mandatory frequencies by AC and BC are completed bilaterally. Once these are completed, brackets of 5 dB may

		be done with priority placed on levels above 70 dB eHL. Brackets of 5 dB are never mandatory though they are preferred in some circumstances.
3.18	CONFIRMATION OF UPPER BRACKET RESPONSE	If there is any doubt at all about ABR positivity at a candidate upper bracket level after obtaining the ~4000 adjusted sweeps tracing (~2000 in A and B primaries) go up 20 dB, for rapid response confirmation and latency guidance, rather than simply doing more tracings at the questionable bracket level.
3.19	STRATEGY OF STIMULUS FREQUENCY & ROUTE	<p>The top priority is to determine 2 kHz hearing loss presence, severity and type, in each ear that referred on AABR screening or bypassed it. If AC 2k is Response Positive (<i>RP</i>) at its <i>Smin</i>, test 4k then 0.5k. If AC 2 kHz is No Response (<i>NR</i>) at 80-100 dB nHL, BC 2 kHz should generally be completed next. There can be valid reasons to deviate from this, but these should be noted in the ABR assessment. AC/BC switching is easiest with hand held BC transducer placement.</p> <p><b>Important: Insert transducers need not be removed for BC testing. Occlusion effects are reported to be negligible in young infants at 4, 2, and 0.5 kHz.</b> See the Details and Rationale Section, Topic 3.18, as well as Small &amp; Hu (2011) in Appendix A.</p> <p><b>For bilateral screening referral or screening bypass, optimal strategy requires both AC/BC switching and adaptive ear switching.</b></p>
3.20	BC STIMULUS ARTIFACT	<p>Whenever BC at the 2 kHz <i>Smin</i> is <i>NR</i>, it is useful to go as high as possible to show unequivocal threshold elevation. Stimulus artifact can be a problem especially at 0.5 kHz. Artifact size varies across babies, sites and testers, suggesting effects of technique. Electrode leads should run directly away from BC transducers, as far as possible from its leads and very close together.</p> <p>Very large stimulus artifacts warrant forensic investigation. A DTC consult is appropriate if routine methods of artifact minimization fail. If artifacts are large enough to be seen clearly in the ongoing EEG, they may significantly reduce the number of adjusted sweeps.</p>
3.21	BC RESPONDING COCHLEA INFERENCE	<p>BC testing at 2 kHz is mandatory if AC testing yields No Response at 10 dB or more above the <i>Sin</i>. If AC 4k is the only elevated AC frequency, then 4 kHz BC is conditionally mandatory. If tympanometry results are abnormal and there is only a 10-dB elevation at 500 Hz, BC is discretionary. Each suspect ear must be stimulated individually on the ipsilateral mastoid. Two recording channels must be displayed. In young infants and at near-threshold levels, the responding cochlea has the earlier and usually larger wave <i>V-V'</i>. The latency cue is the more important. If the dominant cochlea is unclear, go down 10 dB (even below the <i>Smin</i>) to try to eliminate response from one channel. If this is unsuccessful, contralateral noise masking is the only other option.</p> <p>Contralateral response dominance results in an inability to infer activation of the ipsilateral cochlea just because there is response in the ipsilateral channel. Such response may be a shadow from the other side.</p>
3.22	BC CONTRALATERAL MASKING	Insert masking with broadband noise at 60 dB is often appropriate for most situations. Comparisons of masked and unmasked records usually give a clear inference about which cochlea is responding. Masking is not routinely used to determine the responding cochlea because it may not be easy to implement, and normative data on ipsi/contra ABR masking effects are limited.
3.23	ELECTROMAGNETIC 60 HZ ARTIFACT & NOTCH FILTERING	Interference from 60 Hz power sources is not unusual and is most problematic for 0.5 kHz testing. It can be recognized by its slow, sinusoidal waveform, with a period of about 17 ms and sometimes obvious presence at the beginning of the tracing. <b>Often, it can be proven present by not delivering the stimulus to</b>



		<p><b>the ear (tube off or tube clamped) while otherwise recording as usual.</b> Check for 60 Hz sources, and that electrode impedance and lead position are appropriate. Use of the notch filter is a last resort if 60 Hz activity cannot be controlled, as may be the case in operating rooms, for example. If 60 Hz-like activity is not eliminated by the notch filter, a no-stimulus run may still be informative. Use of the notch filter must be documented on the ABR printout.</p>
3.24	<p>ABR UNDER GENERAL ANAESTHESIA (GA)</p>	<p>For an ABR assessment collected under general anaesthesia to be accepted for IHP purposes it must meet protocol requirements with the exception of test environment (1.24). Other deviations might be necessary but these must be documented. Additionally, specifically for ABR under GA, the following is required:</p> <ul style="list-style-type: none"> <li>• Documentation that reasonable effort was made to reduce noise</li> <li>• Indication of whether the ABR was done in combination with other medical/surgical procedures. If yes, documentation of what those procedures were, when the ABR was performed in relation to them, and any limitations they may have posed for the interpretation of the ABR.</li> <li>• Documentation of physician’s report of middle ear status if immittance is not performed by the audiologist.</li> <li>• Otoscopy must be performed preferably by the audiologist, immediately before the ABR with documentation of results.</li> </ul>

## SECTION 4: AUDITORY NEUROPATHY SPECTRUM DISORDER (ANSD) SUB-PROTOCOL

	TOPIC	DESCRIPTION
4.01	OVERVIEW	About 8% of infants with PHL have an ANSD component (e.g., Rance & Starr, 2011; Rance, 2005; Sharma et al, 2015). ANSD, conventional outer hair cell sensory hearing loss (SHL), and conductive hearing loss can occur concurrently. The challenge is to identify and disentangle the components and to know when detection of ANSD is not possible. OAEs and Cochlear Microphonics (CMs) are important tools but are not equivalent diagnostically. CM presence does not necessarily rule out SHL or rule in ANSD.
4.02	ANSD SUB-PROTOCOL ENTRY CRITERION	ANSD may be unilateral but is usually bilateral (e.g., Berlin et al, 2010; Roush et al, 2011; Sharma et al, 2015). One necessary condition for ANSD presence is an absent or highly abnormal ABR. <b>The ANSD sub-protocol is ear-specific and must be done in any ear for which there is no clear ABR wave V-V' complex with a wave V latency between 5 and 10 ms at any tested level above 75 dB nHL at 2 kHz, with at least one such level having been tested.</b>
4.03	ANSD SUB-PROTOCOL TIMING	<b>The ANSD sub-protocol usually should be deferred until ABR thresholds with 10 dB bracketing are completed in both ears.</b> Responses at any frequency can inform ANSD interpretation, and ANSD presence may not invalidate all tonepip ABR thresholds. If a second ABRA appointment appears necessary, as is frequently the case, an opportunity to start the second session with OAEs may prove useful and efficient when executing the ANSD click sub-protocol.
4.04	ANSD TEST PROCEDURES	Stimuli are 90 dB nHL clicks at 21.5/s, with a 25 ms data window, a bandwidth of 150 Hz to 2 kHz and plotted full-page-width. The basic data unit is a 4000-sweep tracing, and a tube-off or tube-clamped 1000 to 2000-sweep tracing for each polarity—rarefaction, and condensation—separately. This specific suite of plots is mandatory and often useful to disentangle stimulus artifact, cochlear microphonics (CM), cochlear Summating Potentials (SP) and ABR (see Details and Rationale Section, Topic 4.04).
4.05	INTERPRETATION OF CM/ABR TRACINGS	Click stimulus artifact is identified using tube-off/tube-clamped records <b>with no piece of equipment (including insert earphone), moved at all except for tube-off/clamped.</b> CM is identified by reviewing tracings for R and C clicks overlaid at the first data point ('butterfly' plots) to look for anti-phasic deflections in the 0 to 3 ms range. CM is measured by subtracting R from C (CM tracing), and ABR is measured by adding R and C (ALL tracing). The ALL tracing also allows for identification of any summation potential. Comparing the R tracing to the C tracing reveals stimulus polarity effects on the ABR, which are not infrequent. When this occurs, the ABR/Wave V (if any) should be measured in the better polarity.
4.06	CLICK ABR WAVEFORM & THRESHOLDS	Click ABRs occasionally are detectable when tonepip ABRs are not, likely due to their broader cochlear excitation. If this is seen, it may be useful to track the waveform down to an approximate threshold. Additionally, in the R+C tracing (ALL tracing) there may be obvious Interruption of the wave I to wave V sequence, with clear early neural waves and delayed or absent wave V. This may reflect a retrocochlear lesion that may not be ANSD. Also, there may be marked differences between the R and the C

		<p>tracings, with V-V' much clearer for one polarity than the other. The R and C records may even appear to be antiphase in the region from 1.5 to 10 ms. In all of these situations, approximate click thresholds may be useful but interpretation may be very challenging and consultation with a DTC is strongly recommended.</p>
4.07	DPOAE ROLE	<p><b>DPOAE measurement is mandatory both when sensorineural HL is suspected or confirmed, and within the ANSD sub-protocol.</b> Normal DPOAE signal-to-noise ratios (SNRs) indicate functioning OHCs and are part of a test battery approach. Present DPOAEs and absent ABR are definitive for ANSD. Definite DPOAE presence at <i>any</i> frequency in the set [2, 3, 4 kHz] implies that a click ABR should be present. If the tympanogram is normal, repeatably absent DPOAEs at 2, 3 and 4 kHz nominal F2 values are consistent with ABR threshold elevation due to OHC dysfunction. If tympanograms are flat, absent DPOAEs are not interpretable, and may have little or no value for differential diagnosis of conventional SHL and ANSD components.</p>
4.08	ACOUSTIC REFLEX (AR) ROLE	<p><b>Acoustic reflex testing is now always discretionary in ABRA.</b> The clinical value of ARs in the context of the detailed ABRA and ANSD protocols is limited. If ARs are done, they are best done with broad-band stimuli, for which ARs are usually the clearest and most likely to be elicited.</p>
4.09	ANSD OUTCOME CATEGORIES	<p>World Health Organization (WHO)-aligned clinical outcome categories are 'Not Suspected', 'Probable', and 'Definite' for an ANSD component, based mainly on quantitative comparison of sensory (OAE/CM) and neural (ABR) measures. Key parameters are CM amplitude, ABR V-V' amplitude and their ratio. The larger the CM or the ratio is, the greater the likelihood of an ANSD component. See the tabulated criteria in the Details and Rationale Section.</p>
4.10	CONDUCTIVE COMPONENTS IN ANSD	<p>Even a slight conductive loss may reduce or abolish DPOAEs; this can lead to missing ANSD. Mid-frequency CHL of 20 dB or more may abolish even the CM at 90 dB nHL, rendering some ANSD undetectable due to the lack of OHC/IHC measures to compare to the ABR. Current recourse when substantial CHL is present is presumptive diagnosis and management as a conventional, possibly mixed loss, with prompt VRA follow-up. Deferral of intervention for several months until VRA is not acceptable, given the low probability of ANSD relative to that of severe/profound SHL. Consideration of etiology of the loss, when known, informs this issue as well. Consult a DTC as needed.</p>
4.11	DTC CONSULTS & ADDITIONAL TESTS	<p><b>It is required that in all cases for which ANSD is considered to be Definite or Probable,</b> the DTC for that region be notified by the Audiologist as soon as they suspect ANSD. Moreover, if there are challenges disentangling sensory and neural components or in determining the ANSD outcome category, consultation with a DTC is strongly recommended. Additional testing may be specified, to be done either by the referring Audiologist or at the DTC. Such testing may include very high stimulus rates and additional manipulations of tracings, to clarify interpretation of records.</p>
4.12	EARLY MANAGEMENT	<p>For definite or probable ANSD, tonepip and click ABR thresholds are either indeterminate or may overestimate true thresholds, but they can still give useful upper bounds for perceptual thresholds. If the baby's age and behaviour permit it, repeat ABRA after 4-8 weeks may be informative. More typical is to wait for prompt VRA at about 6 months of age, to clarify thresholds and inform interventions.</p>

		Key points about ANSD and sources of valid information must be identified. Hearing loss and speech perception deficits vary widely. Most affected children experience significant speech perception deficits in noise. Amplification is beneficial in at least half of cases, as are CIs in others. Both interventions require establishment of reliable behavioural thresholds prior to proceeding (see IHP Provision of Amplification Protocol). Fluctuating hearing is an occasional finding but is not typical. Improvement in hearing over time is possible but is not well-established.
4.13	ANSD FIELD ENTRY IN THE HEALTHY CHILD DEVELOPMENT-INTEGRATED SYSTEM FOR CHILDREN (HCD-ISCIS) DATABASE	The data system (HCD-ISCIS) allows ANSD categories of 'Not Suspected', 'Probable', and 'Definite'. The last two terms correspond to the preferred clinical wording of 'Probable ANSD component' and 'Definite ANSD component', respectively. Permanent Hearing Loss should be entered as 'Yes'. Hearing threshold estimates, <b>if interpretable</b> , in dB eHL should be entered, even though they are likely to be biased.
4.14	POST-ABRA REFERRALS	Completion of ABRA, including the determination of ANSD outcome categories, is the responsibility of the primary ABRA Audiologist with support by a DTC if needed. When the ABRA is finished, referral to specialized centres other than a DTC is discretionary and is beyond the scope of this protocol.

## SECTION 5: ANCILLARY PROCEDURES

	TOPIC	DESCRIPTION
5.01	DISTORTION PRODUCT OTOACOUSTIC EMISSION (DPOAE) TESTING	<p><b>DPOAEs are mandatory both when sensorineural HL is suspected or confirmed and as part of the ANSD sub-protocol. They are discretionary for infants whose ABRs show conductive HL or normal hearing.</b></p> <p>A DPOAE system that satisfies the collection parameters listed in this protocol shall be used. DPOAEs must be measured for nominal f2s of 1.5, 2, 3 and 4 kHz, in descending frequency order. Measurement of DPOAE above 4 kHz is discretionary. To determine response presence or absence, stimulus levels, DPOAE amplitude, noise levels, reproducibility, and frequency profile are relevant. For a single f2, 'presence' requires 8 dB or more above the noise (SNR) and a test-retest difference of under 5 dB. For two or three adjacent frequencies, SNR of at least 5 dB at each f2 is sufficient.</p> <p>Replicated DPOAE traces are discretionary for cases of sensorineural HL and mandatory for ANSD sub-protocol. Replications should be superimposed and left and right ear traces plotted side by side. The related tables are also required.</p>
5.02	MIDDLE-EAR ANALYSIS: TYMPANOMETRY	<p>Tympanometry is required. Equipment must meet the requirements specified in Appendix I. Supplies will be provided by the IHP lead agency. Tympanometry must be done with a 1 kHz probe for infants under six months corrected age and a 226 Hz probe for older children. It must be repeated if not clearly normal. 1 kHz or 226 Hz tympanograms must be plotted with either a hardcopy or electronic copy retained on file. Compensated peak static immittance criteria are age dependent and are given in the Details and Rationale Section 5.02.</p>
5.03	MIDDLE-EAR ANALYSIS: ACOUSTIC REFLEXES	<p><b>Acoustic Reflex (AR) measurement is now always discretionary.</b> ARs have limited value as a cautionary flag if present when ANSD has been inferred as</p>

Definite or Probable. They also may be contributory if ABR thresholds are poorly defined yet severe hearing loss has been inferred. If measured, ARs must be retained on file as a hard copy or electronic copy.

## PROTOCOL TOPIC DETAILS & RATIONALE

### SECTION 1: THE ONTARIO INFANT HEARING PROGRAM (IHP) SERVICE CONTEXT

#### 1.01 WHAT IS IHP ABRA?

IHP ABR-Based Audiologic Assessment (ABRA) is a detailed, multi-component assessment process for confirmation and characterization of hearing disorders that:

- a. Includes hearing threshold estimation and auditory brainstem pathway function evaluation using the ABR;
- b. Is authorized by the Ministry of Children, Community and Social Services (MCCSS) an IHP Designated Training Centre, (DTC, see below), or an IHP Regional Coordinator; and
- c. Is funded by MCCSS.

In most cases, ABRA will be the first Audiologic Assessment on any given child. Complete ABRA usually requires a single test session, because the baby will sleep for the test and hearing will be found rapidly to be within normal limits. In other cases, such as those for which a hearing loss is found, additional test sessions may be required to complete the ABRA.

#### 1.02 WHO CAN CONDUCT ABRA?

ABRA must be carried out only by persons who:

- a. Are Audiologists registered and in good standing with the College of Audiologists and Speech-Language Pathologists of Ontario (CASLPO);
- b. Are authorized by the MCCSS to conduct ABRA (henceforth 'IHP Audiologist'); and
- c. Have satisfactorily completed IHP-designated training in this protocol and meet all the equipment requirements.

At any given clinical encounter, the designated IHP Audiologist is completely responsible for both the conduct of the testing and the interpretation and reporting of the results. These activities cannot be delegated. CASLPO registered Audiologists who have been approved by MCCSS for ABR training may participate in testing. Where consented, students may attend and participate in the testing as long as their supervisor is present throughout. The presence of any observer must not compromise the effectiveness, efficiency or appropriateness of any aspect of the audiologist's technical activities or interactions with the child and the family.

If an IHP Audiologist authorized for ABRA does not carry out IHP ABRA for a period of six months or more, the IHP Regional Coordinator must advise the MCCSS of the lapse in practice. The MCCSS will contact the appropriate DTCs to notify them of the lapse in practice and will arrange for an assessment phone call to determine need for further training. The DTC and the Audiologist will discuss the Audiologist's clinical context and possible options for re-engaging in ABRA. A plan for conducting ABRA within the IHP will be developed collaboratively. In some instances, the Audiologist may only require performance monitoring and adjustment as needed.

#### 1.03 PROTOCOL ADHERENCE IS A REQUIREMENT

This protocol replaces and overrides all previous IHP documentation relating to ABRA. This protocol is based on extensive review of published evidence, analysis of program outcome data from the IHP and from other programs worldwide and, where necessary, from expert consultations globally. A structured comparison of the Biologic NavPro and Vivosonic Integrity EP systems was conducted prior to the release of the 2018.01 protocol in order to determine what changes, if any, needed to occur when using the Integrity. Every effort to limit the number of protocol changes was made, though some were required due to inherent differences

between the two systems. The protocol is considered to be evidence-based. Its purpose is to promote the highest possible quality of clinical services, as reflected in service effectiveness, equity and cost-efficiency.

Experience indicates that if significant deficiencies in the quality of care do occur, they are usually associated with a clinical error or omission that is in non-conformance with protocol. Therefore, program due diligence requires that protocol adherence be specified, facilitated and monitored. Clinical adverse events that are deemed attributable to protocol non-adherence are not defensible programmatically, in contrast to events that could be deemed unpredictable or idiosyncratic.

#### 1.04 LEGITIMATE DEPARTURE FROM PROTOCOL

---

Special situations may arise in individual cases, wherein departure from procedures specified in this protocol may be judged by the Audiologist to be appropriate and clinically justifiable. It is expected that this will occur occasionally, not routinely. When an Audiologist does elect to depart from protocol, the reason must be documented on the clinical ABR records. The reasoning should be brief but cogent and clinically defensible. The three core issues underlying this requirement are quality of care, program risk management, and the ability of any IHP process of records review to evaluate adherence to protocol. If the departure is documented and reasonable, then the departure would not be considered as a non-adherence event.

#### 1.05 CHANGES TO THE ABRA PROTOCOL

---

Systematic changes to ABRA protocol locally or regionally can only be authorized by MCCSS. Such changes may be prompted by regional or local characteristics or challenges, sometimes affecting specific groups of service recipients. The process for systematic change is led by a regional coordinator. It includes documentation of the proposed change, its rationale and anticipated impact, followed by submission to MCCSS; this may be followed by evaluation, discussion, modification and explicit authorization.

A different type of protocol change process arises if any individual IHP Audiologist has a significant concern regarding a specific protocol element. The first step is to discuss the issue with a DTC Audiologist, to ensure that the element and its rationale are fully understood. This raising of issues is welcomed as a way to resolve misconceptions or miscommunications and, potentially to facilitate protocol improvement.

As already noted, the IHP ABRA protocol is based on comprehensive evidence reviews as well as decades of clinical experience. Many data sources are evaluated on an ongoing basis by the DTCs. This can result in specification of procedures that differ from opinions of individuals or the conclusion of specific published reports. Raising an issue may trigger discussion, re-examination of evidence, and provincial consensus development process, prior to province-wide or region-specific protocol change, if the case for change is substantiated.

The negative effects of unaddressed protocol concerns include misunderstandings, clinical errors, and opinion-driven non-adherence to protocol. Variations in viewpoint are inevitable but raising of concerns gives an opportunity to re-examine procedures and change them where change is justified, or at least render a mandatory element discretionary if the evidence for it is determined to be inadequate. Engaged professionals are a major resource for protocol evolution and improvement.

#### 1.06 TARGET POPULATION

---

The target population for ABRA includes neonates or young infants who:

- a. Refer on the Newborn Hearing Screening (AABR) and/or Hearing Loss Risk Factor Screening on the dried blood spot (cCMV, genetic mutations) or
- b. Bypass screening in accordance with IHP protocol; or
- c. Cannot be tested successfully by behavioural methods, or
- d. Any other child under 6 years authorized for testing by an IHP Coordinator, a DTC or the MCCSS.

## 1.07 TARGET DISORDERS

---

A target disorder is an audiologic phenotype that renders any qualifying child with the disorder a candidate for IHP services. IHP target disorders in the defined target population are:

- a. Permanent hearing loss (PHL) of 30 dB eHL or more at any frequency in the range 0.5 - 4 kHz, in any ear;
- b. Auditory Neuropathy Spectrum Disorder (ANSO);
- c. Retrocochlear disorders that may be detectable using the ABR.

The qualifier 'permanent' embraces most hearing losses caused by disorders of the cochlea or the brainstem auditory pathways. It also includes so-called 'structural' conductive losses, which are associated with abnormalities affecting sound conduction through the external or middle ear structures. The essence of the 'permanent' attribute is that the hearing loss will not resolve spontaneously and, therefore, will confer a sensitivity loss indefinitely in the absence of any intervention.

The IHP target disorder definition is more inclusive than that of many programs internationally, in that unilateral, mild and frequency-specific impairments are included, as well as ANSO and certain retrocochlear disorders such as space-occupying or demyelinating lesions affecting the auditory brainstem neural pathways.

IHP target disorders do not include hearing losses less than 30 dB HL or outside the range 0.5 - 4 kHz. At its core, the IHP is a system of care based on newborn hearing screening and hearing loss risk factor screening and such non-target losses do not satisfy World Health Organization (WHO) criteria for population screening that include proven burden of the disorder, accurate screening and confirmatory tests, effective interventions and acceptable benefit-cost balance. For a review and discussion of the WHO criteria, see Hyde (2011). In principle, a hearing loss may be clinically significant yet not satisfy WHO population screening criteria. Hearing losses designated as 'slight' are an example. However, this protocol addresses ABR-based threshold measurement and there is no good evidence that ABR techniques can quantify hearing loss of less than 30 dB reliably, nor is there any good evidence that current OAE or ABR-based screening tests and protocols could detect such losses with acceptable accuracy. In fact, there is good evidence they cannot do so.

## 1.08 CONDUCTIVE HEARING LOSS (CHL)

---

CHL that is not 'permanent' is not an IHP target disorder. The term 'permanent' is not easy to define operationally and parametrically. It reflects duration of continuous presence of the hearing loss, given usual otologic care. But how long, how constant, and what if 'usual otologic care' is not forthcoming or is ineffective? The simplest approach is to identify scenarios that are classifiable as permanent or not and then cover other scenarios by making them discretionary but guided by defined principles.

First and foremost, the ABRA Audiologist must demonstrate presence of hearing loss of severity and frequency within the target disorder range. If a sensory/neural component is ruled out, primarily by bone conduction ABR, the loss is deemed to be conductive. Absence or complete closure of the external auditory canal automatically confers permanence, but in all other cases, presence of conductive loss must be established audiometrically. If a syndrome that is known to be associated with conductive loss is already documented or is suspected by the Audiologist, the CHL may be presumed to be permanent. The same is true if a non-syndromic anomaly or external or middle-ear structure has been identified or is suspected.

Where there is no sensory/neural hearing loss and a relevant syndrome or anomaly are not suspected, classification of permanence is presumptive and is at the Audiologist's discretion, based mainly on tympanometry and ABR-based thresholds. For example, if the tympanogram using an age-appropriate probe frequency is clinically flat and the ABR threshold elevation is only at 0.5 kHz and less than about 55 dB nHL, it is reasonable to infer that the loss is likely to be attributable to a transient middle-ear disorder. Of course, actual presence of middle-ear fluid usually can only be determined definitively by careful otoscopy in experienced hands.

The significance of the provisional classification of CHL permanence is that the IHP is not a systemic replacement for Ontario's medically-driven Ontario Health Insurance Plan (OHIP) system for pediatric hearing health care but, rather, is complementary to it. The management of middle-ear disorders is a medical/surgical matter that should normally fall under the OHIP system, as should associated diagnostic audiologic assessment. Given the common occurrence of middle-ear disorders in infants, routine inclusion of their audiologic management would overwhelm IHP resources and compromise the quality of care for those who actually do have Permanent Hearing Loss. The usual course of events, given detection at ABRA of minor, conductive hearing loss that is audiologically

suggestive of middle-ear disease and asymptomatic, is to discharge the affected infant from the IHP, with appropriate caregiver information and counselling concerning self-referral to a physician if signs or symptoms of active middle-ear disorder occur. Such discharge does not preclude the infants from re-entering the IHP if and when external audiometric or otologic evidence suggesting a structural conductive or sensory/neural hearing loss component emerges and is confirmed by IHP audiologic assessment.

With discretionary exception of minor, conductive losses isolated at 0.5 kHz and accompanied by a flat tympanogram, detection of clinically significant hearing loss indicates referral to a physician. The criteria for and the timing of such referral are also at the discretion of the Audiologist. One view is that immediate referral of infants with isolated CHL is premature, given that watchful waiting is the usual course. It is also wasteful of valuable medical resources, with little tangible benefit to the child and family. One option is that if the CHL at 0.5 kHz is substantial, wherein it may include a loss at 2 kHz, the infant should be re-tested after a waiting period to allow resolution of the loss. On this view, the 'complete' initial ABRA includes confirmation of CHL stability. A merit of this approach is that CHL obstructs accurate and complete assessment, one reason being that BC ABR thresholds are inherently more variable than air-conduction thresholds. If the CHL has resolved on retest, definitive ABRA is then concluded and an arguably premature medical referral is avoided. In contrast, if the CHL is sustained the more informed medical referral is fully justified.

The length of the wait period is discretionary. If the infant failed newborn screening then that failure could be considered the first detection of loss, shown later to be conductive. If the initial ABRA occurred at say 8 weeks corrected age, then only a four-week delay before retesting could be sufficient to establish CHL presence over a three-month period, consistent with medical guidelines for management of Otitis Media. A longer delay gives more time for disorder resolution, but may result in the infant being both too old for easy ABRA and too young for reliable VRA. For these reasons, the retest interval is at the Audiologist's discretion.

Finally, as for the situation in which there is a conductive overlay on an S/NHL, any CHL is a complicating variable that can decrease the accuracy of ABRA and complicate or prevent effective audiologic management of the infant. This is a longstanding challenge that is not specific to the IHP. The management process in the presence of conductive overlays is at the Audiologist's discretion.

## 1.09 ABRA OBJECTIVES

---

The main objectives of ABRA are to:

- a. Determine the presence or absence of a target disorder;
- b. Quantify hearing loss laterality, component types, severities, and configuration with sufficient accuracy and efficiency to inform and facilitate timely, appropriate provision of IHP intervention services elected by the family;
- c. Achieve a. and b. by three months corrected age where feasible medically; and
- d. Discuss test results with families in such a manner as to facilitate understanding, acceptance and positive engagement to the greatest extent feasible.

Objective d. reflects the fact that accurate and efficient ABRA is ineffective unless it leads to prompt and appropriate action by the family. Therefore, laying the groundwork for successful intervention is considered a key component of ABRA that is primarily the responsibility of the Audiologist conducting the Assessment.

## 1.10 AGE AT START OF INITIAL ABRA

---

With the exception of cCMV and proven meningitis, ABRA must be targeted for six weeks corrected age or within four weeks of hospital discharge to home, for babies whose perinatal hospital stay extends beyond 44 weeks gestational age. A 4-week target minimum allows some time for transient external or middle-ear conditions to resolve, increasing the accuracy and efficiency of IHP ABRA. An 8-week maximum allows sufficient time to complete the ABRA in most cases provided that appropriate appointment scheduling procedures are utilized. It should be noted that corrected age is to be calculated using **37 weeks** as full term.

Assessment initiated by the IHP is always conditional upon the recipient's medical condition being appropriate and stable. The timing just specified refers to the first ABRA appointment attended after discharge from hospital. If the baby's treating physician orders ABR testing before discharge from hospital, whether in natural sleep or under general anaesthesia in the context of a medical/surgical procedure, compliance with such a signed order is at the Audiologist's discretion and is a regional policy matter. It is reasonable to alert the ordering physician to the IHP protocol target and rationale, where feasible. If the order is clearly outside target, billing of the procedure to OHIP should be considered, where feasible. If this ABRA protocol cannot be followed by virtue of



the test context or timing, the test is to be considered out-of-protocol and its relevance to subsequent IHP testing is to be determined in discussion with an IHP DTC.

For ABRA to begin at about six weeks, screening must be completed well before that. In so far as the total delay of the start of intervention is the sum of periods spent in the screening and the ABRA processes, the acute challenges of delivering babies to ABRA in a timely fashion increase the need for extraordinarily efficient and timely ABRA processes. This is especially true for babies who bypass screening and require urgent and priority ABRA (e.g., CMV, meningitis). **Babies with cCMV should be seen as soon as possible (medical condition permitting) and no later than 4 weeks corrected age.**

### 1.11 AGE AT COMPLETE INITIAL ABRA

---

The international performance benchmark is **completion** of the ABRA by three months corrected age; this timeline is typically necessary in order to begin intervention by the key benchmark of six months corrected age, where PHL is found. Examples of 'beginning intervention' include fitting of verified hearing aid(s), or first attendance at an appointment for language development services. It does **not** include purely administrative preparatory steps such as 'enrolment' in intervention. **In accordance with the benchmark, IHP ABRA is targeted to be completed at or before three months corrected age.**

Timely completion of ABRA in turn depends on timely screening and referral. Because the majority of babies referred from physiological **hearing** screening will not have a target hearing loss, ABRA typically will be completed in one session and the three month benchmark is relatively achievable. Babies who refer on the hearing loss **risk factor** screening on the dried blood spot will be much more likely to have permanent hearing loss. When sensory/neural hearing loss is present, and particularly if there is concurrent conductive loss, several appointments may be required to complete the ABRA and these must also fall inside the three month completion target. It is these cases to which the three-month benchmark most critically applies, not just to the majority of referrals who have hearing within normal limits. This means that the timing of screening referral and initial ABRA generally must be such as to accommodate the delays inherent in booking of one or even two follow-up ABRA sessions.

**The entire scientific rationale and justification for population newborn hearing screening and risk factor screening is based on achievement of these benchmarks.** Every month of delay beyond the benchmark for ABRA completion reduces the potential benefit of screening, as the age at identification of hearing loss increases towards what would have occurred typically in the absence of population screening.

It is the responsibility of the Regional Lead Agency to develop and implement processes that enable the achievement of the timeline benchmarks to the fullest possible extent. It is the challenge of each IHP Audiologist to take all reasonable steps within her or his control to facilitate the earliest possible access to ABRA appointments. Key performance indicators would be the percentiles of babies whose ABRA was completed by three months corrected age, computed separately for three groups of babies: those who bypass screening (see later), AABR refers at risk and AABR refers not at risk. A plausible criterion for excellence would be 90%.

Other important factors include rapidly decreasing likelihood of accurate and complete testing as well as rapidly increasing costs as babies grow older. Babies under about two months sleep a lot and are usually easy to test accurately and quickly, whereas babies over four months can be difficult or even impossible to test in natural sleep. If PHL is present, several test sessions may be needed and cumulative delays compound the difficulty and cost of an adequate assessment.

### 1.12 SCREENING BYPASS IN VERY HIGH RISK BABIES

---

There are several reasons why babies with certain, specific indicators of very high PHL risk should bypass newborn screening and be routed directly to ABRA. One basic principle is that screening becomes less and less appropriate, the higher the *a priori* likelihood of PHL presence; current screening technology has substantial false-negative rates due to multiple sources of random error and, furthermore, AABR screening with broad-band transient sounds (clicks or chirps) is not sensitive to hearing loss in restricted frequency regions of the cochlea. Another concern is that screening is a discrete event that can miss emergent or progressive PHL, especially in babies at substantial risk for deterioration in auditory system structure and/or function following an identified environmental insult (such as certain *in utero* or neonatal infections). A fourth concern is that passing a screen is likely to reduce a family's vigilance with respect to late onset or progressive hearing loss, yet the likelihood of the latter increases in babies at very high risk of PHL, even if hearing were normal or near normal at the screen.

Since 2019, babies who are identified promptly with either:

- a. **Confirmed meningitis, irrespective of the pathogen (viral, bacterial, fungal);**
- b. **Confirmed Congenital Cytomegalovirus (cCMV) Infection;**
- c. **Unilateral or bilateral congenital aural atresia or meatal stenosis such that an ear insert cannot be placed easily; or**
- d. **CHARGE Syndrome.**
- e. **Positive result on hearing loss risk factor screening (positive genetic mutation, positive cCMV)**

will bypass IHP UNHS in accordance with the current IHP Screening Protocol. Such babies will receive a series of audiologic assessments beginning with ABRA, with timing according to risk-specific IHP Surveillance schedules.

In serologically confirmed meningitis, the common belief that only bacterial meningitis is a genuine risk indicator for PHL *per se* is not well-proven. Issues in meningitis risk include the time of onset of PHL and its progression. In bacterial meningitis, there is also risk of ossification of the cochlea that may compromise cochlear implantation. ABRA must be done as soon as is medically practicable following recovery from the acute phase of the illness, but in accord with the timelines stated earlier. Detection of any sensory/neural abnormality indicates referral to a Cochlear Implant program.

If meningitis is suspected but confirmatory information is not accessible, screening is discretionary. The decision to do ABRA or to defer to later VRA is also discretionary and must be evaluated on a case-by-case basis. The conservative approach of routing to immediate ABRA has little downside, compared with the potential harm of missing an emergent PHL for several months. If a treating physician sees fit to refer the baby for ABRA on the basis of presumptive meningitis, the baby is at risk due to the physician determination itself and the ABRA should be done as soon as medical status permits.

Confirmed congenital CMV (cCMV) infection should be treated equivalently, with initial ABRA as soon as is medically feasible and appropriate. Issues are the high probability of both congenital and late-onset PHL, as well as frequent comorbidities that may complicate or prevent later behavioural testing. Initial ABRA should be done as soon as possible.

When there is an obvious, clearly recognisable anatomic anomaly of the external ear canal such as unilateral or bilateral congenital aural atresia or meatal stenosis, screening bypass is necessary because the probe tip cannot be inserted. The intent is to avoid inappropriate or persistently ineffective attempts to place a probe in a clearly absent or restricted ear canal entrance. Essentially, it is the occurrence of the obvious anatomical anomaly that triggers the screening bypass, not the success or failure of heroic efforts to insert the eartip.

Any baby who has a malformation **of one or both ears** such that successful insert earphone placement for screening appears unlikely should bypass screening and be routed directly to ABRA. In the presence of a unilateral obvious anomaly, covert or invisible anomaly in the other ear is plausible and, in any case, initial ABRA is always an assessment of both ears. Screening of the unaffected ear is permitted.

In any atretic or otherwise grossly malformed ear, the usual issue is primarily cochlear status. Therefore, bone conduction testing on the affected side is necessary, and if the ear permits, insert phone testing is optional once everything else is completed. There is no intensive follow-up sequence, only normal, clinical follow-up contingent upon the initial ABRA findings and typically including VRA as soon as it is likely to be viable with attempts to assess air conduction. Follow-up with special programs for infants with congenital ear malformations is recommended where such programs are accessible. Management options should be discussed with the family to support informed decision making.

If a baby has a positive result for a genetic mutation on the hearing loss risk factor screening hearing screening bypass and direct referral for timely ABRA is warranted.

While AABR screening can occur after 34 weeks gestational age, ABRA itself should not be initiated by the IHP before about 40 weeks gestational age (GA) because neurodevelopmental immaturity can cause ABR interpretive difficulty, inaccuracy and inefficiency. ABRA at less than 40 weeks is contraindicated except when it is ordered by a treating physician as part of medical management, such as for differential diagnosis for CHARGE syndrome.

Irrespective of satisfying the gestational age criterion, ABRA within about a week of birth may be prone to errors associated with transient perinatal conductive hearing loss due to unresolved debris or fluid in the external or middle ear. As noted in Section 1.10, the preferred age at initial ABRA is six weeks corrected age except in the case of cCMV and proven meningitis.

### 1.13 IHP DESIGNATED TRAINING CENTRES (DTC)

---

Three DTCs support the IHP Audiologists and report directly to the MCCSS: the Audiology Department at CHEO (Ottawa), the Audiology Department at HRH (Toronto), and Western University's National Centre for Audiology (London). CHEO and HRH are the DTCs for ABRA and are responsible for matters relating to this protocol.

The DTCs support activities including evidence review, technology assessment, protocol development and support, clinical decision support, outcome measurement, and various aspects of Quality Assurance and Continuous Quality Improvement (CQI), including Audiologist training, IHP standard practice reviews, and adverse event audits.

The need for ABRA training are identified to MCCSS by IHP Regional Coordinators as they arise. **Due to the complexities around testing infants, it is preferred that potential Audiologists who are interested in working in IHP have at least 1 year of past paediatric experience. If this pre-requisite is not met then either a minimum of 3 years of clinical experience, or a work place with direct support from another IHP audiologist in good standing is recommended.** If approved, MCCSS will determine the priority of the training and arrange its scheduling with the DTC.

ABRA training includes two parts. The first is a three-day in person hands-on course, involving technical tutorials, clinical observation, familiarization with instrumentation, hands-on testing of at least four babies, in-depth discussion of results, and rapid, intensive chart reviews. The second part involves monitoring and mentoring the trainee at a distance. This includes monitoring all of the trainee's clinical results in the field, prior to their release, until procedures and interpretations are considered satisfactory by the DTC expert. The monitoring phase of training typically lasts 6 to 12 months, and the training is not considered successfully completed until after this process. It is expected that trainees will be engaged in their clinical practice within two weeks of completing the hands-on training component.

Refresher training may be requested by any IHP Audiologist at any time, through their IHP Regional Coordinator and MCCSS.

### 1.14 ABRA PROTOCOL SUPPORT BY DTCS

---

This protocol includes several changes from the 2016 protocol based on the transition to different ABRA equipment. IHP Audiologists providing ABRA services are strongly encouraged to contact a DTC directly if they have a question or concern about any aspects of the protocol. While peer-to-peer consultation is sometimes helpful, the response of a DTC is definitive. Furthermore, by discussion with Audiologists in the field, the DTC is able to develop awareness of protocol areas that may require clarification or modification for all IHP Audiologists. All interactions with a DTC are confidential.

### 1.15 DTC CONSULTATION OR REFERRAL

---

Even the most skilled ABRA Audiologists may be confronted by difficult challenges of procedure, interpretation or next-step planning. There are many aspects of ABRA for which the underlying scientific evidence is lacking or for which expert consensus is incomplete. In many respects, ABRA is in part evidence-based and in part a clinical art. Clinical decision support from DTCs is not about what is right or wrong or about evaluating the Audiologist – it is about information transfer, two heads being better than one and how to do the best job delivering services for the infant.

Challenges often arise in situations that involve, for example, an ANSD component or mixed conductive/cochlear hearing losses. It is recommended that such cases be referred promptly to a DTC if there is any difficulty of procedure or uncertainty in interpretation (see Appendix B). Some problems in repeated testing and some referrals may be avoided easily by discussion of initial results with a DTC.

ABRA support has been provided by CHEO since January 1, 2015 and by HRH since August 1, 2017. The support may involve answering questions about procedure, protocol or interpretation, discussing a concern or challenge, commenting on next steps in a

current case or arranging a referral for further ABRA at the DTC. Real-time support during actual ABRA testing is currently impractical. While every effort is made to provide prompt feedback, it is helpful if support requests are timed such that the need for DTC response within three business days.

The preferred contact method is email. Clinical records for review should be sent electronically. Faxes are no longer accepted. All records **must** be de-identified and assigned a unique alphanumeric ID to facilitate DTC record-keeping and referencing.

Audiologists may sometimes wish to initiate a consultative referral for ABRA at a DTC. Reasons for this may include inconsistent results, records that are difficult to interpret or persistent challenges achieving a satisfactory test. Alternatively, the Audiologist may wish to procure testing under general anaesthesia/sedation. After discussion and reviewing case materials to date, where appropriate the DTC first may elect to attempt testing in natural sleep, which may be more practicable in a DTC context with additional in-house supports.

When an infant is referred to a DTC for ABRA, the report from the DTC is sent to the referring Audiologist. The DTC acts as an expert laboratory or clinic providing a service to the referring Audiologist, who typically will retain responsibility for further case management on a local basis.

There may be a perceived conflict when a DTC is involved in both clinical decision support and some aspects of CQI that include routine IHP review of Audiologists' records. Audiologists are hereby assured that any specific case raised for discussion with a DTC for decision support will not be included or referenced specifically in any CQI or audit activity involving that Audiologist and the DTC.

## 1.16 TIMELINESS OF ABRA COMPLETION

---

A significant challenge is that completion of ABRA often does not occur in the timely manner defined by international benchmarks for EHDI programs. The two usual ways of quantifying timeliness are age at completion of ABRA and the time interval between referral to ABRA and its completion. Absolute age at completion is clearly dependent on age at referral from AABR screening and age at the first ABRA appointment attended. Timely referral is always a matter of importance. Delay between referral and first appointment attended depends upon the efficiency of both referral generation and ABRA appointment booking by audiology facilities. Both of these elements are also CQI priorities.

It is presumed here that ABRA scheduling tactics such as reserved 'emergency' appointments, pre-linked appointment pairs that allow rapid follow-up to complete unfinished ABRA's, and age-driven appointment priority are routinely practiced by IHP audiology facilities that offer ABRA services. Excellent testing quality is of limited value if timely access is undermined by suboptimal appointment scheduling.

This protocol item addresses the duration of initial ABRA, the time from the first assessment appointment attended through to the point of completion. Two obvious causes of delay are inadequate test conditions and audiologic complexity. The situation of interest here is one of little useful clinical information having been obtained after several ABRA attendances. Common causes include the baby being too old to sleep readily, developmental and/or behavioural factors, mismatch of appointment timing and diurnal sleep patterns, caregiver non-adherence to pre-test instructions, ineffective sleep induction techniques and inefficient testing strategy. The over-riding imperative is that ineffective testing cannot simply be repeated indefinitely - something has to be changed.

Babies who refer on AABR screening bilaterally are especially compromised if testing is not timely. In such babies, if the ABRA is **not** completed within two attended sessions, the Audiologist's options depend on the specific causes of non-completion. If the primary cause is audiologic complexity or difficulty with response identification or interpretation, a DTC must be consulted promptly. If the primary cause is insufficient sleep time or nonadherence to pretest instruction, the Audiologist should either arrange ABRA under sedation at a local facility (if available) or consult/refer to a DTC, which may also result in testing under sedation. Deferral to later VRA-based assessment is the least desirable option, acceptable only if the baby would be over four months corrected age at the date of the earliest available appointment for sedated ABRA **and** there is no clear contraindication to successful VRA at six months of age.

Babies with difficult-to-complete ABRA must be discussed with the Regional Coordinator. Every IHP Audiologist and Regional Coordinator must be familiar with the MCCSS policy document relating to DTC referral (see Appendix B) and must have in place a well-defined process for securing testing under sedation, wherever feasible. Testing under sedation must be done by an IHP Audiologist who is authorized for ABRA and in accordance with this protocol to the fullest extent possible.

A 'substantially completed' ABRA means that enough information has been obtained within the two sessions attended to determine whether there is a need for prompt management and to define at least approximate amplification requirements, where amplification is indicated and elected.

### 1.17 PARENT/GAURDIAN-DRIVEN SECOND OPINION

---

Routine repetition of ABRA is not authorized by the IHP. Occasionally, after the results of the initial ABRA are explained the caregiver may express a strong wish for a second opinion, which may include repeating the ABRA (see IHP Guidance Document). There are several possible reasons, including poor understanding of results, denial of the findings, and lack of confidence in the assessment testing. Any caregiver expressing a strong desire for a second opinion must be informed of their right to have their child's records reviewed by an independent expert at an IHP DTC. If this satisfies the caregiver, the Audiologist may proceed with the review procedure. The DTC will examine the records, discuss them if necessary and issue a review report to the IHP Regional Coordinator with a copy to the Audiologist. If necessary, the DTC may discuss alternative courses of action; occasionally, referral to a DTC for re-assessment may be indicated.

Any family always has a right to seek testing outside of the IHP. The issue that arises and must be explained to the family is that testing over which the IHP has no jurisdiction cannot be assumed to be a valid basis for subsequent receipt of IHP services. That is the situation for ABRA, because of the complex technical and procedural requirements for valid testing, as specified in this protocol.

### 1.18 ABR TESTING OUTSIDE THE IHP

---

ABR testing by individuals who are not specifically authorized by the IHP to conduct ABRA's must be reviewed by a DTC before they can be considered in relation to further audiologic services from the IHP. Authorization to provide VRA or amplification services does not confer authorization to conduct ABRA.

### 1.19 ABRA THAT IS OUT-OF-PROTOCOL

---

ABRA results that are suspected by any IHP Audiologist to be substantively non-adherent to the relevant IHP protocol at the time the results were obtained must be reviewed by a DTC prior to being considered in relation to further audiologic services from the IHP.

### 1.20 CONTINUOUS QUALITY IMPROVEMENT (CQI)

---

Accountability and transparency imperatives oblige the IHP to show that its targets for all major components are achieved and its protocols followed. Therefore, the IHP is implementing more intensive CQI sub-programming for key service areas. These activities are considered to be essential due diligence for program integrity and sustainability, are widely endorsed and are implemented in most leading UNHS-based programs worldwide.

CQI for ABRA has multiple components that are directed towards enabling and supporting Audiologists to deliver the highest possible quality of care to affected children and their families. The key indices of quality are effectiveness, equity and efficiency, which are reflected in the accuracy, completeness, timeliness, and consistency of Assessments.

The CQI components include enhanced training, regularly updated protocols, increased clinical decision support and protocol support, more systematic referral procedures, more intensive process and outcome evaluation, family experience surveys, systematic program practice reviews, and enhanced processes for audit of potential adverse events including continuous quality improvement review for audiologist competency (Feb 23, 2018 v1). Other internet-based quality improvement tools (such as an interactive library of case examples and Question and Answer (Q&A) scenarios) are under consideration by MCCSS.

## 1.21 IHP STANDARD PRACTICE REVIEWS

---

MCCSS is obligated to demonstrate that its protocols in IHP are followed and its objectives are being achieved. To this end, authorization to provide IHP ABRA requires that samples of each Audiologist's clinical records be reviewed periodically as part of the CQI program.

Standard Practice Reviews for ABRA will be carried out by the CHEO and HRH DTCs. All IHP Audiologists providing ABRA services will be reviewed at regular intervals according to a schedule determined by MCCSS. The reviews are intended to be a constructive and helpful mechanism to improve IHP Audiologists' practice. Their burden and obtrusiveness will be minimized. Audiologist feedback on review effectiveness will be sought. A separate document describes this process in more detail.

## 1.22 ADVERSE EVENT REVIEWS & AUDITS & REVIEW FOR AUDIOLOGIST COMPETENCY

---

Adverse Event Reviews (AERs) are completely different from Standard Practice Reviews. They occur as an obligatory program response to specific events or findings that suggest a significant program deficiency. Such events or findings may relate to groups of babies (such as an inference of concern from database process or outcome patterns) or to individual families, such as a concern arising from family complaint, an anomalous pattern of care or a poor outcome. An adverse event review might lead to a review for audiologist competency.

If an AER by a DTC indicates that any specific care recipient is likely to have been significantly disadvantaged as a result of non-adherence to this protocol or any other deficiency of IHP services, an Adverse Event Audit (AEA) may be initiated at the discretion of MCCSS. An AEA is a more rigorous, comprehensive and goal-directed type of AER, the goals of which include full documentation of events, remediation of case-specific disadvantage to the extent possible and implementation of program adjustments as necessary to avoid recurrence.

## 1.23 INFECTION CONTROL (IC) STANDARDS

---

All Assessments must be conducted in full compliance with any and all pertinent standards of the local ABRA facility relating to IC. In the absence of specific facility standards, provincial standards apply (CASLPO, 2010). The IHP does not presume to specify protocols in relation to IC. It does, however, require that where applicable standards exist locally, regionally or provincially, they must be adhered to rigorously with respect to each and every component of IHP service provision.

## 1.24 APPROVED TEST ENVIRONMENTS

---

**With the exception of medical/surgical facilities used for testing under general anaesthesia**, ABRA must be conducted in an environment complying with current ANSI standards for manual puretone audiometry (ANSI (R2013). American National Standard Maximum Permissible Ambient Noise Levels for Audiometric Test Rooms. ANSI S3.1-1999. New York: Acoustical Society of America.). Any environment considered for ABRA in natural sleep that does not satisfy this ANSI standard must be discussed with a DTC, approved by the MCCSS and be deemed satisfactory with respect to lighting, HVAC, visual distraction, transient and steady-state acoustic noise levels, electromagnetic artifact, and audibility of toneburst ABR stimuli at IHP mandatory minimum levels.

## 1.25 APPROVED TEST INSTRUMENTATION & SUPPLIES

---

All instrumentation and supplies used for ABRA must be approved by the MCCSS. ABRA testing must be done using the Vivosonic Integrity software and hardware. Ancillary equipment for DPOAE, tympanometry, and acoustic reflex testing must satisfy the functional specifications detailed in the Appendices.

## 1.26 APPROVED DEVICE PROTOCOLS & PARAMETERS

---

All device protocols and parameters **must** be configured **exactly** as specified in the Appendices. Any departure from the specified parameters may compromise ABRA validity or efficiency and will be considered to be out-of-protocol. Setup is recommended to be

done by the IHP Audiologist who will conduct the ABRA, with support from a DTC if required. The Integrity system setup may be arranged with the device supplier (Vivosonic) for new devices.

## 1.27 CLINICAL RECORDS & DATABASE REPORTING

---

ABRA records and reports must adhere to the requirements of the IHP, CASLPO, and the Personal Health Information Protection Act (2004). The records must be held securely as hardcopy or electronically in clinical case files. Hardcopy or electronic records must be sufficient to fully specify the subject, tester, test date and location, test parameters, source data (including ABR test tracings, DPOAE graphics and numerics, MEA graphics and numerics), interpretation, and contingent recommendations.

**ABR printouts must include the test session listing of records that details the exact order of acquisition of tracings. This information is available in both the Abbreviated and Comprehensive Report printouts within the Integrity software.**

As part of ABRA CQI, the importance of timely data entry into the HCD-ISCIS database system is imperative. After each ABRA session, Audiologists must complete the HCD-ISCIS report and send it to the regional lead agency within ten business days. If completion of an ABRA requires an additional appointment that can be scheduled within one calendar week, the HCD-ISCIS report may be deferred to include the results from the ensuing Assessment. Holding a pending report for more than two ABRA sessions or ten business days is not acceptable.

## 1.28 PERSONAL HEALTH INFORMATION

---

Management of all personal health information arising from IHP service provision must comply with all current legislation.

Transmission of personally-identifiable health information must have the consent of a family member or authorized caregiver. Individual case information transmitted by email, fax, or hardcopy, such as for IHP training follow-up, IHP internal clinical decision support, Standard Practice Reviews Audits or Audiologist Competency review must be uniquely code-indexed and rendered personally non-identifiable to unauthorized third parties.

ABR and OAE records held in databases on IHP Integrity laptops or archived onto removable media must not be personally identifiable by unauthorized persons. Filenames must comprise numeric or alphanumeric codes; code key lists, necessary for retrieval of cases upon request, must be held securely at a separate location from that of the Integrity system.

# SECTION 2: ABRA PRELIMINARIES

## 2.01 URGENCY OF ABRA APPOINTMENTS

---

Once a baby has referred on AABR screening, or referred to Audiology because of a positive result on the dried blood spot hearing loss risk factor screening or has bypassed screening, the need for timeliness of ABRA from its initiation to its completion cannot be overemphasized. First, there is harm due to caregiver anxiety that accumulates over time. Second, in order to meet international performance benchmarks and gain the greatest benefit from newborn screening, the initial ABRA process must be completed by three months corrected age, wherever this is feasible. This requires an early ABRA start, to allow for additional test sessions that are necessary in many babies who have hearing loss and to accommodate inevitable delays due to unforeseen events such as baby indisposition or competing caregiver demands. Third, as babies get older, natural sleep becomes increasingly challenging to initiate and maintain for the required length of testing. This can lead to incomplete ABRA, reduced test accuracy, inconclusive results and increased program resource consumption, including possible need for testing under sedation. The delay of a few weeks between final AABR referral and the first ABRA appointment is indicated in order to facilitate resolution of transient, perinatal ear conditions, ease of handling the baby and some undisturbed caregiver acclimatization to their new circumstance and daily routines. Despite this strong rationale, achievement of timely entry into ABRA continues to show substantial geographic variation throughout the IHP.

It is essential that the caregiver understands the purpose and importance of prompt assessment. This begins with the AABR hearing screener giving appropriate and timely explanation and messaging, which should be reinforced at every opportunity through the

ABRA appointment booking process. Families must be made aware of the importance of securing the earliest available appointment, the reasons for the pressure of time and the possible consequences of delay, especially the necessity of sleep and its increasing difficulty over time. The key message is that the sooner the test is done, the quicker, easier and more accurate it is likely to be. Families also should be made aware that ABRA appointments are a scarce resource for which many other families are waiting, so (i) they should make every effort to keep the appointment and (ii) if they become aware of inability to attend, they should **immediately** notify the ABRA provider site and rebook as soon as possible (iii) they should follow the pretest instructions to ensure the best possible outcome of testing.

While the timeliness of screening referral and subsequent program administration processes in seeking appointments for ABRA are rate-limiting, there are clear indications that access limitations to timely audiology appointments are an important additional delay factor, the size of which varies geographically throughout Ontario. Factors that are reported to facilitate prompt appointments and high attendance rates include:

- Immediate ABRA booking at the time of AABR referral, wherever feasible. This has long been identified as a standard-of-care practice, eg., by the national Newborn Hearing Screening Program in England.
- Appointment slot filling taking due account of the 4-8 week target dates (i.e., not filling all available slots simply on a first-come, first served basis).
- Maintaining reserved slots for high-priority/urgent appointments.
- Automatic allocation of prompt, linked follow-up slots for rapid ABRA completion in a proportion of primary slots (such as one in five, depending on referral population characteristics).
- Reinforcing key messages at every booking/reminder contact, both in writing and verbally.
- Maintaining a short-notice waiting list to fill late-notified non-attendance.
- Routine two-week and two-day appointment reminders and confirmation requests.

In situations of irremediable limitation of access to timely ABRA appointments, ABRA appointment filling should be done in such a way as to maximize program benefit within existing resource constraints. It is important to minimize the occurrence of late access to ABRA for babies who have the highest likelihood of having PHL, such as those who bypass screening, or who refer on AABR hearing screening, or have a positive result on hearing loss risk factor screening. It is known that the likelihood of PHL is much lower in babies who fail unilaterally, especially if not at risk. Scheduling of ABRA for low-likelihood babies should not saturate available appointments in such a way as to cause late access for babies with high likelihood of PHL. A relatively simple way to do this is to allocate babies into a stream of appointments that has priority levels mixed and tuned according to the observed characteristics of the local, referred population.

## 2.02 REQUIRED STATE FOR SUCCESSFUL ABRA

---

ABR threshold estimation can only be done with acceptable accuracy and efficiency in natural sleep or under general anaesthesia/sedation. Natural sleep is highly preferable and must be tried first unless in exceptional circumstances. Natural sleep is rarely difficult to achieve in babies under about eight weeks of age but it becomes progressively more challenging as age increases, such that testing of babies over about four months of age is often time-consuming and inefficient.

Routinely successful induction of natural sleep in a wide range of babies is an adaptive skill that takes time and experience to acquire. It is important that the test environment be conducive to sleep, so it should be dimly lit, quiet and free from visual distractions or other disturbances. Eye contact, engaging facial expressions and verbal communication should be avoided. Physical restriction, gently rhythmic movement and soothing, simple sounds all may be helpful at the right time. Over-engagement with the baby is best avoided – the more interesting the scenario is, the more wakeful the baby is likely to remain.

Testing under general anaesthesia or sedated sleep may be indicated by:

- A known adverse behavior or medical condition;
- Failure to achieve useful duration of natural sleep at up to two previous appointments;
- Any predisposing factor that renders testing failure unacceptable (such as major access difficulty); or
- A recommendation by a DTC.



## 2.03 PRE-TEST BABY STATE

---

Most ABRA testing facilities in Ontario use testing schedules with targeted appointment start and stop times. A typical duration for a routine ABRA appointment is 1.5-2 hours. In that time, it is usually desirable that the baby sleep for at least half an hour, in which period a baby without PHL can often be confirmed as such. Typically, it is desired that the baby arrives for the appointment hungry and tired, though not overtired. After cursory otoscopy and ABR electrode attachment, the baby can be fed and prepared for sleep. It usually follows that the baby should be neither fed nor allowed to sleep within about an hour prior to the appointment.

It is essential that families understand very clearly that successful ABR testing depends on their following pretest instructions carefully. The real underlying message is to ensure that the family understands that the baby needs to sleep readily for at least half an hour for any useful information to come from the visit. It is helpful to have them understand the importance of using both the IHP's and their valuable time and resources to the best advantage. The strength and explicitness of this message differ according to the test facility's standard procedures, the Audiologists' level of comfort and assertiveness and the specific context. In a group practice or institutional situation in which staff who make family contacts for appointments may vary in their engagement and communication skills, obligatory scripts may be helpful to encourage strong and appropriate messaging.

There are clear indications that the degree to which families adhere to pre-test instructions varies across ABRA test facilities in Ontario. Multiple factors are involved and some of those factors are within the scope of influence of the ABRA Audiologist. The best that reasonably can be done is that families hear and fully understand the message, then make an honest effort to comply with the instructions. The bare minimum process requirement to achieve this is that the messages are very simple, brief, clear, strongly directive and consistent, and are presented repeatedly both written and verbally. Written messages must be formatted effectively.

The formatting clarity required are often underestimated. Examples are:

**DO NOT feed your baby within one hour before the appointment time, unless it is necessary medically!**

You will be feeding your baby at the beginning of the test.

**DO NOT let your baby sleep within one hour of the appointment time!**

Your baby **MUST** sleep during the test or it will not be successful.

**If you are driving OR bringing other children as well as your baby, it is preferable that someone come with you.**

You cannot keep your baby awake properly while driving or looking after other children by yourself!

In verbal contacts, identical messages and wording are required, preferably followed by reinforcement and verification that the messages are understood – not, of course, by simply asking 'do you understand?!'

## 2.04 TEST ENVIRONMENT & PARTICIPANTS

---

The infant's safety and comfort are paramount and the infant must be monitored continuously. It is strongly recommended that the tester and ABR/OAE instrumentation be inside the soundroom with the infant. If the Audiologist is not in the soundroom with the infant, this should be clearly documented. Requirements for approved test facilities were noted previously in Section 1.24. The optimal test environment for ABRA is an audiometric soundroom that is electrically shielded. Soundrooms that are not shielded can be acceptable electrically if they are not adjacent to strong sources of electromagnetic (E/M) fields, such as heavy electrical equipment, elevators, HVAC motors, diathermy equipment, large scanners, etc. If a soundroom is shielded, then for optimal effectiveness against external fields, shield continuity (e.g., window mesh) and good grounding are important. Regardless of such shielding, AC mains power cable routing within the soundroom must be appropriately encased in grounded metal conduit and, to the extent possible, outlets that are unused should have metal cover plates.

HVAC is important, especially for infant comfort, sleep promotion and stable electrode-skin attachment (which is affected by sweating). Lighting control is important for sleep promotion; battery-powered LED task lighting is optimal with respect to power line interference. Fluorescent bulbs and tubes are the least desirable option, giving limited control and high likelihood of electromagnetic interference at 60 Hz and its higher harmonics.

Presence in the test room of the baby's caregiver is common practice and is recommended but discretionary. The majority of initial ABRA in the IHP is done with the baby, caregiver and Audiologist inside the test room. In some cases, the Audiologist tests the baby

alone, which requires special attention to optimal positioning of the equipment, baby, cot or bassinet and tester. If special assistance is required, additional personnel such as a nurse, second Audiologist or other assistant may be required.

As is to be expected, caregivers vary in their knowledge of the most appropriate techniques to encourage an infant to sleep, and instruction may be needed to optimize their effectiveness in assisting ABRA. It is not reasonable to expect a lay individual to possess the understanding and skills that may be gained from testing hundreds or even thousands of babies. However, caregiver engagement with the ABRA process can contribute substantially to understanding of test results, the building of trust and the creation of a communicative relationship with the Audiologist that may prove crucial in subsequent management, should the baby be proven to have PHL.

If a caregiver is present during the testing, it is important that the Audiologist pay special attention to appropriate communication of information as the test proceeds. Surveys of caregiver experience with diagnostic assessments in other programs indicate that caregiver satisfaction is often less than ideal, most frequently as a result of not being kept at least minimally informed about what is going on. At the start of the visit it is important to provide some key information about the testing session to the caregiver. In particular, it is helpful to explain first that for all ABRs regardless of outcome it is typical for the audiologist to look intently at the computer screen and at the baby, and to make adjustments to leads, the insert, other pieces of equipment and to the position of the baby. Secondly, that the test can be quite long due to many factors, and that the audiologist cannot easily predict how long the test will take. Thirdly, and most importantly, that the audiologist will explain the results at the end of the test, unless review by a DTC is required, so the family will not have to wait for example for the results to go to the baby's physician. A running commentary by the Audiologist is neither appropriate nor practicable, given the technical demands of ABRA, but reasonably frequent, brief explanations of what is being done can alleviate the caregiver's sense of being 'kept in the dark' and lacking control. Discretion and good judgement in communication are essential if the Audiologist is facing what appears to be a baby with major PHL. However, in that situation, some of the groundwork for imparting difficult news and encouraging acceptance and positive engagement can begin. One way of viewing this is that the process of intervention begins with the process of diagnosis, though some would argue that it really begins during the process of screening.

## 2.05 TONEPIP STIMULUS PARAMETERS

---

IHP ABR testing must be done using the Vivosonic Integrity system. ABR application software in current use is the Vivosonic Integrity 8.8.1.2. All application test protocol and parameter files must be configured exactly to IHP specifications (see Appendices).

The core of ABRA is estimation of hearing thresholds using tonepip ABR methods. The accuracy of the threshold estimates depends upon many details of the stimulation and recording methods specified in this protocol. Part of the estimation process involved re-analysis of normative data on the relationship between ABR thresholds and subsequent behavioural thresholds obtained by VRA that were obtained by Stapells and his colleagues. The re-analysis involved switching dependent and independent variables, variable range restriction and censoring in linear and quadratic regression, use of nonparametric methods and data transformations. The results of this underlie the numeric bias adjustment factors ('correction factors') that are used to convert ABR thresholds in dB nHL to estimates of perceptual thresholds in dB HL. These values were validated through a chart review conducted by the Western DTC in collaboration with four IHP ABRA sites. Comparison of ABR threshold estimates to VRA thresholds using the nHL to eHL corrections from the ABRA Protocol 2016.02 indicated close agreement. Therefore, the current ABR correction factors provide a good prediction of perceptual thresholds infants with normal hearing and hearing loss.

Furthermore, as part of an evaluation of the Vivosonic Integrity, it was determined that with calibration and collection parameters outlined in this protocol, threshold estimates were similar to the Biologic NavPro. Therefore, no further correction to the ABR threshold estimates are needed when using the Integrity with the current protocol.

**The correction factors used in this protocol are specific to the stimulus parameters, recording and analysis techniques described in this document. Use of any other types of stimuli, including Blackman tonepip envelopes and changes in nominal tonepip frequency, or changes in any of several specific aspects of ABR recording and analysis (such as averaging strategy or Residual Noise criteria) will render the threshold estimation process invalid and of unknown bias and precision. Conversely, the correction factors used here cannot be assumed to be valid for stimulation and recording methods that differ from those specified in this protocol.**

This protocol specifies the use of constant correction factor values for an ABR threshold range from 25 to about 105 dB nHL. These correction factors do not apply for ABR thresholds less than the Smin specified for each test frequency. There is also a tendency for differences between ABR and VRA thresholds to decrease at high dB nHL values; this effect is to be expected from the known characteristics of auditory single-unit tuning curves in individuals with various degrees of conventional sensory hearing loss. However, the effect is small in terms of estimated behavioural threshold accuracy and is offset by the use of 5 dB steps in bracketing of high ABR thresholds.

It should be noted that the IHP tonepip stimuli are specified to have trapezoidal envelopes with linear rise and fall; the rise, plateau and fall times are 2-1-2 cycles. Such stimuli may not be optimal for ABR elicitation; for example, the net energy-equivalent duration of the 4 kHz stimulus is only about 0.6 ms, whereas the wave V stimulus energy integration time for maximum amplitude is probably at least 2 ms. Conversely, the 0.5 kHz stimulus 4 ms rise time is arguably too long. However, the original choice of cycle-based tonepip envelope was dictated by the availability of high-quality normative data for these particular stimuli and the wealth of clinical and research experience gained with these stimuli has cemented the rationale for their continued use.

## 2.06 STIMULUS CALIBRATION & CHECKING

---

Manufacturer's default calibration files for ABR stimuli must not be used, because their experimental and psychophysical basis is not available for evaluation. The calibrations to be used are detailed in Appendix D. ABRA tonepip and click stimuli must be calibrated electro-acoustically, annually. Listening checks for air and bone transducer malfunction or intermittency in leads and connections must be done at least at the start of each day's testing. A backup insert and bone-conduction transducer, as well as spare leads, are recommended.

In the course of clinical testing, immediate stimulus checks must be done whenever ABR absence is seen unexpectedly or is seen at the maximum level used for any stimulus type and route. The most common cause of stimulus insufficiency is eartip blockage.

## 2.07 STIMULUS TRANSDUCERS

---

All stimulus transducers must be of the type specified by the IHP. Where inserts are contraindicated anatomically, BC is the recommended choice in order to confirm the status of the inner ear. The use of supra-aural earphones is discretionary.

For BC ABR testing in infants, transcranial sound transmission losses can vary across infants from about 5 to 30 dB (Yang & Stuart, 1990). Therefore, each ear must be tested individually, with transducer placement on the mastoid supero-posterior to the canal opening of the test ear. The transducer must be held firmly in place either by a Velcro band or tensor bandage, or by finger pressure perpendicular to the transducer rear surface (see Appendix F for clinical tips). Application force measurements are unnecessary, but positioning must be consistent and the pressure must be light but firm. Family members are not permitted to hand hold the BC transducer as they are not properly trained on the procedure.

**Note that it is not necessary to remove an ear insert transducer when testing a given ear by bone conduction ABR. Evidence to date indicates that occlusion effects are clinically insignificant in infants (see Small et al. 2007) and this is supported by substantial clinical experience with ABR thresholds in other EHDI programs.**

## 2.08 ELECTRODE POSITION

---

Snap electrodes compatible with Vivosonic leads must be used. The non-inverting electrode must be placed on the midline forehead as high and as close to the hairline as possible. An inverting electrode must be on each mastoid process and the common electrode must be on the lateral forehead at least 3 cm from the non-inverting electrode.

A common error is non-inverting electrode placement too low on the midline forehead, at which point ABR wave V amplitude loss will occur, relative to points higher on the midline. On the International EEG Federation's 10-20 System for Electrode Placement, the goal is to position the non-inverting electrode as close as possible to Fz, not at the mid-forehead frontal pole denoted as Fpz. Using sticky pads on the skin, the anterior proximity to Fz is usually limited by the position of the hairline. See American Electroencephalographic Society (1994).

## 2.09 ELECTRODE IMPEDANCES

---

Effort must be made to obtain impedances of 5 k $\Omega$  or less for all electrodes and, even more importantly, impedance differences for each forehead-mastoid pair of no more than 1 k $\Omega$ .

Differences in non-inverting and inverting electrode contact impedance reduce the ability of the differential amplifier to reject input signals common to these two electrodes. This ability (common-mode rejection, CMR) is important to achieve the best ABR-to-noise ratio from the head. Large signals from the heart, for example, are similar at the forehead and mastoid and greatly reduced by differential recording. The same is true for signals from distant, off-body sources such as radio waves, for which the body acts as an antenna.

Note that the ABR usually seen in a differential recording has the actual ABR at the mastoid subtracted from the actual ABR at the high forehead. Wave V is more broadly scalp-positive and larger in the midline.

CMR reduction depends on the absolute difference in impedance, so 2 k $\Omega$  of difference is twice as bad as 1 k $\Omega$ . The lower both impedances are, the smaller the difference will tend to be, so it usually makes sense to reduce the larger impedance. When the baby is deeply asleep and the EEG is quiet, loss of CMR may not matter, but when the baby is lightly asleep or dozing intermittently and the EEG noise is larger, loss of CMR may determine whether ABR testing is successful.


Higher but equal absolute impedances have negligible direct effect on CMR but they increase artifact voltage pickup due to electromagnetic current induction in the electrode leads or across the baby's scalp. E/M current may be induced by any rapidly changing E/M field surrounding the electrode leads, such as may be generated by AC 60 Hz power leads, outlets, switches, lights, dimmers or other nearby electrical devices. Fluorescent lights can be problematic due to higher harmonics of 60 Hz. Battery-powered LED lighting does not cause E/M current induction and is readily available at low cost.

## 2.10 RECORDING CHANNELS

---

For all ABR thresholds a two channel setup with the inverting mastoid electrode ipsilateral to the stimulated ear should be used. If a single channel is used, the rationale for the departure from protocol must be documented in the clinical records.

For most AC ABR threshold measurement, the practical benefit from displaying two channels is negligible. Doubling the number of displayed or plotted tracings increases clutter and the difficulty of waveform organization and rapid visual inspection. An exception is unilateral sensorineural loss that is severe or greater, with either normal hearing or conductive hearing loss on the contralateral side. In these cases, two-channel recording might reveal a contralateral responding cochlea at high stimulus levels. When this occurs, the contralateral tracings must be displayed with the full suite of waveforms including A, B and A - B. See example below (Figure 2.10.1), which shows a clear response in the contralateral channel. Similarly, two channels might reveal a stimulated ear or electrode connection error by showing a lateralized wave I on the wrong side.



**Figure 2.10.1 Two-channel recording revealing a contralateral response at high stimulus levels.**

In BC threshold estimation, inference of which cochlea is responding to the stimulus requires comparison of ABR characteristics from channels ipsilateral and contralateral to the stimulated mastoid. Furthermore, much larger BC stimulus artifact in the ipsilateral channel can flag inadvertent stimulus or electrode errors.

## 2.11 SORTING AND DISPLAYING TRACINGS FOR PRINTOUT

---

Consistent and optimal organization of waveform printouts facilitates rapid visual inspection and interpretation, as well as review by other persons such as colleagues or DTCs. It also expedites any type of review, including training or updating reviews, consultations, second opinions, standard performance reviews or adverse event audits. Therefore, a standard format is necessary and is mandatory.

For all tonepip ABRs, the suite of tracings should be displayed using the 'Clinical Sort' tool in the 'split' view; with the RIGHT tracings on the left hand side, and the LEFT tracings on the right (to correspond with the convention for the audiogram). The suite of tracings is made up of the compound tracing, the A and B primary tracings, and the A-B (A minus B) tracing.

Using the 'Clinical Sort' tool for all tonepip ABR has three advantages. First, it separates the tracing suites, providing easy visibility of individual tracings and handles. Second, it improves the ability to see trends in the A and B primaries, which is often helpful in assessing reproducibility and identification of large noise artifacts in individual tracings. Third, the automatic separation of tracings is not subject to waveform identification bias that can easily arise when the examiner is free to superimpose potential response waveforms. The practice of arbitrary vertical shifting is to be avoided in record printouts, though it may be subjectively helpful in the course of data acquisition, to assess reproducibility and averaging needs.

The A-B (A minus B) must be displayed. This will allow subjective evaluation of noise levels and allow comparison to the compound tracing for better identification of RP and NR judgements.

For BC ABR, for each stimulus ear-frequency-level, ipsilateral and contralateral tracings are obtained and the full suite of tracings is displayed including the A and B primary tracings, and A-B (A minus B), with the contra immediately below the ipsi and with these units ordered overall by descending stimulus level. This facilitates the visual comparison of ipsi and contra waveforms and their trends across levels, usually necessary in order to identify which cochlea is being activated preferentially by the given stimulus. This is easily achieved by using the required clinical sort feature.

## SECTION 3: HIGH-EFFICIENCY ABR THRESHOLD MEASUREMENT

### 3.01 TEST EFFICIENCY IS CRUCIAL & FEASIBLE

---

In the IHP, as well as in many other programs worldwide, timely and accurate completion of ABRA is a challenge. Continuous effort and ingenuity are needed to increase the efficiency of ABR threshold measurement in particular, without loss of accuracy and, preferably, with increased accuracy and reduced errors or omissions. The emphasis here is on improvements in procedure that will increase the rate of clinical information gain and reduce the likelihood of significant clinical decision errors or omissions. Most of the protocol elements specified here are routinely practiced by the most skilled ABR testers globally. Even with rigorous adherence to this protocol, there is ample room for the additional exercise of great clinical skill and high-level judgement. For example, pervasive clinical questions are 'in how few tracings can I define this ABR threshold to an acceptable level of precision and adherent to protocol?' and 'if this baby wakes up in one minute, have I done absolutely the best possible job in obtaining the most critical clinical information in the time I had available?'

The following points illustrate some key aspects of more efficient testing that will be explained in more detail in the subsequent sections:

- **Throughout threshold estimation, make every choice of the next stimulus condition the one for which determining ABR presence or absence will have the greatest impact on clinical management, given what you already know or do not know at that precise moment of choice.**
- **Don't allow high-amplitude EEG into a good tracing; pause the collection if intervention is required.**
- **The bigger (more sweeps) the tracing, the less efficient it becomes in terms of information gain per unit test time. Use sweep counts of about 2,000 sweeps (A, B buffer of about 1000 sweeps each) and stop there if clear RP. Clear NR almost always requires more than 2000 sweeps in the compound tracing**
- **Start initial testing in a referred ear. The information gain from testing a passed ear is much smaller, as is the probability of a significant permanent hearing loss in a passed ear.**

- Start at the minimum stimulus level but go up in large steps (30 then 20-30 dB) to get a clear response latency and waveform guide as quickly as possible in the event of an *NR*, or *INC* decision at *Smin*.
- Use a strategy of progressive refinement of threshold accuracy. Do not use 5 dB brackets unless and until you have finished all 10 dB threshold bracketing.
- Once you've established 2k AC threshold, go to either BC or AC 4k.
- Use 10 dB ascent only to confirm response at a lower level, not in the search phase.
- Proving response absence is often far more time-consuming than proving response presence, so try to minimize doing it.
- More than two tracings per stimulus condition are rarely useful; go up instead.
- If two consecutive intensities for a given frequency are *INC*, with a clear *RP* above and a clear *NR* below, a third tracing to resolve at least one of the *INCs* is indicated.
- *INC* should only be used relatively rarely; once all mandatory and conditionally mandatory procedures are completed, an attempt should be made to resolve an *INC* with an additional tracing.
- Use information obtained on previous ABR/CBA testing to inform testing choices such as starting level frequency, ear, and modality on subsequent ABR. Avoid repeating known information, instead try to 'fill in the blanks' to obtain as much information as possible.

### 3.02 OPTIMIZING CLINICAL INFORMATION GAIN

---

ABR threshold measurement must be done with the highest possible clinical efficiency, assuming that testing can be terminated at any time with no further attendance. Each and every choice of next stimulus condition must be such that clinical management will depend strongly on the answers obtainable for the chosen condition.

Common situations that limit the efficiency of threshold measurement are:

- Getting bogged down in threshold accuracy before answering bigger clinical questions.
- Using ascending step sizes that are too small, losing time getting to threshold bracketing regions.
- Lengthy or repeated averaging when response is highly questionable (i.e., chasing shadows), rather than going louder to get a clear guideline response.
- Not doing BC early enough and/or switching ears early enough.

The general strategy of successful ABRA is the opposite of standard audiometry in a cooperative adult subject. In an infant, the required mindset is that the testing may be terminated permanently at any moment, perhaps after the very next tracing. This means that the next stimulus condition (route, frequency, level...) to be chosen must be the one that will make the biggest difference to clinical management, of all the stimulus choices available. If this strategy were followed continuously, then no matter when the session does end, it would not have been possible to get more valuable clinical information in the time that turned out to be available.

Time is a constant pressure in ABRA. It is challenging to achieve consistently accurate and complete initial ABRA followed by appropriate intervention within the timelines established as international benchmarks. There is never any time to waste taking measurements that are not clinically important. The need for a top-down approach with progressive refinement of information cannot be overstated.

The first question to be answered in ABRA is whether any ear that gave a UNHS Refer has a target PHL. If the UNHS Refer is unilateral, the Referred ear is the starting point, whereas if bilateral, the starting ear is a matter of convenience.

Absence of hearing loss is answered by ABR detection at the lowest appropriate stimulus levels across the target frequency range, denoted as *Smin* values. In the range 0.5 to 4 kHz, the most valuable of all single answers in relation to early language development and the epidemiology of hearing loss in newborns is at 2 kHz.

Most babies referred from UNHS will have normal or near-normal hearing. It follows that the initial starting condition must be the AC 2 kHz *Smin*. Starting higher at 2 kHz is inefficient because usually a clear ABR will be obtained at *Smin*.

If there is no response at the 2 kHz Smin, important clinical questions are: (1) how big is the loss, (2) is it permanent, (3) what about other frequencies and (4) what about the other ear?

When there is no response at the 2 kHz Smin, immediately go up 30 dB. Getting a positive response quickly at about 60 dB nHL is much more informative than getting an inconclusive or negative result having gone up by only 10 dB, for example. In addition, getting no response at 60 dB has major clinical impact and is much more informative than getting no response at 40 dB and avoids time wastage chasing shadows.

If no response is obtained at 60 dB, the next step should be 80 or even 90 dB. If no response is present at 80 dB, Smax should be tested followed by BC.

When going to BC, a question is whether to start at the BC 2 kHz Smin or a higher level, given no response for AC at 30 or 60 dB. The Smin has priority because the ability to state that BC is normal has major clinical impact.

There are two important general points here. First, information theory tells us that in a situation of choosing between two alternatives, the more probable one is relative to the other, the less information is gained by knowing the answer; when one answer is almost certain, discovering that it is true yields little new information. It follows that the greatest information gain occurs when the alternatives are equi-probable.

The second point is that the relative clinical importance of a given stimulus condition changes as the answers come in from other stimulus conditions, so the whole process of choosing the most influential next stimulus condition is dynamic and constantly evolving as the Assessment proceeds.

### 3.03 MANDATORY & DISCRETIONAL PROCEDURES

---

A complete ABRA must include otoscopy, ABR testing, and Middle Ear Analysis (Tympanometry). The ABR testing must include AC tonepip ABR threshold estimation; where indicated, it may include BC tonepip ABR and a sub-protocol for evaluation of ANSD as well as other retrocochlear disorders that commonly affect the ABR. MEA must include tympanometry and may include acoustic reflex testing.

ABRA test components are specified below. The tests are grouped as procedures that must always be done (Mandatory), procedures that must be done if a specific situation occurs (Conditionally Mandatory) and procedures that may be done if the Audiologist so chooses (Discretionary).

#### **Mandatory Procedures**

- Otoscopy
- AC ABR thresholds at 2 kHz, 4 kHz, and 0.5 kHz with 10 dB final bracketing
- Tympanometry at 1 kHz under 6 months corrected age, 226 Hz at 6 months or more

#### **Conditionally Mandatory Procedures**

- BC ABR threshold at 2 kHz if AC 2 kHz is abnormal
- BC ABR threshold at 0.5 kHz if 0.5 kHz is the only AC threshold abnormality and AC threshold is elevated by more than 10 dB
- BC ABR threshold at 4 kHz if 4 kHz is the only AC threshold abnormality

If AC 2 kHz **and** 0.5 and/or 4 kHz are abnormal, BC 2 kHz is *Mandatory* and BC 0.5 and 4 kHz are *Discretionary*.

- AC ABR threshold at 1 kHz (10 dB bracketing), if AC 2 kHz *TH* minus AC 0.5 kHz *TH* exceeds 25 dB nHL
- DPOAE amplitude and noise measurements at 1.5, 2, 3 and 4 kHz nominal f<sub>2</sub>, where sensorineural PHL is suspected or confirmed. Replication of tracings is discretionary if DPOAEs are absent in the presence of an ABR showing sensorineural HL.
- Sub-protocol for ANSD or retrocochlear disorders, if there is no clear tonepip ABR wave V-V' at 15 ms or less for any 2 kHz level tested above 75 dB nHL. The sub-protocol Includes:



Rarefaction and condensation clicks (separated) at 90 dB nHL, for assessment of:

- Cochlear microphonic potentials (CM)
- Cochlear summing potentials (SP)
- ABR wave presence, morphology, latency, amplitude
- DPOAE amplitude and noise measurements at 1.5, 2, 3 and 4 kHz nominal f2. Replication of tracings in mandatory.

#### Discretionary Procedures

- DPOAE amplitude and noise measurements at 1.5, 2, 3 and 4 kHz nominal f2 for infants whose ABRs show conductive hearing loss or normal hearing.
- Ipsilateral acoustic reflexes (preferably to wide-band noise bursts).
- AC ABR thresholds at 2 and 4 kHz with 5 dB bracketing, if all mandatory measurements are completed and time permits.
- Approximating click ABR thresholds within ANSD sub-protocol.

#### Component Test Priorities and Order

Otoscopy is a required preliminary in any Assessment. Its purpose is to detect foreign bodies, canal occlusion and any other physical condition of the ear that may invalidate or otherwise contra-indicate the Assessment or indicate referral to a physician. Otoscopy is usually followed by electrode attachment, then feeding to promote sleep.

**At the first ABRA session, tonepip ABR thresholds are the immediate priority as soon as the infant sleeps.** Other procedures such as tympanometry (mandatory) or DPOAE (discretionary) are usually deferred because they are secondary to ABR and can interfere with falling asleep. One of the facets of successfully inducing sleep in many babies is minimization of auditory, visual and somatosensory stimulation.

Because abnormal AC tonepip ABR thresholds trigger BC measurements, direct hard evidence of conductive hearing loss is usually obtained thereby. Tympanometry is usually deferred at least to the end of the first session. Its findings complement ABR-based inferences and provide limited cross-validation of ABR air-bone gaps.

**Acoustic reflex measurements are now discretionary.** They have limited value as a crosscheck when ABRs are absent at high stimulus levels, in that reflex presence contradicts inference of both ANSD and profound conventional cochlear hearing loss. In general, reflex presence may be clinically informative whereas reflex absence is rarely so.

**After the tonepip thresholds are substantially completed, if the 2 kHz ABRs are absent or abnormal at high levels then ANSD presence must be evaluated, using both OAEs and the click ABR ANSD protocol.** These tests are normally deferred to the end of the first ABRA session.

### 3.04 AC & BC TEST FREQUENCIES

---

AC tonepip ABR thresholds may be measured only at nominal frequencies of 0.5, 1, 2 and 4 kHz, where 2, 4 and 0.5 kHz are mandatory and 1 kHz is conditional. AC testing at other frequencies must not be done because there are no adequate normative data on the relationships between ABR and perceptual (behavioural) thresholds at other frequencies, for the type of stimuli specified in this protocol.

BC 2 kHz must be done if AC 2 kHz shows no response at the minimum level. BC 0.5 kHz must be done if AC 0.5 kHz is the only abnormality, but is discretionary if both AC 0.5 and 2 kHz are abnormal. Inference of conductive loss at 0.5 kHz does not imply that a loss at higher frequencies also must be conductive, whereas if a loss at 2 kHz is purely conductive it is reasonable to assume that a loss at 0.5 kHz is also conductive. Similar to 0.5 kHz, if AC 4 kHz is the only abnormality, then BC 4 kHz is mandatory. BC testing must not be done at any other frequency than 0.5, 2, and 4 kHz, again because there are no normative data of adequate quality.

### 3.05 MINIMUM (Smin) & MAXIMUM (Smax) TONEPIP LEVELS

---

The IHP target disorder set defines the lower limit of puretone hearing loss (25 dB HL) that it is desired to measure. This defines mandatory minimum stimulus levels (Smin) that depend on stimulus frequency and route and are in the range 25-40 dB nHL. Lower levels must not be used, primarily because the relationship between behavioural thresholds and ABR thresholds obtained with common, clinical protocols is currently unknown or non-existent at ABR threshold levels that correspond to about 25 dB HL or less. This is to be expected, given the typical variability of individual measurements of both ABR and VRA thresholds. The only exception to this is for BC testing when it may be necessary to go below Smin levels to isolate the responding cochlea (see p. 52).

Absolute maximum levels for tonepips (Smax) are determined by the upper limit of transducer linearity. In terms of damage risk to the cochlea, there is no good evidence of auditory system damage risk for the tonepips used in ABR threshold measurement. Even at the highest tonepip levels with the largest feasible, high-frequency SPL increases in small canals taken into account, conventional noise exposure calculations indicate no damage risk. However, this is not necessarily the case for click stimuli (see later). Smax values are typically in the range 95-105 dB nHL.

There are, however, unanswered questions about the nature and origin of large positive or negative waveforms that are sometimes seen under 5 ms latency at very high stimulus levels. E/M artifacts, transducer nonlinearity and ringing, amplifier ringing, unusual cochlear receptor potentials and vestibular potentials are all possibilities.

Is there much clinical value in being able to differentiate hearing thresholds of, say, 90 vs 100 dB HL? The contribution to clinical management of such a discrimination is not obvious. Unless the benefit of such a distinction becomes established as substantial, it is reasonable to set a provisional maximum of 95 dB HL.

AC Smin: 4kHz@25dBnHL (25dBeHL), 2kHz@30dBnHL (25dBeHL), 1kHz@35dBnHL (25dBeHL), .5kHz@40dBnHL (25dBeHL)  
BC Smin: 4kHz@25dBnHL (25dBeHL), 2kHz@30dBnHL (25dBeHL), .5kHz@25dBnHL <1yr old, .5kHz@30dBnHL >1y old (25dBeHL)

AC Smax: 4kHz@95dBnHL (95dBeHL), 2kHz@100dBnHL (95dBeHL), 1kHz@105dBnHL (95dBeHL), .5kHz@105dBnHL (90dBeHL)

### 3.06 AMPLIFIER GAIN & KALMAN WEIGHTED AVERAGING

---

A fixed preamplifier gain of 150,000 is set in the Integrity software and can not be changed. If the EEG noise level increases, the proper course is to determine the cause of the increase and make every effort to fix it at the source.

Large myogenic artifacts in the ongoing EEG are the most common cause of inefficient and inaccurate ABR thresholds. In the past, the Audiologist had the option of adjusting artifact rejection to provide cleaner sweeps when necessary. Using Kalman weighted averaging, artifact rejection is not necessary and is therefore disabled, **but collection still needs to be paused if large myogenic artifact is seen in the EEG**. Due to the nature of Kalman-weighted averaging, there is no longer a need for an artifact rejection criterion. Large discrepancies between number of stim and noise adjusted sweeps means either there is too much noise and intervention is required, or that the collection was paused. See Section 3.11 for details on actual versus adjusted noise sweeps.

**Collection should be paused if intervention is deemed necessary. A quiet, flattish EEG trace with fluctuations that occupy only a small fraction of the distance between the display y-scale (which at minimum is 0.15  $\mu$ V but fluctuates with increasing noise) should be regarded as good because it is quiet.**

### 3.07 DIMINISHING RETURNS IN AVERAGING

---

The standard model of signal-to-noise ratio enhancement by averaging is one of a constant ABR (signal) added to random EEG noise that has constant variability over time (the statistical term is 'stationary noise'), as reflected in its underlying standard deviation (SD). Under that model, as the tracing progresses the value of the underlying ABR does not change because the average value of a constant is the constant itself. But, the standard deviation of the averaged noise decreases as a result of partial cancellation of positive and negative noise values. For standing averaging, after N sweeps, the SD of the averaged noise is the original SD divided by the square root of the number of adjusted sweeps. Therefore, the signal to noise ratio (SNR) increases by the square root of N; this is known as the 'root N law'. Because the improvement in SNR follows the root N law, the amount by which the SNR improves in a fixed period of time decreases steadily as averaging progresses. What this means is the larger number of sweeps contributing to a tracing is, the smaller the improvement obtained by continuing to record for a fixed number of sweeps.

The Integrity system calculates and displays the SD of the A minus B buffers as it accumulates and this value is referred to as the 'residual noise' or RN of the tracing. If the EEG noise is truly stationary, the RN will tend to decrease steadily as the number of adjusted sweeps increases. The value will fluctuate, because the EEG is random noise and samples from a random process will show some variability, but the larger the N, the smaller the fluctuation will be and the smaller the RN itself will be. Note that if the EEG at the baby's head is contaminated by bursts of myogenic noise with a large SD, this makes the source noise non-stationary and violates the root N law. The Integrity system uses Kalman-weighted averaging which optimizes the reduction in RN. See section 3.11 ACTUAL VS ADJUSTED NUMBERS OF SWEEPS below.

The Table below shows model data for the RN in nV, which is basically the amount of wiggle in the tracing that is due to noise, after standard averaging for various numbers of sweeps, along with the reduction in RN achieved by adding another 1000 sweeps. Every extra 1000 sweeps takes about half a minute of test time. For example, going from 1000 to 2000 sweeps reduces the RN by 25 nV or about 50 nV of improvement per minute. In contrast, going from 4000 to 5000 sweeps reduces the RN by only 1 nV, or about 2 nV per minute. This means adding another 1000 sweeps to the first 1000 is more than twenty-five times as effective in reducing noise in the tracing as adding another 1000 to an existing 4000 sweeps.

**Table 1: This example is constructed for a fairly noisy EEG situation with a source noise SD of 2 microvolts or 2000 nanovolts (nV), yielding an RN of 58 nV after recording 1000 sweeps (2000/root 1000):**

Sweeps	RN (nV)	Change per 1000 sweeps
1000	58	-
2000	33	25
3000	31	2
4000	28	3
5000	27	1
6000	26	1
7000	24	2
8000	24	0

Now consider the best way to spend about two minutes of collection time. You could gather about 4000 sweeps, which at 37.7 per second means about 100 seconds. An alternative is to do two separate tracings of about 2000 sweeps. As will be shown in the next section, you would have two sets of A and B waveforms, with 1000 sweeps each, giving you the ability to assess the reproducibility of the waveforms.


The practical bottom lines are:

- **Averaging rapidly becomes less and less efficient the more you do it.**
- **If things are not becoming clear by about 6000 sweeps total in the compound tracing they will not become much clearer within a practicable amount of test time, so change the stimulus conditions (eg., go up 10 or 20 dB) instead of continuing on with more collections.**
- **A tracing with 2000-4000 noise adjusted sweeps provides 1000 to 2000 noise adjusted sweeps in each of the A and B primaries allowing subjective assessment of waveform reproducibility. Nothing is lost as long as the A and B primaries are themselves of reasonable size and there are very few pairs of them. Assessing reproducibility across say 5 or 10 even smaller sweep count tracings is not recommended and is a completely different and more difficult pattern recognition problem than comparing a single set of A and B, or at most two sets of A and B containing a reasonable number of noise adjusted sweeps.**

### 3.08 SUITE OF TRACINGS

With the Integrity what is initially collected is a compound tracing that generates two separate primary tracings, referred to as A and B. The required display or plot for the tracings for a given stimulus is as a level-specific grouping called the suite of tracings; the compound tracing will be on top with its component primaries A and B immediately below, stacked closely together but with some separation such that A and B are individually identifiable. The A-B (A minus B) tracing is to be displayed directly below. This can be achieved by using the Clinical Sort tool found on the Integrity user interface.

**Figure 3.08.1** A compound tracing must never be plotted overlapping its component A and B primaries, because that creates a false illusion of reproducibility, which is inevitable because the tracing is made up from its A and B components. The compound tracing is usually the best single sample estimate of the true waveform. It is, essentially, just a 'grand average' of two measurements that simply happen to be waveforms collected simultaneously. The Clinical Sort feature is the "C" circled in blue at the top right of the figure, which allows for proper layout of the tracings. Some minor tweaking of the position of the waveforms may be necessary after using Clinical Sort, in order to avoid the waveforms being superimposed, and to improve the ability to follow individual waveforms.



A-B should be displayed for all tracings. By subtracting B from A it provides a visual representation of the noise and helps to verify NR vs RP.

Note: the number of actual and adjusted sweeps, stimulus parameters, as well as RN can be located at the bottom of the test screen under **Test Conditions**.

### 3.09 RESPONSE JUDGEMENT CATEGORIES & CRITERIA

For any given stimulus route (AC or BC) and frequency, there are three common overall outcomes from any given ABRA session:

- The ABR threshold (*TH*) is considered bracketed. A bracket is complete when there are RP and NR tracings separated by no more than 10 dB; the RP then becomes *TH*. It is acceptable to have the occasional bracket which includes one INC step in between RP and NR. This would mean that the TH tracings is separated from the NR tracing by 20 dB. This should be the exception. If this occurs more than very occasionally, consultation with a DTC is required.
- There is no response at the highest level tested, which yields a lower bound for the (unknown) threshold ( $TH > \text{highest level tested}$ ), or
- There is response at the lowest level tested, which yields an upper bound ( $TH \leq \text{lowest level tested}$ ).

Both the levels and the crucial bracket or boundary decisions must be documented routinely (see Figure below). This greatly facilitates reporting, retrospective review or evaluation of threshold estimates, of particular value in serial testing or in cases of unexpected change or discrepancy across measurements.

**Response detection judgements at each threshold bracket level and at each range boundary must be categorized and annotated as 'Response-Positive (RP)', 'Threshold (TH)', 'No Response (NR)' or 'Inconclusive (INC)'. For each such stimulus level, there is one, single response judgement that applies to the entire set of tracings at that given level. RP, TH, and NR decisions reflect high confidence and are NOT the result of guesswork or a 'balance of probabilities'. INC decisions are required whenever RP, TH, or NR can not be determined with confidence.**

An *RP* decision at an *S<sub>min</sub>* requires:

- At least one tracing of a minimum of about 2000 sweeps that has a negative-going deflection with peak-to-trough amplitude of at least 50 nV (0.05 µV) in the interval 6 to 20 ms. Note: this is the latency range for 4k through .5k, a possible 2k RP at 20 ms would be highly suspect, as would a .5k RP at 6ms. Note that if subjectively repeatable deflections are seen at several locations throughout the tracing, the repeatability at a plausible response latency loses significance and reliance on latency trend with stimulus level becomes more influential.
- Deflection latency no less than that of the similar feature for the same stimulus at any higher level that gave an *RP* decision.
- Absence of any *NR* decision for the same stimulus route and frequency at a higher level in the same test session

A *TH* decision at any upper bracket level requires:

- At least one tracing of a minimum of no less than 2000 sweeps and often closer to the ~4000 maximum, that has a negative-going deflection with peak-to-trough amplitude of at least 50 nV (0.05 µV) in the interval 6 to 20 ms. Note: this is the latency range for 4k through .5k; a possible 2k RP at 20 ms would be highly suspect, as would a .5k RP at 6ms.
- Deflection latency no less than that of the similar feature for the same stimulus at any higher level that gave an *RP* decision.
- Presence of a *NR* decision for the same stimulus route frequency 10 dB lower in the same test session (or rarely 20dB lower, with *INC* in between).

**For *TH* decisions, wave V should be marked on the tracing where the Audiologist believes it to be for infants with hearing loss. The purpose is to aid in the clinical decision process as it helps to understand the reasoning behind *RP* and *TH* judgements. This is especially important for records sent to DTC for review.**

An *NR* decision at any lower bracket level or at an *S<sub>max</sub>* requires:

- At least one tracing of a minimum of about 4000 sweeps for which the maximum and minimum amplitude in the range 6-21 ms differ by no more than 0.05 µV (50 nV), **and**
- For which the corresponding A and B buffers, and A-B (A minus B) are subjectively 'flat', **and**
- Absence of any *RP* decision within the same test session at the same level or lower.

An *INC* decision applies to any scenario that is not *RP*, *TH*, or *NR*. Common examples are somewhat noisy tracings that are not quite flat enough to qualify as *NR*, or tracings where a potential *RP* appears present in only one primary waveform, but not in the other. In either case, the best action is usually to go louder. In the Search phase, a large step up of 20-30 dB is indicated; in the Bracketing phase a smaller step size is usually better. It is permissible to have the occasional *INC* separating a *TH* and *NR*. However, this means that the resultant audiogram will only be resolved to within 20 dB for that frequency, which will impact the accuracy of degree of loss and the effectiveness of the ensuing intervention. For this reason, a substantial effort should be made to resolve any *INC* decision **after all mandatory and conditionally mandatory elements** are completed. *INC* can usually be resolved by collecting an additional compound tracing at the intensity in question and summing the two tracings together if needed. This summed tracing should be the one labelled. Remember that a tracing that is not valid (e.g. electrode fallen off, baby awake and moving, less than 1000 sweeps, etc) is not *INC*, but is simply uninterpretable and invalid and should not be used to make a decision regarding response presence or absence.

Note that for *TH* and *NR* tracings, while a sweep count of 2000 is acceptable with a clear V-V' deflection for *RP*, and a very quiet and flat tracing for *NR*, it is more common and generally recommended to have about 4000 adjusted sweeps (A and B primaries of about 2000). While tracings with as few as 1000 adjusted sweeps (A and B with around 500 sweeps each) showing clear *RP* may be used in

the Search phase. Upper and lower brackets (TH, NR) and minimum levels (Smin) require between ~2000 to 4000 adjusted sweeps in the tracing (~1000-2000 adjusted sweeps in A and B buffers). See section 3.11 for important notes about numbers of sweeps targeted. The figure below shows an example of response judgement annotation.




Figure 3.09.1 Example of proper response judgement and labelling.

**An NR decision is NOT simply the absence of an RP or TH decision. For a valid NR decision, it must be true that if a response were present then it would surely have been recognized. Therefore, to decide on NR or TH, EEG noise conditions and averaging tactics must be good enough to detect the minimal ABR waveform required for an RP or TH decision.**

### 3.10 RESIDUAL NOISE (RN) LEVELS & 'NO RESPONSE' (NR) JUDGEMENTS

The data model underlying averaging is that the signal (ABR) is identical for each stimulus and the electrical noise from all sources (brain, musculature, etc.) is random with constant standard deviation (SD), a condition called 'stationarity'. In that case, the signal to noise ratio (SNR, the ratio of ABR amplitude to noise SD) approximately increases on the Integrity from its value in a single sweep by the factor root N, where N is the number of noise adjusted sweeps in the tracing. The ABR is assumed constant but, in contrast, there is partial cancellation of the stationary random noise. As N increases, the tracing becomes less and less variable, converging either to a flat zero line or to a nonzero response waveform. The averaged noise on the Integrity is called the 'Residual Noise' or RN level and is obtained by calculating the SD of A minus B buffers during the post-stimulus period 1 to 13 ms. The RN is displayed continuously as the tracing progresses and its value in microvolts ( $\mu\text{V}$ ) is printed in the test conditions tab on the bottom of the test screen.

The earlier section on artifact rejection addressed an issue of bursts of high-amplitude noise in a background of quiet EEG. This is a situation called noise 'non-stationarity'. For standard averaging, it violates the root N law because a burst of high noise can cause the RN to suddenly increase dramatically. The Integrity system optimizes this problem by using Kalman-weighted averaging which assigns a lower weight to sweeps that contain higher noise. A lower weight reduces the contribution of a noisy sweep to the tracing. During noisy periods, the adjusted number of sweeps (reported as Neq.) will increase more slowly than the actual number of stimulus presentations (reported as N).

In the real world, a 'small' ABR would be no bigger than about  $0.1 \mu\text{V}$  (100 nV) peak-to-peak for the positive-negative complex V-V', typically the most prominent ABR waveform feature in threshold estimation. The SD of fairly quiet EEG in infant ABR measurement is about  $1 \mu\text{V}$ , so the SNR in the raw EEG (a single sweep) is about 0.1. After about 2000 sweeps, for which root N is about 45, the SNR

is 4.5 and the SD of the averaged noise would be about  $1/45 \mu\text{V}$  which equals  $0.022 \mu\text{V}$  or about 22 nV. A random process with mean zero and SD  $0.022 \mu\text{V}$  will fluctuate over time within about  $\pm 2 \text{ SD}$  from a zero baseline, or  $\pm$  about  $0.044 \mu\text{V}$ . An averaged ABR of about  $0.1 \mu\text{V}$  would be easily visible and usually highly replicable. In fact, it can be shown that an ABR V-V' as small as only about 50 nV peak-to-trough will be detectable most of the time, given typical, quiet EEG and an efficient averaging protocol based on tracings of about 2000-4000 sweeps.

If we require that a response of only  $0.05 \mu\text{V}$  must be detectable with quite high probability, then we require that the RN be no greater than about  $0.020 \mu\text{V}$ ; this will mean that the V-V' for the smallest response deemed acceptable is at least twice the RN, which adds up to reasonable detectability in a reasonable time-frame for a typical signal, noise and test time scenario. It is easy to fail to detect a genuine ABR; all that is required is to do too little averaging. But in order to decide that a response is absent in a valid and reliable way, we must achieve sufficient statistical power to be able to detect the smallest ABR that would be considered as of interest. Only then can failure to observe any such ABR be interpreted as that it is really not present. If we define the minimum ABR to be  $0.05 \mu\text{V}$ , then it can be shown statistically that an RN of about  $0.020 \mu\text{V}$  is a reasonable net target for the averaging at any given stimulus condition for which we wish to conclude that there is no response.

An RN of about  $0.020 \mu\text{V}$  is a reasonable target to be able to make an *NR* decision, but it is not a 'hard' target in the sense of being rigid or mandatory.

Except when very close to ABR threshold, the RN has less influence on *RP* decisions than it does on *NR* decisions. *RP* decisions are based primarily on the SNR and response reproducibility. When well above ABR threshold, large responses can be identified with confidence even if the RN is above  $0.03 \mu\text{V}$ . At threshold, however, a quiet EEG and a low RN are necessary in order to detect a small ABR.

### 3.11 ACTUAL VS ADJUSTED NUMBERS OF SWEEPS

---

**The minimum number of adjusted sweeps in any compound tracing must be targeted to be no less than about 2000 sweeps.**

When the Integrity accumulates a tracing while computing the RN, it displays the updated tracing and RN. Therefore, all collected sweeps contribute to the final display and parameter listing and therefore no time is wasted regardless of where the sweep count stops.

**It is important to monitor the discrepancy between the number of sweeps and the number of noise adjusted sweeps. If the tracing has not been paused, a large discrepancy will mean poor sweep collection and intervention is required.**

### 3.12 TONEPIP ABR THRESHOLD DEFINITION


---

For any tonepip route (AC or BC) and frequency, the ABR threshold, denoted as *TH*, is the lowest level judged as *RP* (the 'upper bracket' level) for which there is a level either 5 or 10 dB lower that is judged as *NR* (the 'lower bracket' level). If the lowest *RP* level is a minimum stimulus level (*Smin*), then the ABR threshold is denoted as  $\leq S_{\text{min}}$  and is an upper bound of a threshold range considered 'within normal limits' (WNL) for IHP purposes. Conversely, if the highest level tested is judged as *NR* then the ABR threshold is ' $> \text{NR level}$ ' and *NR level* is the lower bound of a range. If *NR level* is a maximum stimulus level (*Smax*), the threshold cannot be specified. Very occasionally *TH* is separated from *NR* by one intensity step designated *INC*. This should be the exception. Time permitting, once all frequencies have been completed, an attempt should be made to resolve any *INC* tracings by a second tracing collecting at the same intensity. If *INC* occurs regularly, consultation with a DTC is required.

In some ABR instrumentation, objective, statistical response detection criteria that are implemented and validated appropriately are not available. Implementations of a correlation coefficient in the Integrity system must not be used in IHP Assessments because they have not been properly validated for use with this protocol. Therefore, ABR threshold must be estimated subjectively. The reliability of this process is improved by extensive training, ongoing decision support, and a standardized and consistent protocol grounded in statistical decision theory and random process analysis.

In practice, ABR threshold is defined using the V-V' downslope as the key feature, because V-V' is usually the most detectable peak-to-trough component of the ABR waveform at stimulus levels near threshold. Note that there may not be any actual peak (local maximum) developed for wave V, nor any actual trough (local minimum) developed for wave V'. One or both of these may not

necessarily appear but, even when that is the case, a clear and reproducible downslope is a consistent feature of ABR presence. This variation in degree of definition of waves V and V' occurs most frequently with 0.5 kHz stimuli near threshold (see below).



**Figure 3.12.1. Clear ABRs for tracings at the minimum stimulus levels required by this protocol.** The dB nHL levels shown are all equivalent to 25 dB Estimated Hearing Level (25 dB eHL). Note the marked increase in wave V latency and loss of fine structure at 0.5 kHz. The tracing with 2000 sweeps takes less than 30 seconds each.

If earlier waves (eg., I or III) are clearly present but V-V' is not, an ABR threshold cannot be defined in conventional terms because historically most normative ABR threshold data are based on wave V. Moreover, absence of V-V' with present wave I implies retrocochlear pathology, for which ABR threshold inferences are inherently questionable.

### 3.13 ESTIMATED HEARING LEVELS

**Tonepip ABR threshold estimates in dB nHL must be adjusted by the correction factors listed in Appendix G, in order to derive hearing threshold estimates in dB eHL.**

The core business of ABRA is the estimation of key puretone hearing thresholds in dB HL. This is based on determination of tonepip ABR threshold estimates in dB nHL, followed by adjustments that are based on known, normative statistical relationships between tonepip ABR and VRA-based behavioural thresholds. Note the changes for AC 500 Hz correction factor from the values previously listed in the 2016.02 IHP ABRA protocol.

ABR thresholds are generally not the same as true perceptual thresholds but they are usually good statistical correlates or predictors of them. The answers obtained in ABRA are point estimates of true puretone thresholds in a statistical 'maximum likelihood' sense, that is, in answer to the question 'given the observed ABR threshold estimate, for what value of the (unknown) true puretone threshold would the observed ABR threshold have the highest probability?'. While a more complete outcome would be a probability distribution over a range of dB HL values, the simplicity of single point estimates is popular. What should not be forgotten is that there is a range of possible true dB HL values for any given ABR threshold estimate.



The correction factors used in this protocol have been derived by statistical re-analysis of published and unpublished normative data, particularly that of Stapells and his colleagues. The corrections are similar to those used in the British Columbia Early Hearing Program, but are not identical in every case. The correction factor for a given stimulus route and frequency is based on the estimated population median difference in dB between reliable, paired ABR and VRA thresholds in large, representative groups of young infants. The overall value of the median difference (ABR minus VRA) is rounded to the nearest 5 dB, for simplicity of use. The median is more appropriate than the mean because the difference distributions at various values of the ABR threshold are systematically skewed with occasional extreme values. The ancillary regression analysis testing for linear and nonlinear trend has the behavioural threshold as the dependent variable and the ABR threshold as the independent variable. The range of the independent variable must be restricted from about 30 dB nHL to about 90 dB nHL. Between those limits there is an approximately constant relationship between the two types of threshold. Below 30 dB nHL, there is no apparent relationship at all, and above about 90 dB nHL the relationship is distorted by distributional censoring of either the ABR or VRA thresholds at device intensity maxima. Extension of regression analysis below 30 dB nHL introduces systematic, segmental nonlinearity that renders a straight-line fit over the entire range of dB nHL inappropriate. This was validated during the comparison of the Biologic NavPro and Vivosonic Integrity systems prior to program-wide implementation.

In conventional, sensory hearing loss of the type affecting first the outer hair cells then the inner hair cells as well, there is a weak tendency for the median threshold difference to decrease progressively above about 70 dB nHL. The convergence is approximately linear, but is clinically insignificant relative to other sources of bias and imprecision in behavioural threshold estimation (such as inflation of VRA thresholds due to responsiveness effects).

The IHP correction factors are valid only for the stimulus parameters and recording techniques specified in this protocol. They do not apply to estimation of hearing levels lower than the IHP target disorder limits and they cannot be assumed to apply to stimulation and recording methods that do not follow this protocol. It is important to note that publications to date purporting to address the appropriateness of IHP adjustment factors have not satisfied these criteria, nor have the data analytic methodologies used been comparatively evaluated with respect to validity, bias and precision.

### 3.14 THRESHOLD SEARCH & BRACKET PHASES

---

Each ABR threshold determination sequence can be conceptualized as a Search phase followed by a Bracket phase. In the Search phase, the goal is to reach the threshold upper bracket level very quickly. In the Bracket phase the emphasis is on response detection decision accuracy, especially a very low rate of false positive response detection at the upper bracket. It follows that stimulus level tactics, averaging tactics and response detection decisions are different in the two phases.

The Search phase is guided by the known epidemiology of PHL in newborns and infants, known properties of OAE and ABR screening tests, important results of statistical decision theory and clinical factors. The benefits of reaching an *RP* decision quickly are many, but the positive predictive value of ABR screening failure is small, especially in well babies who have no risk indicators. Thus, the Search phase typically starts at 2 kHz (arguably the single most important frequency psychoacoustically) at the *S<sub>min</sub>* (because most babies tested will have hearing within normal limits) and then ascends in initially large but rapidly diminishing stimulus level step sizes. Search phase ascent in 10 dB steps (or, worse still, 5 dB steps) is usually extremely inefficient and is strongly discouraged unless there is a very strong clinical rationale.

Decision theory shows that an optimal strategy for identifying a random number distributed uniformly over the range 40 to 100 dB with only yes-no questions is a series of questions 'is it less than x?' where x approximately bisects the current range of uncertainty. This is a crude but reasonable model of the Search phase, with an ABR *RP* as the answer 'yes' and an *NR* as the 'no', after first asking whether the mystery number (the true ABR threshold) is 30 or better.

The clinical speculation that large ascending steps will awaken a sleeping baby is not valid for initial 30 dB ascent, nor for a second step of at least 20 dB. At levels above about 80 dB nHL, 10 dB steps are acceptably efficient. Close monitoring of the baby's EEG myogenic noise level and physical behaviour allows for timely intervention, if needed.

In general, number of accepted sweeps may be smaller in the Search phase. If after a large-step ascent there is no clear response, it is generally more efficient to go up again rather than replicate. Replication of tracings should be a rarity in the Search phase.

### 3.15 NUMBER OF SWEEPS & TRACINGS

---

It is recommended that any tracing should not contain less than about 2000 or more than about 4000 adjusted sweeps. For any given stimulus condition, no more than three tracings or a total of about 12000 sweeps should be used. The only reasonable exception to this maximum is a situation in which one of the primaries (A and B buffers) in each tracing is clearly different from the others, such as obviously damaged by large artifact or having a much larger RN, or for which there is reason to suspect electrode or transducer problems.

### Search Phase

For any given AC stimulus frequency and route, the usual starting condition is at an  $S_{min}$ , except for 4 kHz at which it is logical to start 10 dB above a previously obtained upper bracket level at 2 kHz.

The first and most critical tracing might be judged as potentially an  $RP$  after as few as about 1000 sweeps. In that case, usually there would be an immediate attempt at conversion to a true  $RP$  by continuing to collect that tracing until sweep count was ~2000-4000. In contrast, the first tracing might yield a potential  $NR$ , after only 2000 sweeps. If it is flat or nearly so, it is usually more efficient to go up 30 dB. If the actual ABR threshold elevation were small, going up 30 dB would often give a potential  $RP$  after only 1000 sweeps, confirming that the loss is minor and justifying an attempt to convert the provisional  $NR$  to a true  $NR$  at the  $S_{min}$ . If the up-30 tracing also gives a potential  $NR$ , which would occur in a significant hearing loss, the ascent continues. This will avoid multiple tracings at the  $S_{in}$  when there is no indication yet that the threshold is even near-normal. Persistent, repeated recording at the  $S_{min}$  is not usually the most efficient way to prove whether hearing is WNL or not. The reason is that the initial potential  $NR$  has already increased the probability of hearing loss substantially beyond that of simply failing a prior AABR.

If there is a potential  $NR$  at  $S_{min}$  and  $S_{min}+30$ , the next step is to go up another 20 or 30 dB. Ascent in 10 dB steps is rarely appropriate, except near  $S_{max}$ . Given a potential  $NR$  at the  $S_{min}$  and a potential  $RP$  at  $S_{min}+30$  or  $S_{min}+60$ , going up further or pursuing conversion of a potential  $RP$  to a true  $RP$  is a judgement call that depends on multiple cues, including the perceived likelihood that a potential  $RP$  is real, given its size, morphology, latency, and growth pattern. The ability to predict correctly most of the time whether to replicate recording or continue an ascent is a crucial clinical skill that usually grows with experience and critical self-evaluation of tactical efficiency.

### Bracket Phase

An upper bracket  $RP$  must be based on at least one tracing, with ~2000-4000 adjusted sweeps.

A lower bracket  $NR$  (or at  $S_{max}$ ) tracing should not be based on less than about 4000 total sweeps. When judging the replication of A and B for a potential  $NR$ , the credibility of a subjectively flat record is inherently better than that of a questionable, response-like deflection. Comparing the compound tracing and its component primaries to the A-B (A minus B) is generally helpful. There are many ways in which a false impression of response may arise from constructive superposition of random noise but, if there is a genuine response present, a flat record would require that the random noise happened to summate in exactly the right antiphasic waveform needed to cancel out the true ABR.

## 3.16 SUMMING COMPOUND TRACINGS

---

Two compound tracings that are collected for a given frequency/intensity may be summed together to create one tracing, referred to as the SUM. The handle of the summed tracing will indicate which two compound tracings have been added together to create the sum. This sum will result in the primaries of each tracing being added together (summed A and summed B primary waveforms).

This tool is particularly useful for resolving INC tracings. The protocol allows for the occasional INC judgement between TH and NR, but it stipulates that once all mandatory and conditionally mandatory elements are completed, effort should be made to resolve any INC tracings. An additional tracing can be collected, and if needed summed with the earlier INC tracing. The summed tracing often yields a clear NR or RP. However, it is important to note that any compound tracing that is of poor quality (e.g. large artifact, noise, poor insert positioning, etc.) should not be summed.

Additionally, this tool may be helpful in situations where in the search phase a given compound tracing was only collected to ~2000 sweeps, but as the ABR progresses that intensity becomes a potential lower or upper bracket and a full ~4000 sweep tracing is desired for making a confident judgement. In this case, a second tracing at the same level should be collected with another ~2000 sweeps and summed with the first one to make a ~4000 sweep tracing.

Compound tracings may be summed during the ABR collection, or afterwards when reviewing the ABR from the database.

### 3.17 THRESHOLD BRACKET STEP SIZE

---

For a completed ABRA, the final threshold bracket step size for all required AC frequencies must be no greater than 10 dB. Time permitting, once all AC/BC frequencies are completed, 5 dB steps sizes are recommended starting with TH above 70dB eHL. The increased precision may be relevant to accurate prescription of amplification, if the residual dynamic range is very limited. It also satisfies the level-dependent correction for estimating perceptual thresholds that has been shown in data comparing ABR and VRA thresholds in children with hearing loss (e.g., McCreery et al, 2015). However, frequently it is challenging to make clear *RP* and *NR* decisions with steps of only 5 dB, which can cost valuable test time to little clinical benefit, and if the threshold is below 70 dB eHL the clinical benefit is negligible or zero (McCreery et al, 2015). Therefore, 5 dB steps should not be used at levels below 70 dB eHL unless all core thresholds have been estimated satisfactorily to 10 dB brackets and hearing loss type(s) have been determined.

### 3.18 CONFIRMATION OF UPPER BRACKET RESPONSE

---

**It is stressed that if there is any residual uncertainty about the presence of response at a threshold upper bracket level, a tracing of ~1000-2000 sweeps must be done at a level 10-20 dB above that upper bracket level, where allowable by Smax. Response presence must be clear in that tracing, in order to accept the threshold bracket as valid.**

If there is any doubt at all about ABR positivity at a candidate TH level, going up by 10- 20 dB for rapid response confirmation and latency guidance, rather than simply doing more tracings at the questionable bracket level is essential. The choice of step size (10 or 20 dB) is guided by the level of doubt, the nearness to Smax, what is known about the TH at adjacent frequencies, and the same frequency in the other ear.

### 3.19 STRATEGY OF STIMULUS FREQUENCY & ROUTE

---

While test strategy must be responsive to many factors in the individual child and context, the following points reflect common principles of effective and efficient testing. It is assumed that cursory otoscopy indicates no canal occlusion and the baby is asleep:

- In the absence of either prior IHP ABRA results or atresia/microtia/canal stenosis, testing must begin by AC at the 2 kHz Smin of 30 dB nHL in a Referred or otherwise suspect ear. In a baby who bypassed screening because of very high risk of PHL, both ears are assumed to be suspect. In the case of atresia/microtia/canal stenosis start with BC at 2 kHz Smin of 30dB nHL
- If both ears are suspect and ear switching is practicable, pick any ear and do 2k at 30 dB. If it is *RP*, switch ears and do 2k30 in the opposite ear and continue. If 2k 30 result in the first ear is *NR*, continue and switch later. Switching ears is usually easy in younger infants sleeping supine with two inserts in, but when the baby is in the caregiver's arms special attention to positioning for ear accessibility and insert stability is needed.
- If the 2 kHz Smin is *RP*, immediate shift to 4 kHz Smin is recommended, before shifting to Smin at 0.5 kHz. Responses at 4 kHz are often very clear and confirmable quickly with smaller number of sweeps. Isolated hearing loss at high frequencies may be more common than formerly suspected and may foretell progressivity.
- If AC 2 kHz is *NR* at 30 and 60 dB, go up to 80 dB. If still *NR*, go up to Smax 100. At this point it is important to determine the nature of the hearing loss; BC 2 kHz should therefore be completed next. **Note that the insert need not be removed in order to apply the bone conductor by hand to the test ear mastoid. The occlusion effect is negligible for ABR thresholds in young infants.**
- After checking BC, if 2 kHz is *NR* at Smin and at Smin +30 dB, prompt verification of insert placement, eartip occlusion, stimulus audibility and electrode impedances is recommended.

- If the AC 2 kHz abnormality is valid and BC is also abnormal, follow the AC Search phase ascent to bracketing then switch to 0.5 kHz at the Smin for Search and bracketing, before shifting to 4 kHz. If a conductive component is found at 2 kHz, then the accuracy with which AC thresholds need to be bracketed is discretionary.
- If BC at 2 kHz reveals a conductive component, a conductive component at 0.5 kHz may be assumed and its proof by 0.5 kHz BC is discretionary. The converse is **not** true; if a conductive component at 0.5 kHz is proven, it cannot be assumed that abnormality at 2 kHz is conductive and absence of a sensory component at 2 kHz **must** be proven definitively.
- If AC 2 kHz is normal and 4 kHz has been completed, switch ears wherever possible if both ears have referred on screening. The immediate clinical question at that point is whether the other referred ear is normal at 2 kHz.
- The BC 0.5 kHz Smin has been changed to 25 dB with a 0 dB adjustment factor, reflecting current normative data on BC ABR in young infants under one year corrected age.
- If 4 kHz is the only AC abnormality, 4 kHz BC testing must be done.
- AC at 1 kHz must be done if there is a difference of 25 dB or more in the AC thresholds at 0.5 and 2 kHz in dB nHL. If the difference is less than 25 dB, testing at 1 kHz is discretionary but not recommended unless **all** other ABR measurements have been completed.

### 3.20 BC STIMULUS ARTIFACT

---

The amount of electromagnetic (E/M) BC stimulus artifact is variable across babies and across Audiologists. It tends to be most intrusive at 0.5 kHz because of the electroacoustic properties of the transducer and the relatively long stimulus duration at that frequency (about 10 ms). It is sometimes large at levels above about 40 dB nHL. Appropriate procedures to minimize BC stimulus artifact must be used. The most important steps are routing transducer leads and electrodes as far as possible from each other, keeping electrode leads close together and pointing away from the transducer, and the electrode impedance factors noted earlier. If the AC threshold at 0.5 kHz were, say, A dB eHL then BC testing capability up to that level would be desirable. Maximum dB eHL level for BC at 0.5 kHz is about 55 dB, but stimulus artifact is often very large at that level for some babies. If BC 0.5 kHz is *NR* at its Smin, the next step is to go up as high as possible, up to including A dB eHL or the level of maximum tolerable artifact, whichever is the lower. The closer the highest acceptable stimulus level is to A, the more helpful the BC ABR is in resolving conductive and sensorineural hearing loss components.

BC-evoked ABRs that are near threshold at 0.5 kHz typically have V-V' latencies of about 10 ms or more, so even a large stimulus artifact of 10 ms total duration will not necessarily render the ABR undetectable. At 2 kHz, the artifact tends to be smaller and its duration is only about 2.5 ms, so it is rarely a problem.

### 3.21 BC RESPONDING COCHLEA INFERENCE

---

BC measurements must be done with transducer placement on the mastoid of each desired test ear, using two forehead-mastoid recording channels (Fz - M1 and Fz - M2). The responding cochlea is inferred by comparing the ABRs in the channels ipsilateral and contralateral to the test ear (see example in the figure below).

In contrast to standard BC testing in adults, in infants the BC transducer must be placed on each test ear of interest. Transcranial acoustic field patterns differ in infants, the result being as if there were transcranial attenuation differences as high as 20 dB and highly variable across subjects. The exact mechanism of these differences may be dynamically very complex, but the net effect is superficially as if the bony plates of the skull were less strongly coupled in infants, to varying degree.


Using two forehead-mastoid channels, if one channel shows a clear ABR wave V-V' and the other channel does not, the response channel indicates the responding cochlea. This is a puzzling phenomenon that is not well-understood, bearing in mind that conventional wisdom is that wave V is primarily forehead-registered and the two channels have the forehead in common. Clearly, lateral differences are attributable to mastoid field effects on the net differential waveforms in each channel. This effect is most apparent at low stimulus levels and in young infants, but the detailed effects of level and age are not fully understood.

**Figure 3.21.1 Inference of the responding cochlea in BC testing.**

*In this example, there is clear contralateral dominance, showing that the right cochlea is responding preferentially.*

If there is response in both channels, wave V latencies are compared and the shorter latency indicates the responding cochlea. In the event of no clear latency difference, response amplitude may be used if there is a clear amplitude difference, the larger amplitude indicating the responding cochlea. If there is no clear difference in latency or amplitude, stimulus levels should be reduced in an attempt to isolate the responding side, even by going below the BC Smin if necessary. If none of these manoeuvres is successful, then it is necessary to resort to contralateral insert noise masking.

If there is response in both channels and the responding cochlea is inferred to be contralateral, the presence of response in the ipsilateral channel does **not** imply that the cochlea on the stimulated side is necessarily responding. The ipsilateral waveform could be a shadow response from the contralateral cochlea. The converse is also true: if the inference is that the responding cochlea is ipsilateral, presence of a response in the contralateral channel does not imply that the contralateral cochlea is also responding.



### 3.22 BC CONTRALATERAL MASKING

Normative data for contralaterally masked ABR tonepip thresholds are limited for BC stimulation, one reason why in the IHP, contralateral masking is not used as the first-line approach to ensuring activation of the desired cochlea. The need for contralateral masking in tonepip ABR threshold estimation is limited to situations in which:

- Channel comparisons have not proved informative for inference of the responding cochlea in BC testing,
- Interaural AC threshold differences of at least 60 dB at any given frequency.

For the BC situation, wide-band insert masking at 60 dB is usually appropriate. For the situation of large interaural threshold difference, the concern is that an *RP* at a very high stimulus level in the poorer ear could result from cross-activation of the contralateral cochlea. This is only a possibility given direct extra-cranial acoustical leakage and a stimulation level exceeding about 80 dB nHL in the poorer ear, such that the effective AC stimulus to the contralateral ear is at least 20 dB nHL. This may be less problematic than it appears, because upper bracket *RPs* at high levels in ears with severe sensory losses usually show well-defined responses with relatively short latencies just above the ABR threshold, whereas contralateral responses would have latencies and waveform characteristics more typical of low dB nHLs.

### 3.23 ELECTROMAGNETIC 60 Hz ARTIFACT & NOTCH FILTERING

**Systematic procedures must be in place to minimize contamination of tracings by 60 Hz power line artifact from sources within the test area.**

ABR threshold estimates can be seriously compromised by the presence of power line artifact at 60 Hz. Such artifact is usually sinusoidal with a typical period of about 17 ms. Power line artifact is most problematic for threshold measurements at 0.5 kHz, because of the artifact duration and the similar morphology of 60 Hz artifact and near-threshold ABRs at that frequency. However, large 60 Hz interference can render tracings uninterpretable or unreliable for any tonepip frequency and higher harmonics of 60 Hz may be present. The best fix for 60 Hz contamination of tracings is to avoid or at least minimize it by controlling its sources and pickup.

When 60 Hz artifact is present, there is often an environmental or procedural issue that can be identified and addressed. To reduce problematic near-field 60 Hz electromagnetic radiation pickup, the baby and the ABR electrodes should be as far as possible from the closest live power outlet (used or unused) and essential power leads. Outlets that are never used should have metal cover plates. Non-essential power leads should not be plugged into outlets. Long power leads should NOT be coiled; the least-radiating configuration is planar and Z-folded like a concertina.

E/M artifact pickup generally increases, the larger the area of the loop formed by the inverting and noninverting electrode leads, the baby's head and the headbox. The electrodes should be physically arranged to run as close together as possible to the headbox. In any given test area, changing electrode lead positions and orientations may change pickup levels significantly but the absolute amount of pickup will vary from baby to baby, due to multiple factors, especially electrode impedance asymmetry.

Tracings always must be inspected for possible 60 Hz artifact. Suspicion is high if a smooth, slow wave is large and clearly begins in the first 10 ms of a tracing. If suspected, the stimulus condition should be repeated immediately with the insert tube clamped or detached and moved away from the transducer. If the slow wave remains then it is probably not a physiologic response. Procedures to reduce or eliminate the source of the artifact must be implemented, such as those outlined in the preceding section. If large 60 Hz artifact cannot be eliminated, the 60 Hz notch filter may be tried. The use of that filter must not be routine and must be documented. Consultation with a DTC is strongly recommended if 60 Hz artifact problems are persistent.

### 3.24 ABRA UNDER GENERAL ANAESTHESIA

---

ABR testing under general anaesthesia (GA) poses some unique challenges. The environment has multiple hazards that run the risk of reducing the ability to find responses at low intensity levels. Electrical artifact must be carefully monitored, reported, and managed as far as possible. Environmental noise is another pitfall. There are generally at a minimum two additional people in the room—anesthesiologist, and RT/RN at the patient's head talking, with equipment noise from monitors etc. also positioned at head level. In some instances, the room may have three or more additional people—surgeon, interns, nurses— all talking. There may be pagers and telephones ringing, and in some locations overhead announcements. Clearly, environmental noise must be managed. The audiologist needs to be able to request silence, to have monitors at the softest level acceptable, and to have any additional noise sources managed as best as possible. As with any instance of non-adherence to the ABRA protocol, it must be clearly and completely documented in the chart.

Another important aspect of ABR under GA that must be considered and documented is whether the ABR was the sole procedure, or was done in combination with other procedures. This becomes particularly important when the ABR is performed in combination with ENT procedures such as myringotomy, tube insertion, and suctioning of the outer and/or middle ear. Temporary threshold shift (TTS) from suctioning is well documented. The only way to ensure that this has not occurred is to measure BC before and after the procedure. This is not always feasible due to time constraints, but any elevated AC or BC threshold after suctioning is suspect. Dry myringotomy does not pose the same threat of TTS but does run the risk of blood in the canal. Clearly, in the case of myringotomy, or myringotomy with tube insertion, otoscopy must be performed **after** the procedure to ensure the canal does not contain blood. Without this confirmation, elevated AC thresholds are suspect. Ciprofloxacin and dexamethasone (Ciprodex) drops are generally used following myringotomy with or without tubes; obviously their use renders elevated AC results invalid. Again, all of this must be documented in the report.

Other procedures at the patient's head, due to surgical draping, may make inspection of the electrode placement, insert tip placement, and BC placement difficult or impossible. If elevated thresholds are found, and draping or other hazards may have impeded careful inspection of placement, this must be documented.

Finally, if previous audiological testing exists for a given patient, it must inform the testing strategy for the ABRA under GA. ABRA under GA poses some risk to the child, is a finite and relatively costly resource often with long wait times, and is usually performed

under difficult conditions with significant time constraints put on the audiologist. Consequently, the IHP audiologist **must** carefully and completely review previous audiological results and have a clear and detailed plan for what needs to be collected and a strategy for how best to accomplish this. This needs to be documented. An ABRA under GA performed by an IHP audiologist for IHP purposes that fails to meet this requirement could be considered an adverse event and result in an adverse event review.

For an ABR assessment collected under general anaesthesia to be accepted for IHP purposes, it must meet protocol requirements with the exception of test environment (1.24). It is understood that other deviations from protocol might be necessary, but as with any deviation in any circumstance, these must be documented. Additionally, specifically for ABRA under GA the following is required:

- documentation that reasonable effort was made to reduce noise (e.g. request for silence or whispered voice during testing, reduced sound level on monitors if possible) and indication if acceptable quiet was achieved throughout the test.
- indication of whether the ABRA was done in combination with other medical/surgical procedure. If yes, what those procedures were, when the ABRA was performed in relation to them, and any limitations they may have posed for the interpretation of the ABRA must be documented. This is particularly important for any procedure done at the ear including but not limited to suctioning, myringotomy, and tube insertion.
- documentation of physician's report of middle ear status if immittance is not performed by the audiologist.
- Regardless of physician's report of outer and middle ear status (which may have been done **before** other procedures and therefore not account for current conditions in the ear) otoscopy must be performed, preferably by the audiologist, immediately before the ABRA with documentation of results.

## SECTION 4: AUDITORY NEUROPATHY SPECTRUM DISORDER (ANSD) SUB-PROTOCOL

### 4.01 OVERVIEW

Current evidence suggests that 7-10% of infants who have significant PHL may have ANSD. So-called 'conventional' cochlear hearing loss affects the outer hair cells (OHCs) first and at greater severities may also involve loss or damage to the inner hair cells (IHCs) and supporting structures. In contrast, ANSD is a disorder that is not known to affect OHC function but reflects abnormalities of the IHCs, their synaptic linkages to primary auditory neurons or the neurons themselves. Only the last of these alternatives is a true neuropathy, but in 15-20% of all ANSD cases there is MRI evidence of dysgenesis or agenesis of the cochlear nerve. It cannot be assumed that only one site or mechanism of ANSD expression is necessarily involved in any given individual. For a recent, detailed exposition on the pathophysiologic mechanisms of ANSD, see Appendix A: Rance & Starr (2015).

One functional result of ANSD-type pathology is a deficiency in the number and/or the temporal pattern of afferent nerve impulses elicited by sounds. Such abnormalities have a range of perceptual sequelae that are measurable psycho-acoustically in older children and adults, notably including reduced ability to detect temporal modulations of sound and difficulties with speech perception in noise that are more marked than in cases of conventional cochlear pathology with matched severity of sensitivity loss. A further complication is that some ANSD phenotypes appear to share etiologies (such as severe perinatal hypoxia) with conventional cochlear hearing loss. Because there is no reason to assume that ANSD, conventional cochlear hearing loss and conductive hearing loss are necessarily mutually exclusive, they are referred to here as ANSD, OHC-based SHL and CHL *components*.

Mismatch between gross measures of OHC and afferent neural function is the initial hallmark of ANSD. The first necessary condition is an ABR that is absent or at least significantly depressed and/or delayed. At present, it is widely (but not universally) accepted that any elicitation of a complete ABR wave sequence at normal latencies rules out ANSD. Conversely, a completely absent ABR to a high-intensity click stimulus indicates that an ANSD component is possible but other causes include profound OHC-based PHL and mixtures of it with CHL. Between normal and absent ABR lies a spectrum of ABR abnormality within which differential diagnosis of an ANSD component can be very difficult.

The second necessary component is a measure of OHC function. The best indicator of normal OHC function is normal OAEs. CMs are an alternative tool but they are NOT equivalent to OAEs in either simplicity of interpretation or diagnostic strength. OAEs are a pure

OHC phenomenon with fairly well-understood generation place characteristics, but click CM may be generated by IHCs even if the OHCs are extensively damaged; also, gross CMs at a periauricular skin electrode may arise from any part of the cochlea, not necessarily the 2-4 kHz region that normally dominates the click ABR at high levels. This raises the concern of comparing phenomena from what may or may not be different parts of the cochlea, parts that might be subject to different pathophysiology.

A major limitation of OAEs in the ANSD context is that they are reduced or abolished by even small CHLs. Therefore, while OAE presence is highly informative, OAE absence is not. When both OAEs and the ABR are absent, two possible explanations are either severe, OHC-based sensory hearing loss plus a minor conductive overlay or ANSD, so the ANSD could be missed because of the OAE absence.

In addition, there are many possibilities that are less well-defined than 'present OAE and absent ABR', such as situations of abnormal but not absent ABR and/or reduced or partial OAEs. Also, the click may be more effective at ABR elicitation than a tonepip.

Therefore, it is appropriate to try high-level clicks when ABR to high-level tonepips are absent or poorly defined and an added benefit is that responses to condensation and rarefaction stimuli are easily available. For these reasons, it is appropriate to measure click ABR and CM whenever the possibility of ANSD is indicated in the course of tonepip threshold estimation. Such measurement should be deferred until tonepip ABR thresholds are completed to 10 dB bracketing. Bracketing tonepip thresholds to 5 dB is not appropriate if the ANSD sub-protocol indicates ANSD component presence.

#### 4.02 ANSD SUB-PROTOCOL ENTRY CRITERION

---

The ANSD sub-protocol is ear-specific and must be done in any ear for which there is no clear ABR wave V-V' complex with a wave V latency between 5 and 10 ms at any tested level above 75 dB nHL at 2 kHz, with at least one such level having been tested. In the rare event that this condition is satisfied but there is an unequivocally normal wave V ipsilaterally to BC 2 kHz at any level, the entry into the ANSD sub-protocol is discretionary.

The requirement for the ANSD protocol is ear-specific, that is, it may be required in one ear only or in both ears. The majority of ANSD is bilateral, but unilateral ANSD or asymmetric ANSD severity are not uncommon. In any given ear, as soon as presence of PHL is confirmed at any frequency, the probability of ANSD has increased from about 0.0002 in the newborn population at large through about 1% in all AABR. Refers to at least 5% in all cases with confirmed PHL. But, as soon as a clear positive response is obtained with a wave V latency within normal limits well above threshold, the ANSD probability becomes close to zero. ABR threshold definition and wave V clarity and latency are often much better defined at 2 kHz than at 0.5 kHz, so a rational ANSD flag is lack of an *RP* record having a wave V latency under 10 ms at any level above 75 dB nHL at 2 kHz. This criterion is satisfied, for example, by 2 kHz results such as an *NR* at 80 dB, an *INC* at 100 dB or an *RP* at 90 dB with wave V latency over 10 ms.

The ANSD sub-protocol may be done discretionally if the audiologist considers the tonepip response data to be anomalous, even if the criteria for mandatory entry are not satisfied, provided that so doing does not compromise efficient capture of mandatory threshold data. An example of anomalous data might be very poor suprathreshold growth of 2 kHz response amplitude over a large intensity range.

#### 4.03 ANSD SUB-PROTOCOL TIMING

---

The ANSD sub-protocol usually should be deferred until after all required tonepip ABR thresholds have been established bilaterally to 10 dB bracketing. Given that there is at least severe HL or ANSD present (or both), the requirement for the ANSD protocol sometimes is established early in the initial ABRA appointment. However, it does not follow that the ANSD protocol should be entered immediately. First, unless OAEs have already been done and are normal, which is not usually the case, even complete absence of ABR at high 2 kHz tonepip levels is much more likely to have been caused by OHC-based PHL than by ANSD, so tonepip thresholds may well be valid. Second, testing at 500 Hz and 4 kHz may be clinically useful even if ANSD is present, not the least because any measurable ABR strongly suggests auditory perceptibility at the evoking stimulus level or lower. Even abnormal ABRs in ANSD can give clinically useful threshold upper bounds, and if the ABR is completely absent, the time spent confirming that for all key frequencies will be small. It follows that at least the basic threshold Search phase for 2, 4 and 0.5 kHz in each ear should be attempted first, with 10 dB AC bracketing in the event that a late wave V is recognized.

If and when AABR Referral is bilateral, neither ear tests normal and at least one ear has the ANSD Sub-Protocol indicated, then it would be unusual to complete the basic mandatory protocol in both ears within the first ABRA session. It follows that the ANSD protocol will usually be done in a second session.



## 4.04 ANSD TEST PROCEDURES

---

The following procedures must be followed in each ear for which the ANSD sub-protocol entry criteria are met. For all tracings, the following (modified from 2008) parameters must be used:

**Clicks, 90 dB nHL, 21.5/s, window (sweep) length 25 ms, 0 ms delay, bandwidth 150-2000 Hz, full page-width plotting. All compound tracings must be ~4000 sweeps each. Important: Masking is required if ANSD is suspected in one ear and the other ear is normal.**

1. One Rarefaction tracing, denoted as *R*.
2. One 2000 sweep Rarefaction tracing with tube clamped or tube off, *Rns* (Rarefaction, no-stim).
3. One Condensation tracing, *C*.
4. One 2000 sweep Condensation tracing with tube clamped or tube off, *Cns*.
5. Add *R* and *C* into combined overall average, 'All'. This is done using the "+/-"
6. *R* and *C* are subtracted in Step 5 to generate the CM tracing.

**Then organize, plot and annotate the tracings (see Appendix J), in the following sequence from the top down:**

Superimposed <i>R</i> and <i>C</i> "Butterfly plot"	Superimpose the <i>R</i> and <i>C</i> compound tracings, exactly, at the first data point: this 'butterfly' plot accentuates antiphase CM components and latency-shifting ABR components
<i>Rns</i> :	Reveals Rarefaction stimulus artifact
<i>Cns</i> :	Reveals Condensation stimulus artifact
All ( <i>R</i> + <i>C</i> )	Best overall estimate of the ABR; removes CM and stimulus artifact
CM ( <i>R</i> – <i>C</i> )	Best overall estimate of CM, removes ABR if <i>R</i> and <i>C</i> ABRs are identical

Note: Alternating Split is an option offered in the CM modality of the Integrity system. At this time, not enough evidence is available to support its use in the IHP ANSD sub-protocol. Recording tracings in Alternating Split is a discretionary part of this sub-protocol and should only be done after all mandatory and conditional elements are completed; if Alternating Split is recorded, about 4000 sweeps is recommended

## 4.05 INTERPRETATION OF CM/ABR TRACINGS

---

Stimulus artifact for each polarity is revealed by the tube-off (or tube-clamped) tracings. This helps to identify genuine CM components, though the artifact is brief, earlier than the CM and usually easy to distinguish from it. Click stimulus artifact is usually over within about 0.5 ms. If it is very large, the EEG preamplifier may generate 'ringing' due to the artifact impulse; interpretation is more complex and review by a DTC is recommended.

Antiphase (mirror-image) CM components are revealed most clearly by the CM butterfly plot. Asymmetry of the CM is reflected in the curve formed by the 'butterfly wing intersection points' (nodes), which should match the All waveform over the first few milliseconds. Clear departure from zero reflect asymmetry of the CM, which is usually interpreted as SP; this may overlap with wave I (if present) after about 1.5 ms.

The record denoted as 'CM' may show high-frequency oscillation of variable duration, in the region from 0.5 through 1.5 ms. It is recommended that the maximum peak-to-trough or trough-to-peak amplitude should be recorded, along with the total number of high-frequency antiphase segments or wing-spreads in the butterfly and their approximate overall duration. Such parameters may become useful clinically as new knowledge is acquired about CM properties in relation to ANSD subtypes, severity gradation and mixtures with other hearing loss types.

ABR components also may be present at any point after about 1.5 ms. They may or may not be different in the *R* and *C* records, both in amplitude and latency. If different, there may be partial or complete wave cancellation as well as a visual impression of phase

shift in the 'All' tracing. Additional testing is likely to be required in order to resolve the neural components. If a wave V candidate response tracing is clearly identifiable, the peak-to-trough amplitude should be recorded. If there is partial or total wave cancellation in the 'All' tracing relative to the R and C tracings, the larger of the R and C wave V-V' complexes should be used.

#### 4.06 CLICK ABR WAVEFORM & THRESHOLDS

---

Given that the 2 kHz tonepip ABR was absent or at best showed a small and/or late ABR wave V-V' complex above 75 dB nHL in order for the ANSD sub-protocol to be entered, a normal click ABR at 90 dB would be a rare occurrence. Far more common is a late and broad waveform that is presumptively a V-V'. If a clear and replicable such waveform is identified in response to clicks at 90 dB, the click ABR threshold must be approximated as quickly as possible by bracketing. Step size of 20 dB is sufficient but 10 dB is discretionary. If there is a clear difference in wave V-V' size or Rarefaction and Condensation clicks, the polarity with the larger V-V' must be used, otherwise alternating polarity may be used for threshold. The click threshold correction to dB eHL is to subtract 10 dB.

Such thresholds should be noted in any clinical report but are not entered into the HCD-ISCIS database. Clinically it can be noted that hearing in the middle or higher frequencies is X or better, where X is the approximate dB eHL of the upper bracket.

If the Rarefaction and Condensation waveforms show marked latency differences or morphology in the region of the later ABR waves (typically from about 4 to 10 ms), it may be very difficult to distinguish these waves from long CM, for example. Additional, specialized and situation-specific testing may be required and review by the HRH or CHEO DTC is strongly recommended.

Another occasional occurrence with click testing at 90 dB is an ABR waveform in the 'All' tracing that shows early ABR waves with a clear delay or absence of wave V. This pattern suggests a possible retrocochlear lesion (such as an acoustic tumour or other brainstem lesion) that may not be typical of ANSD. Again, review by the HRH or CHEO DTC is strongly recommended.

#### 4.07 DPOAE ROLE

---

DPOAE measurement is discretionary for infants whose ABRs show conductive hearing loss or normal hearing. They are mandatory if sensorineural HL is suspected or confirmed, and as part of the ANSD sub-protocol. Including DPOAEs in a test battery of infant hearing assessment supports the cross-check principle. When coupled with absent ABRs, normal DPOAE amplitudes and signal-to-noise ratios exceeding about 5 dB at F2 frequencies from 2 to 4 kHz are virtually definitive for either ANSD or, more rarely, other neuropathies that compromise action potential generation in the auditory nerve. Repeatable DPOAE presence at even a single frequency of 2, 3 or 4 kHz is incompatible with absent ABR, though presence isolated to lower frequencies is not.

DPOAEs are known to originate in the OHCs specifically. As such, they can provide clear evidence of OHC functional status, though they do not offer a clear quantification of residual OHC function or a means of accurate prediction of hearing thresholds in their own right. Absence of DPOAEs at any specific F2 frequency suggests an SHL of about 40 dB or more at or near that frequency, but the overlap of DPOAE amplitude distributions for groups with and without SHL of about 30-40 dB is substantial and the distributions are quite broad.

The contribution of DPOAE testing to identification of ANSD is limited by their reduction or abolition by even minor conductive pathologies and hearing losses. DPOAEs that are clearly present are highly informative in relation to ABR characteristics, whereas DPOAEs that are absent or questionable are not. For example, an absent ABR and absent OAE cannot be reliably interpreted as uniquely indicative of severe SHL, because ANSD in combination with a minor middle ear pathology would be likely to give the same results.

Normal tympanometry suggests the absence of substantial middle ear pathology but does not rule out minor conditions that might compromise DPOAE development, so even if high-frequency tympanometry is normal, absence of OAEs does not guarantee major OHC dysfunction.

It could be argued that the specific finding of normal DPOAEs removes the need to do the CM component of the ANSD protocol. However, it is often not appropriate to do DPOAE testing before ABR testing and the measurement of CM is a helpful adjunct outcome of click ABR testing, which is necessary in any case to explore the causes of abnormal ABR waveforms and thresholds. CM is generally less affected by minor middle ear pathology than are the DPOAE, and the combination of DPOAE and click CM/ABR results is often highly informative clinically. For these reasons, both DPOAE and click CM/ABR measurement are mandatory components of this protocol.

## 4.08 ACOUSTIC REFLEX (AR) ROLE

---

**AR testing is now discretionary throughout any ABRA.** It might be useful in the context of ABRA only if ANSD is under investigation and even then only if tympanometry is normal. ARs are reportedly absent in most cases of an ANSD component, but the actual sensitivity of this finding is unknown and absence due to severe/profound, conventional sensory loss or significant conductive loss (the other differentials) is to be expected. Absent reflexes add little clinical information when tonepip ABRs are absent or have very high thresholds. In contrast, reflex presence is an anomaly if ABRs are absent at very high stimulus levels and should prompt critical re-evaluation of test findings, so AR testing could be seen as a crosscheck. However, it might be reasonable to assume that in the context of this protocol, such crosschecking should be considered redundant. If ANSD is considered definite, such as in a situation of normal OAEs and absent ABR, reflex testing is not useful because even reflex presence would not carry sufficient weight to change the ANSD inference.

## 4.09 ANSD OUTCOME CATEGORIES

---

**It is a requirement that the tracings associated with all ANSD outcome categories except Not Suspected be anonymized and sent to the HRH or CHEO DTCs for information and review. This will allow the assembly of a provincial IHP dataset that will be used to improve ANSD category definition and protocol efficiency.**

### Category Determination

- If DPOAEs present at 2, 3 or 4 kHz and click ABR V-V' < 0.1  $\mu$ V: **Definite ANSD component**
- If DPOAEs present at 2, 3 or 4 kHz and click ABR V-V' 0.1 - 0.2  $\mu$ V: **Probable ANSD component**
- If DPOAEs absent or unreliable at 2, 3 and 4 kHz, **apply table below:**

CM, pk-pk, $\mu$ V	Click ABR V-V' pk-pk, $\mu$ V		
	< 0.1	0.1 – 0.2	> 0.2
< 0.1	<i>NS</i>	<i>NS</i>	<i>NS</i>
0.1 - 0.2	<i>Probable</i>	<i>See Ratio</i>	<i>NS</i>
> 0.2	<i>Definite</i>	<i>Probable</i>	<i>See Ratio</i>

NS = ANSD Not Suspected

In cells labelled 'See Ratio', calculate the amplitude ratio CM/ABR using the peak-to-peak values. If the ratio exceeds 1.5, the outcome is 'Probable ANSD component', otherwise it is 'ANSD is not suspected'.

The 'ANSD component' terminology is used to remind report recipients that ANSD, conventional (OHC) sensory and conductive hearing loss components may be present concurrently and that 'Sensory/Neural HL' does not mean simply **either** conventional sensory hearing loss **or** ANSD.

## 4.10 CONDUCTIVE COMPONENTS IN ANSD

---

When the ANSD protocol is indicated by AC 2 kHz it is very unlikely, though not impossible, that a clear ABR with normal wave V latency is obtained with BC 2 kHz at 55 dB or below. That finding implies a substantial conductive component, which renders the ANSD protocol virtually useless. A CM will not be seen to a 90 dB click with a mid-frequency conductive component of 20 dB or more. Also, it is almost certain that DPOAEs will be absent. Because these clues concerning the functionality of OHCs are not available, ANSD cannot be detected or classified with adequate reliability. Fortunately, with a normal BC ABR waveform and a correctly attributed responding cochlea, ANSD can be presumed to be absent and the ANSD sub-protocol can be treated discretionally.

If AC 2 kHz ABRs are absent at high levels and BC 2 kHz ABRs are also absent, a conductive component cannot be ruled out except by normal DPOAEs. If DPOAEs are absent, a flat tympanogram suggests a conductive component but does not prove it and does not

quantify it. Alternatively, absent DPOAEs and a normal age-appropriate tympanogram strongly suggests absence of a substantial conductive component. The ANSD click CM/ABR protocol is indicated in both cases and may prove informative.

All in all, if a substantial conductive component cannot be ruled out, ANSD is unlikely to be detectable and a conventional SHL component may be overestimated. The overall interpretation will default to a severe or profound sensory/neural hearing loss with a possible or probable conductive component and ANSD not suspected. In this situation, it is desirable to wait at least 4-6 weeks and retest with tympanometry, OAEs and tonepip ABR at 2 kHz, to determine and interpretable change.

#### 4.11 DTC CONSULTS & ADDITIONAL TESTS

---

It is required that in all cases where the ANSD protocol is entered and the ANSD outcome category is definite or probable, either the HRH or the CHEO DTC should be notified by email and sent the anonymized full ABRA including toneburst and ANSD sub-protocol printout. This notification increases the program's information bases relevant to planning, protocol and resource allocation, as well as triggering useful DTC comment on individual cases, if requested or indicated.

In complex ANSD cases, such as those with no DPOAE and unusual or inconsistent response morphology to rarefaction or condensation clicks, additional testing may be indicated and undertaken by referral to a DTC. Such testing may include very-high-rate (91.1/s) click ABR to suppress and delay neural components, as well as manipulations of tracings to clarify CM, SP, and neural response components. A common challenge is overlap and confusion among oscillatory CM, SP, and the ABR.

When ANSD is present, audiometric threshold estimates are impossible or at best biased and potentially unreliable. Waiting for VRA remains an option that is far from ideal but the options are limited at present. For infants aged six months or more in whom VRA is either likely to be, or is found to be, unsuccessful, advanced Assessment may include threshold estimation using late cortical potentials (LCPs) (typically of 200-400 ms latency) in response to long tone bursts, which are far less sensitive to loss of neural synchrony than the ABR. LCP testing is currently not available through the IHP. See, for example, He et al (2013) in Appendix A of this protocol, for information on cortical testing in children with ANSD.

#### 4.12 EARLY MANAGEMENT

---

ANSD may in some cases be determined to be present under about two months corrected age, in which case repeat ABRA at about four months is usually appropriate; the ANSD sub-protocol should be prioritized at such retests. More commonly, in the IHP ANSD is initially confirmed at about 3-5 months corrected age. It is common to wait for behavioural thresholds by VRA, prior to considering amplification (IHP Amp protocol, Walker et al, 2016). VRA should be tried at the earliest reasonable opportunity, typically at about six months, unless there are contraindications. Agreement or discrepancy between ABR and VRA results may alter the diagnostic picture and follow-up recommendations. Careful communication with caregivers is required if the ANSD test outcome category is 'definite' or 'probable'. ANSD is not easy to explain, especially its relationship to 'ordinary' hearing loss, the consequent inaccuracy of the ABR and the waiting period prior to VRA and decision-making about interventions. Other issues include the variable quality of information about ANSD available on the internet, as well as the number of misconceptions that exist about the disorder, even across hearing health professionals.

Some basic, key points to be explained to families are:

- When ANSD is present, hearing cannot be predicted from the ABR test.
- Infants with ANSD have a wide range of hearing losses, but most have some degree of loss.
- Behavioural hearing testing usually will be tried at about 6 months of age.
- Family observations of response to sounds may give useful information.
- Many children with ANSD have difficulty understanding speech, especially if there is a lot of background noise or other people talking.
- The extra difficulty understanding speech happens because ANSD interferes with the timing of sound signals as they travel up the hearing nerves to the brain.
- Some children (about 50%) with ANSD will benefit from amplification.
- Amplification is usually not provided until reliable behavioural thresholds are obtained.
- Some children with ANSD who do not get much benefit from amplification may do well with cochlear implants.

- Much information about ANSD available from the Internet is incomplete or invalid.

See Roush et al (2011) in Appendix A for a comprehensive review of audiologic management of children with ANSD. See Teagle et al (2010) on cochlear implants in ANSD. See Walker et al, 2016 for language outcomes of children who have ANSD.

It is often quoted and written that fluctuation of hearing and possible improvement in hearing over time are common occurrences with ANSD, or even key characteristics of it. These statements are incorrect. Fluctuation of hearing levels in ANSD is not a common finding and is probably confined to specialized sub-types of ANSD. Similarly, while it is possible that hearing levels may change over time in a few cases, the actual incidence of progression or improvement is not well-understood and may be very low. The evidence to date for improvement in hearing levels is not of high quality; it should be evaluated critically in relation to individual candidacy for interventions such as cochlear implants.

#### 4.13 ANSD FIELD ENTRY IN THE IHP DATABASE

---

If ANSD is definite or probable, tonepip thresholds are likely to be positively biased and in many cases will comprise a lower bound value expressing No Response at the required maximum stimulus levels. These values must be entered in the HCD-ISCIS database frequency threshold fields as if they were valid, but must be qualified by an entry indicating ANSD as 'Not Suspected', 'Probable', or 'Definite'. PHL must be reported as 'Yes'.

#### 4.14 POST-ABRA REFERRALS

---

It is the responsibility of the individual IHP Audiologist, preferably with support from a DTC, to determine the ANSD category and complete the ABRA protocol. When those steps are completed, if ANSD is definite or probable then referrals for additional investigations are discretionary and are outside the scope of this protocol. It is suggested that all referrals that normally would be undertaken for an infant with non-ANSD PHL should be considered. The special concerns, particularly with definite ANSD, are primarily related to delay in definitive audiometry and the increased likelihood of agenesis or dysgenesis of the cochlear nerve(s) which are of clear relevance to amplification, CI candidature and planning of early communication development services.

### SECTION 5: ANCILLARY PROCEDURES

#### 5.01 DISTORTION PRODUCT OTOACOUSTIC EMISSION (DPOAE) TESTING

---

##### **Purpose and Priority**

DPOAEs reflect cochlear OHC function. They can be reliably recorded in sleeping newborns in a quiet environment. They are measured best with an f2/f1 ratio of about 1.22 and f1/f2 levels of about 65/55 dB SPL, respectively. DPOAEs yield an approximate yes/no (DPOAE absence/presence) test for significant sensory hearing loss at each f2 value tested, with an effective binary decision criterion at about 40 dB HL.

DPOAEs do not yield accurate hearing threshold estimates. The sensory hearing loss that abolishes the DPOAE is widely distributed across the infant population. Some babies who have near-normal hearing may have reduced or absent OAEs, while some babies with sensory losses of over 50 dB HL have OAEs of near-normal amplitude. OAEs may be abolished by conductive losses as small as 5-10 dB, so an unknown proportion of cases of OAE absence with apparently normal hearing may be due to conductive effects. This vulnerability to minor conductive disorders that may not be detected reliably with tympanometry limits the clinical value of DPOAEs: present DPOAEs may be very informative as a test of OHC functional status, but absent OAEs yield little diagnostic information.

In the context of initial ABRA, DPOAE measurement is now mandatory only if the indications for ANSD sub-protocol entry are met. If not, DPOAE testing is discretionary but before embarking on such measurement, the Audiologist should have a clear purpose and action plan for the possible test outcomes. When ABR absence or abnormality is established at high 2 kHz levels, ANSD has substantial probability. DPOAE testing is recommended to occur after tonepip thresholds are completed and before the rest of the ANSD sub-protocol. Typically, this might occur at the end of the first ABRA session or the start of the second.

Because the primary purpose of ABRA is ABR threshold measurement, if a baby is sleeping then ABR testing is usually the immediate priority. Doing OAEs at the start of an ABRA test session is discretionary but if the baby is merely drowsy, doing OAEs may interfere with falling asleep. OAEs are never a substitute for ABR thresholds, though if ABR thresholds are abandoned due to persistently poor EEG, trying OAEs may salvage at least some useful clinical information.

### **Procedure**

DPOAE testing must adhere to this protocol, using the parameters specified in Appendix H. Nominal f2 frequencies are 1.5, 2, 3 and 4 kHz, with descent from 4 kHz. If the SNR (the difference between the DPOAE and noise floor levels) at every nominal f2 frequency is at least 8 dB, the test is Normal and need not be repeated. If not, DPOAEs must be replicated. Results must be plotted with replicates overlaid and Left and Right ears side by side, where feasible. Hardcopy or electronic plots and tables are retained. The 2008 IHP Protocol specified display of normative amplitude data percentile curves as part of the printout graphics, but it is now recommended that those data not be displayed because they are not useful clinically. Note that DPOAE testing above 4 kHz is discretionary, pending normative data development

Interpretation considers absolute DPOAE and noise levels, SNRs, and differences across replicates, at every f2 and for all of them collectively. Step 1 is to evaluate stimulus conditions. Systems often auto-calibrate to 65 and 55 dB SPL and show responses that are flat and level. A little droop at low frequencies is acceptable but suggests of imperfect probe fit. Major droop indicates inadequate probe fit that invalidates the test.

Step 2 is to assess replicability. Test retest differences of similar size to the average SNR at any f2 cast doubt on inference of DPOAE presence or absence. Conversely, highly reproducible profiles or smooth trends across frequency strengthen inference of DPOAE presence even if the SNRs at individual f2s are small. Step 3 is an evaluation of specific numerical values of DPOAE, noise and the difference between them, frequency by frequency, noting reflex absence, presence or indeterminacy due to excess noise. Step 4 is to assess patterns. This is a search for trends across frequencies or remarkable differences in values at single frequencies. At each f2, the question is if the DPOAE level is real or due to noise. DPOAE amplitude and SNR are relevant. For a single f2, a conservative criterion for DPOAE presence is an SNR of at least 8 dB and a test-retest difference under 5 dB. An 8 dB criterion will yield about 1% false-positive detection whereas a 3 dB criterion would give about 10%. Infants may have greater SNRs than adults, and this may change with maturation, ear canal growth, and may be affected by the specific in situ calibration technique or measurement parameters used by the DPOAE equipment (Hunter et al., 2018).

When two or more adjacent frequencies show positive SNRs, each frequency adds to the probability that the DPOAE is genuine, so use a 5 dB criterion for genuine DPOAE presence at each frequency in a string of adjacent, positive differences. High noise levels limit the opportunity for an OAE to be detected reliably.

### **Clinical Implications**

DPOAE presence for all f2 suggests grossly normal functioning of the middle ear and the cochlear OHCs. Significant conductive disorders are ruled out. OHC-based cochlear hearing loss greater than 40 dB HL is unlikely; more than 60 dB HL is virtually ruled out. ANSD does not affect OAEs. Normal OAEs and an absent or grossly abnormal ABR to high-level 2 kHz tonepips or to high-level clicks are virtually definitive for an ANSD component, which is thereby ruled in, as noted previously.

Unfortunately, many factors other than a target PHL can obscure, reduce or abolish DPOAEs. These include a noisy environment, active baby, inadequate probe placement, eartip blockage and an array of middle ear conditions. The net result is that absence or marked reduction of DPOAEs carries little diagnostic information. Their value lies in their presence and the consistency of that presence with observed ABR characteristics. DPOAE presence with, say, a 2 kHz tonepip ABR threshold above 50 dB nHL should lead to careful review of the ABR threshold validity. More marked discrepancy raises the ANSD index of suspicion more strongly than any other test finding, but there is a large gray zone of borderline incompatibility between clear DPOAE and abnormal ABR features for which current knowledge is insufficient for interpretation.

## **5.02 MIDDLE EAR ANALYSIS: TYMPANOMETRY**

---

Tympanometry is mandatory in all ABRA (see Appendix I). Tympanometric abnormality criteria are set at the 5th percentiles of age-specific normative distributions of compensated peak static admittance, where a clear peak or peaks have developed. In the case of double peaks, the larger peak is used. Admittance change without development of a genuine peak is abnormal regardless of the

amount of admittance change. Caution is required in applying these criteria to young neonates, in whom canal wall collapse may lead to steep negative tails.

The clinical utility of other tympanometric measures such as peak pressure, width and gradient is unclear in infants. Reported 90% range boundaries for tympanic peak pressure are from approximately -150 to -100 daPa up to 0 to 50 daPa.

The equipment required up to and including the IHP 2008 Assessment Protocol was the Tymptstar. That has now changed to include any equipment capable of providing the measures and procedures specified in this 2018 ABRA protocol, that is, the specification is now functional.

#### **Babies and Infants of corrected age less than six months**

Tympanometry must be done with a 1 kHz probe frequency for neonates and infants under six months corrected age. The test must be repeated if the trace is noisy or if it is not clearly normal. A clearly normal tympanogram need not be repeated. The key abnormality criterion is a compensated peak static admittance of  $\leq 0.6$  mmho, compensated from the negative tail at -400 daPa. All tympanograms at 1 kHz must be plotted and retained on file.

#### **Infants of corrected age six months or more**

For infants aged six months or more, the probe frequency must be 226 Hz. The abnormality criterion in the range 6-12 months is a compensated peak static admittance of 0.1 mmho, compensated from the positive tail at +200 daPa. From 13-18 months, the criterion is 0.15 mmho. Above 19 months, the criterion is 0.2 mmho. At any age, a tympanogram that is noisy or not clearly normal must be repeated. Tympanograms at 226 Hz in all cases should be plotted and retained on file

### **5.03 MIDDLE EAR ANALYSIS: ACOUSTIC REFLEXES**

---

Acoustic reflex (AR) measurement is now always discretionary but may be clinically contributory in the context of suspected ANSD. When an ANSD component is actually present, a clear AR is an unusual finding that should lead to careful re-evaluation of any evidence for inference of a Definite or Probable ANSD component. AR presence also has some clinical value as a crude crosscheck when AC ABR thresholds are poorly defined and suggest hearing levels over about 80 dB eHL. If such situations occur then the reliability of the ABR threshold should be re-examined and possible causes of poor threshold definition should be identified and remedied as a normal requirement of high-quality ABRA.

If ipsilateral ARs are elected to be done, a 1 kHz probe must be used for infants under six months corrected age and a 226 Hz probe for infants aged six months or more. The eliciting stimulus may be a 1 kHz tone or Broad-Band Noise (BBN), which is a protocol change from the 2008 version. BBN is the preferred stimulus because it is usually more effective than tonal stimuli for reflex elicitation, which reduces false-positive reflex absence. The BBN option is a hardkey under 'stimulus' on the right side of the Tymptstar. The goal is not to establish an accurate reflex threshold, but to show presence or absence of reflexes at an appropriate stimulus level. The starting level should be 85 dB. In infants under six months of age, the maximum nominal level must not exceed 100 dB, because of the SPL variability across young infants due to differences in canal volume and geometry. For older infants, very small canals are uncommon and the maximum nominal stimulus level is discretionary. Printouts are mandatory as reflex waveform anomalies do occur. It is the reproducibility of the elicited waveform, not its precise morphology, that is the primary factor in response identification.

## APPENDICES

### APPENDIX A: REFERENCES

- American Electroencephalographic Society (1994). Guideline thirteen: Guidelines for standard electrode position nomenclature. *J Clin Neurophysiol* 1994;11:111-113.
- American Speech-Language-Hearing Association (2004). Guidelines for the Audiologic Assessment of Children From Birth to 5 years of Age [Guidelines]. Available from [www.asha.org/policy](http://www.asha.org/policy).
- ANSI (R2013). American National Standard : Maximum Permissible Ambient Noise Levels for Audiometric Test Rooms. ANSI S3.1-1999. New York: Acoustical Society of America.
- Berlin CI, Hood LJ, Morlet T, Wilensky D, Li L, Mattingly KR, et al (2010). Multi-site diagnosis and management of 260 patients with auditory neuropathy/dys-synchrony (auditory neuropathy spectrum disorder). *Int J Audiol*; 49(1):30-43.
- BC Early Hearing Program (2012). Audiologic Assessment Protocol. v 4.1, November 2012. Available at [www.phsa.ca/documents/bcehpaudiologyassessmentprotocol](http://www.phsa.ca/documents/bcehpaudiologyassessmentprotocol)
- Hunter, L. L., Blankenship, C. M., Keefe, D. H., Feeney, M. P., Brown, D. K., McCune, A., Fitzpatrick, D. F., & Lin, L (2018). Longitudinal development of distortion product otoacoustic emissions in infants with normal hearing. *Ear and hearing*, 39(5), 863–873.
- Hyde, M. (Ed.) (2011). Principles and Methods of Population Hearing Screening in EHDI. San Diego, CA: Plural.
- Infection Prevention and Control Guidelines for Audiology (2010). An interorganizational group for speech-language pathology and audiology, retrieved from: [http://www.caslp.com/sites/default/uploads/files/GU\\_EN\\_Infection\\_Prevention\\_Control\\_Guidelines\\_Audiology.pdf](http://www.caslp.com/sites/default/uploads/files/GU_EN_Infection_Prevention_Control_Guidelines_Audiology.pdf)
- McCreery R, Kaminski J, Beauchaine K, Lenzen N, Simms K, Gorga M. (2015). The impact of degree of hearing loss on auditory brainstem response predications of behavioral thresholds. *Ear Hear*; 36(3): 309-319.
- Personal Health Information Act (2004). Chapter 3, Schedule A, Government of Ontario, retrieved from: <https://www.ontario.ca/laws/statute/04p03>
- Rance G. (2005). Auditory neuropathy/dys-synchrony and its perceptual consequences. *Trends in Amplification*; 9:1–43.
- Rance G, Starr A. (2015). Pathophysiological mechanisms and functional hearing consequences of auditory neuropathy. *Brain* 2015;138:3141-3158.
- Rance G, Starr A. (2011). Auditory neuropathy/dys-synchrony. In: Seewald R, Tharpe AM, editors. *Comprehensive handbook of pediatric audiology*. Chapter 13. San Diego: Plural Publishing; 225–42.
- Rosenfeld, R. M. et al. Clinical practice guideline: otitis media with effusion (update). *Otolaryngol. Head Neck Surg*. 154, S1-S41 (2016). Downloadable from: [https://www.aafp.org/patient-care/clinical-recommendations/all/otitis-medial.html#Otitis\\_Media\\_With\\_Effusion](https://www.aafp.org/patient-care/clinical-recommendations/all/otitis-medial.html#Otitis_Media_With_Effusion)
- Roush P, Frymark T, Venediktov R, Wang B (2011). Audiologic management of Auditory Neuropathy Spectrum Disorder in children: A systematic review of the literature. *Am J Audiol*, 2011;20:159-170.
- Sharma, A, Cardon, G. (2015). Cortical development and neuroplasticity in Auditory Neuropathy Spectrum Disorder. *Hearing Research* 2015;330:221-232
- Small SA, Hatton J, Stapells D (2007). Effects of bone oscillator coupling method, placement location, and occlusion on bone-conduction auditory steady-state responses in infants. *Ear and Hearing* 2007;28(1): 83-98.
- Small SA, Hu N (2011). Maturation of the occlusion effect: a bone conduction auditory steady state response study in infants and adults with normal hearing. *Ear Hear* 2011;32(6):708-19.
- Stapells D (2011). Frequency-specific threshold assessment in young infants using the transient ABR and the brainstem ASSR. Ch. 20 in Seewald R & Tharpe AM (2011). *Comprehensive Handbook of Pediatric Audiology*. Plural Publishing, Inc., San Diego, CA.
- Stapells DR (2011). Threshold estimation by the tone-evoked auditory brainstem response: a literature meta-analysis. *J Sp-Lang Pathol Audiol* 2000;24:74-83.
- Stapells DR (2000). Frequency-specific evoked potential audiometry in infants. In RC Seewald (Ed): *A Sound Foundation through Early Amplification*. Phonak AG, 2000, pp 13-32.
- Stapells DR, Oates P. Estimation of the pure-tone audiogram by the auditory brainstem response: A review. *Audiol Neuro-Otol* 1997;2:257-280.
- Stapells DR: HAPLAB Website: a good source of information on AEPs generally and tonepip ABR specifically: [audiospeech.ubc.ca/haplab/ThreshABR.html](http://audiospeech.ubc.ca/haplab/ThreshABR.html)
- Teagle H, Roush P, Woodard J et al. (2010). Cochlear implantation in children with Auditory Neuropathy Spectrum Disorder. *Ear Hear* 2010;31(3):325-35.



- Walker E, McCreery R, Spratford M, Roush P (2016). Children with auditory neuropathy spectrum disorder fitted with hearing aids applying the American Academy of Audiology Pediatric Amplification Guideline: Current Practice and Outcomes. *JAAA*; 27(3): 204-218.
- Yang, E. Y., & Stuart, A. (1990) A method of auditory brainstem response testing of infants using bone-conducted clicks. *Journal of Speech-Language Pathology and Audiology*, 14(4), 69-76, 1990.

## APPENDIX B: ACCESSING A DESIGNATED TRAINING CENTRE (DTC) FOR CONSULTATION OR REFERRAL

### Overview

The Designated Training Centre (DTC) structure was put in place at the inception of the Infant Hearing Program (IHP) in 2001. DTCs provide protocol and clinical decision support, as well as training, and second opinion to IHP Audiologists. The goals of DTCs are to:

- Support the timely and accurate execution of IHP protocols for assessment and the provision of amplification;
- Help IHP Audiologists meet the IHP goals of early identification and intervention for children with permanent hearing loss; and
- Serve as a clinical resource to IHP Audiologists.

The DTCs for each aspect of the IHP are as follows. For Assessment, a regional breakdown of which DTC to contact is included.

DTC	Topic Area for Support	Contact Information	Regional Breakdown
Humber River Hospital (HRH) Toronto	ABR CBA: VRA & CPA	Jill Witte, M.A. (ABR) <a href="mailto:JWitte@hrh.ca">JWitte@hrh.ca</a> 416-242-1000 X21437	Central South Essex-Kent Kenora Rainy River Simcoe Muskoka Parry Sound
		April Malandrino, M.Ci.Sc (CBA) <a href="mailto:AMalandrino@hrh.ca">AMalandrino@hrh.ca</a> 416-242-1000 X21420	Toronto Tri-Region
Children's Hospital of Eastern Ontario (CHEO) Ottawa	ABR CBA: VRA & CPA	Marie Pigeon, M.Sc. <a href="mailto:Pigeon_m@cheo.on.ca">Pigeon_m@cheo.on.ca</a> 613-737-7600 X2709	Central West Eastern Northeast Southeast Southwest Thunder Bay
Western University London	Amplification Outcome Measures	Marlene Bagatto, Aud.D., Ph.D <a href="mailto:bagatto@nca.uwo.ca">bagatto@nca.uwo.ca</a> 519-661-2111 X88949	All

Support is available to IHP Audiologists for a range of topics such as:

- Answering questions about IHP protocols;
- Case discussion and records review;
- Recommendations for additional testing;
- Up-front request from the IHP Audiologist for the DTC to retest a child.

APPENDIX C: SUMMARY OF KEY INTEGRITY STIMULATION AND RECORDING PARAMETERS

PROTOCOL FILES	See detailed SETUP procedure notes following this summary Table.	
ELECTRODE SITES	Noninverting: High midline forehead, referenced to Inverting for Channel 1: Left mastoid Inverting for Channel 2: Right mastoid Common: Lateral forehead > 3 cm from Noninverting electrode	
CHANNELS	Air Conduction: Two channel or single channel ipsilateral to stimulated ear Bone Conduction: Two channel, ipsi and contra to stimulated ear	
<b>FILTERS</b>		
HIGH-PASS ('LOW')	Tonepip thresholds	30 Hz
	All click recordings	150 Hz
LOW-PASS ('HIGH')	Tonepip thresholds	1500 Hz
	All click recordings	2000 Hz
NOTCH FILTER	Off, except as a last resort when 60 Hz artifact is severe.	
ARTIFACT REJECT	<b>Off</b>	
AMPLIFIER GAIN	150,000 (not adjustable)	
AVERAGING	<b>2000-4000 adjusted sweeps per tracing, 1 to 3 tracings per condition.</b>	
EPOCH LENGTH	25 ms	
RESIDUAL NOISE TARGET	<b><math>\leq 0.020 \mu\text{V}</math>, recommended for Response-Negative judgement.</b>	
INTENSITY LEVELS	<b>Starting at 0, 5 dB intervals until max level</b>	
<b>STIMULI</b>		
TONEPIPS	Linear ramp (Trapezoidal envelope), 2-1-2 cycle rise/plateau/fall times. Alternating polarity. Repetition rate 37.7/s.	
CLICKS	100 $\mu\text{s}$ drive voltage pulse duration Alternating, condensation, rarefaction polarity as specified. Repetition rate 21.5/s	
MASKING	Ipsilateral: None. Contralateral: discretionary 60 dB broad-band noise.	
STIMULUS TRANSDUCER CALIBRATION OFFSETS	See Appendix D for IHP Integrity Stimulus Transducer Calibration. See Appendix E for IHP Integrity Protocols.	

## APPENDIX D: IHP VIVOSONIC INTEGRITY STIMULUS TRANSDUCER CALIBRATION

All IHP Vivosonic Integrity's must be set up identically, as specified in this protocol. The application software version in current use in the IHP is the Integrity 8.7 with calibration files of Version 8.3.3 (see table below).

Whichever software is installed on any given Integrity, correct stimulus calibration settings are essential in order to use that Integrity for IHP ABRA. The stored values are not dB SPL values but are internal 'offset' values in dB peSPL that produce the desired SPLs for 0 dB 'dial' to equal 0 dB nHL for the specific stimuli to be used in ABRA. See the table below.

On the Integrity, to access the transducer calibration version, click on the **System screen**. In the middle of this screen, you should see the version number under **RETSPL Conversion File**. The current RETSPL Conversion File is 8.3.3.

### **ABR Integrity V500 G2 RETSPL adjustment for 0 dB nHL**

These values are numbers specified by the IHP that are intended to produce appropriate stimulus levels, such that dial values approximate dB nHL values.

Transducer	<i>Frequency (Hz)</i>				Click
	500	1000	2000	4000	
ER-3A	25	23	28	30	38
B-71W	62	49	47	39	47
HAD-300	30	17	16	21	30

## APPENDIX E: IHP VIVOSONIC INTEGRITY PROTOCOLS

The DTCs will help IHP Audiologists to set up their own protocols. If there are changes to the parameter below, the changes will be uploaded via TeamViewer or emailed through the DTCs. Below are the protocol parameters for reference. There is also a quick guide to protocol setup for general information.

### IHP ABR PROTOCOLS

#### Air Conduction 500 Hz, 1000 Hz, 2000 Hz, 4000 Hz

Stimulus type: 500 Hz, 1 kHz, 2 kHz or 4 kHz	High Pass Filter Cutoff Frequency: 30
Transducer Type: <b>Insert Earphone</b>	Low Pass Filter Cutoff Frequency: 1500
Stimulus Rate: 37.7	High Pass Filter Rolloff: 12 dB/Octave
Maximum Number of Stimuli: Unlimited (33930)	Low Pass Filter Rolloff: 24 dB/Octave
Windowing: Linear	Artifact Rejection: Checked off
Ramp Number of Cycles: 2-1-2	Display Zoom: 25 ms
Polarity: Alternating	Default Masking Level: None
Level: Checked from 0 to max DB in 5 dB step size	

#### Bone Conduction 500 Hz, 2000 Hz, 4000 Hz

Stimulus type: 500 Hz, 2 kHz or 4 kHz	High Pass Filter Cutoff Frequency: 30
Transducer Type: <b>B-71</b>	Low Pass Filter Cutoff Frequency: 1500
Stimulus Rate: 37.7	High Pass Filter Rolloff: 12 dB/Octave
Maximum Number of Stimuli: Unlimited (33930)	Low Pass Filter Rolloff: 24 dB/Octave
Windowing: Linear	Artifact Rejection: Checked off
Ramp Number of Cycles: 2-1-2	Display Zoom: 25 ms
Polarity: Alternating	Default Masking Level: None
Level: Checked from 0 to max DB in 5 dB step size	

#### Air Conduction Click

Stimulus type: <b>Click</b>	High Pass Filter Cutoff Frequency: 150
Transducer Type: <b>Insert Earphone</b>	Low Pass Filter Cutoff Frequency: 2000
Stimulus Rate: <b>21.5</b>	High Pass Filter Rolloff: 12 dB/Octave
Maximum Number of Stimuli: Unlimited ( <b>18990</b> )	Low Pass Filter Rolloff: 24 dB/Octave
Windowing: Linear	Artifact Rejection: Checked off
Ramp Number of Cycles: <b>2-0-2</b>	Display Zoom: 25 ms
Polarity: <b>Rarefaction</b>	Default Masking Level: None
Level: Checked from 0 to max DB in 5 dB step size	


For Reference: **AEP SETUP**

Double click the *Integrity* icon to open the program. A system menu will appear, click on *Diagnostics*.


### SETUP DISPLAY PARAMETERS

In the Main Menu shown at the top of the screen on startup:

- 1) Choose any existing protocol in the list found on the left
- 2) Change the parameters according to new IHP protocol
- 3) Click on **Save Protocol** located in the top right corner




- 4) Name the new protocol according to the parameters used (e.g. IHP Insert 2 kHz)
- 5) Click **OK**
- 6) **Note: You cannot make additional changes to the protocol once it is saved. If changes are made, you will be required to create a new protocol.**
- 7) If you would like to remove protocols from the drop down list in the Test Screen, uncheck the box corresponding to the protocol. To permanently remove a protocol, click on **Delete Protocol**



## APPENDIX F: CLINICAL TIPS FOR A HAND-HELD OR TENSOR BANDAGE BONE OSCILLATOR

When hand-holding or using a tensor bandage for BC ABR, proper placement and consistent pressure of the bone oscillator are important. The following tips are recommended:

- Ensure the oscillator is flat against the baby's temporal bone.
- Place the oscillator high on the temporal bone rather than low, as in the image below.
- Ensure even pressure is applied. If the baby is being held during the test, instruct the caregiver to keep the baby still (i.e., no rocking or other motion) during BC recordings



**Notice the difference in bone BELOW the ear canal opening in an adult vs an infant skull. This is why BC is generally better with a high placement**

Source:  
Audiology  
Department,  
Children's  
Hospital of  
Eastern Ontario

APPENDIX G: IHP MINIMUM STIMULUS LEVELS & ABRA THRESHOLD CORRECTIONS FOR dB eHL

	AIR CONDUCTION				BONE CONDUCTION		
Frequency (Hz)	0.5k	1k	2k	4k	0.5k	2k	4k
Minimum Level (dB Dial)	40	35	30	25	25 <1 yr 30 ≥1 yr	30	25
Correction Factor (dB)*	-15	-10	-5	0	0	-5	0

THRESHOLD CORRECTIONS AND IHP MINIMUM TEST LEVELS

The correction factors for 500 Hz AC and BC have been adjusted to reflect recent data and to approximate more closely the BC Early Hearing Program values.

**The IHP minimum levels are now set at dial values that correspond to 25 dB eHL after correction, for all stimulus conditions.** These levels are consistent with a target impairment equivalent to 30 dB HL or greater at any frequency in the set [0.5, 1, 2, 4 kHz].

\* For AC ABR threshold estimates greater than 70 dB dial, if 5 dB final step size is used for the threshold bracket then the absolute value of the Adjustment should be reduced by 5 dB at any frequencies. The rationale is that with a 10 dB step size, the possibility of response presence at a level 5 dB lower (untested) is included in the statistical adjustment for bias, whereas with a 5 dB step there is no such possibility, because the 5 dB lower level was now demonstrated to be No Response.

Examples: 2k 80 dB nHL (RP), 70 (NR):  $EHL = 80 - 5 = 75$  dB eHL  
 2k 80 dB nHL (RP), 75 (NR):  $EHL = 80 - (5 - 5) = 80$  dB eHL

\*where (RP) and (NR) represent definite response detection outcomes (see Protocol text).

For any AC ABR threshold, it is discretionary to reduce the absolute value of the Adjustment by 5 dB, if the response at the lowest level considered Response Positive is minimal AND the EEG noise level is very low (such as a Residual Noise Level below 20 nV). The rationale is that with exceptionally quiet EEG, the ability to identify small, near-threshold responses is increased, and if such a response is seen, the negative offsets normally used are likely to be on average excessive.

Examples: AC 500 Hz 60 dB nHL (RP), 50 (NR):  $EHL = 60 - 15 = 45$  dB eHL  
 AC 500 Hz 60 dB nHL (RP, small, very low noise, e.g., 18 nV), 55 (NR):  
 $EHL = 60 - (15 - 5) = 50$  dB eHL

Because current correction factors typically reflect only the mean or median values of the normative difference between ABR thresholds and measured behavioural thresholds in the same subjects, and both measures are subject to random error, it is statistically possible that valid RP outcomes might occur at dB eHL levels that are judged NR by BC, implying negative air-bone gaps. This occasional finding is to be expected, and the lower of the two thresholds should be assumed to be correct.



## APPENDIX H: DPOAE PARAMETERS

Use of specific makes and models of DPOAE measurement equipment is now at the discretion of the IHP test facility. Clinics should use settings that are matched closely to those shown below. For the Vivosonic Integrity system, the “Fast” protocol is recommended and may be used with the S/N Ratio of 8 dB. Use of “Accurate” or “Medium” will provide higher DPOAE levels with longer test times and their use is therefore discretionary. Infant normative data for the “Accurate” protocol are available (Hunter et al., 2018).

### Spectrum Ranges

**Upper Frequency Limit (kHz): 10**

**Autoscale Frequency: check**

**Decibel Range (dB): 100**

**Bar Plot Spectral Data: blank**

### DP-Gram Analysis Range

**Maximum Level (dB): 70**

**Maximum Frequency (Hz): 16000**

**Reference Data: do not use.**

**Minimum Level (dB): -30**

**Minimum Frequency (Hz): 250**

### Setup/Collection Parameters

**Frequencies and Levels**

**F2/F1 Ratio: 1.22**

**L1 Level dB: 65**

**Protocol Name: 1-4 kHz Diagnostic Test**

**Frequency Begin: 4000**

**Frequency End: 1000**

**Points per Octave: 2**

**L2 Level dB: 55**

### Stopping Criteria

**Min DP amplitude (dB): -5**

**S/N Ratio: 8**

**Sample Size: 1024**

**Minimum # Samples 50**

**Noise Floor (dB): -17**

**Point Time Limit (sec): 20**

**Number of Tests: 1**

The DPOAE report should display the Left and Right Ears side-by-side, with the replicate measurements superimposed in each graphical panel.

## APPENDIX I: MIDDLE-EAR ANALYSIS TECHNICAL SUMMARY

### TYMPANOMETRY

Middle ear analysis may be completed using any make or model of equipment, provided that it meets calibration requirements, and offers a 1 kHz probe tone for use with infants younger than 6 months corrected age. As per CASLPO (2008) requirements, middle ear analysis must be performed using a type 1 tympanometer. A pressure sweep range that includes -200 daPa is required to facilitate measurement of negative middle ear pressures.

**For tympanometry**, the following normative ranges are recommended, and intended for use with a 226 Hz probe tone unless otherwise specified. Visual examples of flat and normal tympanograms are available in Rosenfeld et al., (2016) Clinical Practice Guideline: Otitis Media with Effusion (Update)

If the tympanic membrane is intact: <sup>1</sup>				
Age group	Equivalent ear canal volume (Vec)	Static compensated admittance (Y <sub>tm</sub> )	Tympanometric Width <sup>2</sup>	Tympanometric peak pressure (TPP)
<6 months (1000 Hz probe)	0.2 – 0.8 cc	> 0.6 mmho (negative tail compensation)	<150 daPa	N/a
6 – 18 months	0.5 – <1.0 cc	≥0.2 mmho	<250 daPa	-75 to + 25 daPa are typical, but peak pressure as low as -199 may be consistent with transient middle ear issues and may resolve. Consider results together with other findings.
>18 months – 10 years	0.6 – 1.2 cc	≥0.3 mmho	<200 daPa	
If otoscopy reveals a patent tube or perforation				
1 to 7 years <sup>3</sup>	1.0 – 5.5 cc			

### MIDDLE-EAR MUSCLE REFLEXES (ACOUSTIC REFLEXES, ARs)



ARs are always discretionary but their measurement is recommended as a limited crosscheck in situations of suspected ANSD. If a significant ANSD component is present, ARs are usually absent, but the quantitative evidence for such a finding is limited. ARs may be elicited by a 1 kHz tone or a broad-band noise (BBN) stimulus; the latter is preferable because BBN stimuli are more effective than tones for reflex elicitation, thereby reducing false-negative reflex absence. The AR is measured ipsilaterally using a 1 kHz probe frequency. Stimulus level should start at 85 dB and increase in 5 dB steps up to no greater than 100 dB. Note that for a given nominal level, real-ear SPLs in young infants may be up to 20 dB greater than in adults. Reflex presence is usually defined by a repeatable, clear, negative deflection, though biphasic and even positive deflections sometimes occur. Printout is discretionary but is recommended if the AR is given substantive clinical weight in overall interpretation of test findings.

<sup>1</sup> Hunter, 2013, BSA 2013, Rosenfeld et al., 2016

<sup>2</sup> For information purposes only

<sup>3</sup> ASHA, 2004

APPENDIX J: ANSD PLOTTING EXAMPLES



ABR WAVEFORM DATA

Channel	Corr. Coef.	RN $\mu$ V	Time (ms)										Amp ( $\mu$ V)		Ratio (V-V')/(I-I')	SS	SE		
			I	I'	II	III	IV	V	V'	I-III	III-V	I-V	I-I'	V-V'					
1 90 CH1	—	0.013	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
2 L 90 CH1	—	0.013	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
3 L 90 CH1	—	0.018	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
4 L 90 CH1	—	0.020	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
5 L 90 CH1	—	0.021	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
6 L 90 CH1	—	0.055	—	—	—	—	—	—	—	6.14	7.29	—	—	—	—	—	0.15	—	—
7 L 90 CH1	—	0.030	0.99	1.56	—	—	—	—	—	—	—	—	—	—	—	—	0.39	—	—